2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof

Abstract

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Description

BACKGROUND

Technical Field

This disclosure relates to inhibitors of one or more proteins in the Wnt pathway, including inhibitors of one or more Wnt proteins, and compositions comprising the same. More particularly, it concerns the use of an indazole compound or salts or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Background

The Wnt growth factor family includes more than 10 genes identified in the mouse and at least 19 genes identified in the human. Members of the Wnt family of signaling molecules mediate many short- and long-range patterning processes during invertebrate and vertebrate development. The Wnt signaling pathway is known for its role in the inductive interactions that regulate growth and differentiation, and it also plays roles in the homeostatic maintenance of post-embryonic tissue integrity. Wnt stabilizes cytoplasmic 3-catenin, which stimulates the expression of genes including c-myc, c jun, fra-1, and cyclin D1. In addition, misregulation of Wnt signaling can cause developmental defects and is implicated in the genesis of several human cancers. The Wnt pathway has also been implicated in the maintenance of stem or progenitor cells in a growing list of adult tissues including skin, blood, gut, prostate, muscle, and the nervous system.

SUMMARY

The present disclosure provides methods and reagents, involving contacting a cell with an agent, such as an indazole compound, in a sufficient amount to antagonize a Wnt activity, e.g., to reverse or control an aberrant growth state or correct a genetic disorder due to mutations in Wnt signaling components.

Some embodiments disclosed herein include Wnt inhibitors containing an indazole core. Other embodiments disclosed herein include pharmaceutical compositions and methods of treatment using these compounds.

One embodiment disclosed herein includes a compound having the structure of Formula I:

as well as prodrugs and pharmaceutically acceptable salts thereof.

In some embodiments of Formula (I):

R¹, R², and R⁴ are independently selected from the group consisting of H and halide;

R³ is selected from the group consisting of -heteroaryl(R⁶)_q and -heterocyclyl(R⁷)_h;

R⁵ is selected from the group consisting of -heteroaryl(R⁸)_q, -heterocyclyl(R⁹)_h, and -aryl(R¹⁰)_k;

each R⁶ is one substituent attached to the heteroaryl and is independently selected from the group consisting of halide, —(C_1-6 alkyl), —(C_1-4 alkylene)_pheterocyclyl(R¹¹)_h, —(C_1-4 alkylene)_pcarbocyclyl(R¹²)_j, —(C_1-4 alkylene)_paryl(R¹³)_k, —NHC(═O)R¹⁴, —NR¹⁵R¹⁶, —(C_1-6 alkylene)NR¹⁷R¹⁸, and —OR²⁴;

each R⁷ is one substituent attached to the heterocyclyl and is independently selected from the group consisting of —(C_1-4 alkyl), halide, —CF₃, and —CN;

each R⁸ is one substituent attached to the heteroaryl and is independently selected from the group consisting of —(C_1-6 alkyl), halide, —CF₃, —OCH₃, —CN, and —C(═O)R¹⁹;

each R⁹ is one substituent attached to the heterocyclyl and is independently selected from the group consisting of —(C_1-6 alkyl), halide, —CF₃, —CN, and —OCH₃;

each R¹⁰ is one substituent attached to the aryl and is independently selected from the group consisting of —(C_1-6 alkyl), halide, —CF₃, —CN, —OCH₃, —(C_1-6 alkylene)_pNHSO₂R¹⁹, —NR¹⁵(C_1-6 alkylene)NR¹⁵R¹⁶, —(C_1-6 alkylene)_pNR¹⁵R¹⁶, and —OR²⁷;

each R¹¹ is one substituent attached to the heterocyclyl and is independently selected from the group consisting of amino, —(C_1-4 alkyl), halide, —CF₃, and —CN;

each R¹² is one substituent attached to the carbocyclyl and is independently selected from the group consisting of —(C_1-4 alkyl), halide, —CF₃, and —CN;

each R¹³ is one substituent attached to the aryl and is independently selected from the group consisting of —(C_1-4 alkyl), halide, —CF₃, and —CN;

each R¹⁴ is independently selected from the group consisting of —(C_1-9 alkyl), -heteroaryl(R²⁰)_q, -aryl(R²¹)_k, —CH₂aryl(R²¹)_k, -carbocyclyl(R²²)_j, —CH₂carbocyclyl(R²²)_j, —(C_1-4 alkylene)_pNR²⁵R²⁶, -heterocyclyl(R²³)_h, and —CH₂heterocyclyl(R²³)_h;

each R¹⁵ is independently selected from the group consisting of H and —(C_1-6 alkyl);

each R¹⁶ is independently selected from the group consisting of H, —(C_1-6 alkyl), —CH₂aryl(R²¹)_k, and —CH₂carbocyclyl(R²²)_j;

each R¹⁷ is independently selected from the group consisting of H and —(C_1-6 alkyl);

each R¹⁸ is independently selected from the group consisting of H, —(C_1-6 alkyl), —CH₂aryl(R²¹)_k, and —CH₂carbocyclyl(R²²)_j;

each R¹⁹ is a —(C_1-6 alkyl);

each R²⁰ is one substituent attached to the heteroaryl and is independently selected from the group consisting of —(C_1-4 alkyl), halide, —CF₃, and —CN;

each R²¹ is one substituent attached to the aryl and is independently selected from the group consisting of —(C_1-4 alkyl), halide, —CF₃, and —CN;

each R²² is one substituent attached to the carbocyclyl and is independently selected from the group consisting of —(C_1-4 alkyl), halide, —CF₃, and —CN;

each R²³ is one substituent attached to the heterocyclyl and is independently selected from the group consisting of —(C_1-4 alkyl), halide, —CF₃, and —CN;

each R²⁴ is independently selected from the group consisting of H, —(C_1-6 alkyl), —(C_1-4 alkylene)_pheterocyclyl(R²³)_h, —(C_1-4 alkylene)_pcarbocyclyl(R²²)_j, —(C_1-4 alkylene)_paryl(R²¹)_k, and —(C_1-6 alkylene)_pNR²⁵R²⁶;

each R²⁵ is independently selected from the group consisting of H and —(C_1-6 alkyl);

each R²⁶ is independently selected from the group consisting of H and —(C_1-6 alkyl);

each R²⁷ is independently selected from the group consisting of H, —(C_1-6 alkyl), —(C_1-4 alkylene)_pheterocyclyl(R²³)_h, and —(C_1-6 alkylene)_pNR²⁵R²⁶;

each p is independently 0 or 1;

each q is independently 0 to 4;

each h is independently 0 to 10;

each k is independently 0 to 5; and

each j is independently 0 to 12.

Some embodiments include stereoisomers and pharmaceutically acceptable salts of a compound of Formula (I).

Some embodiments include pro-drugs of a compound of Formula (I).

Some embodiments of the present disclosure include pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier, diluent, or excipient.

Other embodiments disclosed herein include methods of inhibiting one or more members of the Wnt pathway, including one or more Wnt proteins by administering to a patient affected by a disorder or disease in which aberrant Wnt signaling is implicated, such as cancer and other diseases associated with abnormal angiogenesis, cellular proliferation, cell cycling and mutations in Wnt signaling components, a compound according to Formula (I). Accordingly, the compounds and compositions provided herein can be used to treat cancer, to reduce or inhibit angiogenesis, to reduce or inhibit cellular proliferation and correct a genetic disorder due to mutations in Wnt signaling components.

Non-limiting examples of diseases which can be treated with the compounds and compositions provided herein include a variety of cancers, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, mycotic and viral infections, osteochondrodysplasia, Alzheimer's disease, lung disease, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), polyposis coli, osteoporosis-pseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-Amelia syndrome, Müllerian-duct regression and virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease, and Rett syndrome.

Some embodiments of the present disclosure include methods to prepare compounds of Formula (I).

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.

DETAILED DESCRIPTION

Provided herein are compositions and methods for inhibiting one or more members of the Wnt pathway, including one or more Wnt proteins. Other Wnt inhibitors and methods for using the same are disclosed in U.S. application Ser. Nos. 12/852,706; 12/968,505; 13/552,188; 13/800,963; 13/855,874; 13/887,177 13/938,691; 13/938,692; 14/019,103; 14/019,147; 14/019,940; 14/149,948; 14/178,749; 14/331,427; and Ser. No. 14/334,005; and U.S. Provisional Application Ser. Nos. 61/232,603; 61/288,544; 61/305,459; 61/620,107; 61/642,915; and 61/750,221, all of which are incorporated by reference in their entirety herein.

Some embodiments provided herein relate to a method for treating a disease or disorder including, but not limited to, cancers, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, mycotic and viral infections, bone and cartilage diseases, Alzheimer's disease, lung disease, osteoarthritis, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), polyposis coli, bone density and vascular defects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG) and other eye diseases or syndromes associated with defects or damaged photoreceptors, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Müllerian-duct regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease, and Rett syndrome.

In some embodiments, non-limiting examples of bone and cartilage diseases which can be treated with the compounds and compositions provided herein include bone spur (osteophytes), craniosynostosis, fibrodysplasia ossificans progressive, fibrous dysplasia, giant cell tumor of bone, hip labral tear, meniscal tears, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), osteochondritis dissecans, osteochondroma (bone tumor), osteopetrosis, relapsing polychondritis, and Salter-Harris fractures.

In some embodiments, pharmaceutical compositions are provided that are effective for treatment of a disease of an animal, e.g., a mammal, caused by the pathological activation or mutations of the Wnt pathway. The composition includes a pharmaceutically acceptable carrier and a compound as described herein.

Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents, applications, published applications, and other publications are incorporated by reference in their entirety. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.

As used herein, “alkyl” means a branched, or straight chain chemical group containing only carbon and hydrogen, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, sec-pentyl and neo-pentyl. Alkyl groups can either be unsubstituted or substituted with one or more substituents. Alkyl groups can be saturated or unsaturated (e.g., containing —C═C— or —C≡C— subunits), at one or several positions. In some embodiments, alkyl groups include 1 to 9 carbon atoms (for example, 1 to 6 carbon atoms, 1 to 4 carbon atoms, or 1 to 2 carbon atoms).

As used herein, “alkylene” means a bivalent branched, or straight chain chemical group containing only carbon and hydrogen, such as methylene, ethylene, n-propylene, iso-propylene, n-butylene, iso-butylene, sec-butylene, tert-butylene, n-pentylene, iso-pentylene, sec-pentylene and neo-pentylene. Alkylene groups can either be unsubstituted or substituted with one or more substituents. Alkylene groups can be saturated or unsaturated (e.g., containing —C═C— or —C≡C— subunits), at one or several positions. In some embodiments, alkylene groups include 1 to 9 carbon atoms (for example, 1 to 6 carbon atoms, 1 to 4 carbon atoms, or 1 to 2 carbon atoms).

As used herein, “carbocyclyl” means a cyclic ring system containing only carbon atoms in the ring system backbone, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclohexenyl. Carbocyclyls may include multiple fused rings. Carbocyclyls may have any degree of saturation provided that at least one ring in the ring system is not aromatic. Carbocyclyl groups can either be unsubstituted or substituted with one or more substituents. In some embodiments, carbocyclyl groups include 3 to 10 carbon atoms, for example, 3 to 6 carbon atoms.

As used herein, “lower alkyl” means a subset of alkyl having 1 to 3 carbon atoms, which is linear or branched. Examples of lower alkyls include methyl, ethyl, n-propyl and isopropyl. Likewise, radicals using the terminology “lower” refer to radicals having 1 to about 3 carbons in the alkyl portion of the radical.

As used herein, “aryl” means a mono-, bi-, tri- or polycyclic group with only carbon atoms present in the ring backbone having 5 to 14 ring atoms, alternatively 5, 6, 9, or 10 ring atoms; and having 6, 10, or 14 pi electrons shared in a cyclic array; wherein at least one ring in the system is aromatic. Aryl groups can either be unsubstituted or substituted with one or more substituents. Examples of aryl include phenyl, naphthyl, tetrahydronaphthyl, 2,3-dihydro-1H-indenyl, and others. In some embodiments, the aryl is phenyl.

As used herein, “arylalkylene” means an aryl-alkylene-group in which the aryl and alkylene moieties are as previously described. In some embodiments, arylalkylene groups contain a C_1-4alkylene moiety. Exemplary arylalkylene groups include benzyl and 2-phenethyl.

As used herein, the term “heteroaryl” means a mono-, bi-, tri- or polycyclic group having 5 to 14 ring atoms, alternatively 5, 6, 9, or 10 ring atoms; and having 6, 10, or 14 pi electrons shared in a cyclic array; wherein at least one ring in the system is aromatic, and at least one ring in the system contains one or more heteroatoms independently selected from the group consisting of N, O, and S. Heteroaryl groups can either be unsubstituted or substituted with one or more substituents. Examples of heteroaryl include thienyl, pyridinyl, furyl, oxazolyl, oxadiazolyl, pyrrolyl, imidazolyl, triazolyl, thiodiazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyranyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thiazolyl benzothienyl, benzoxadiazolyl, benzofuranyl, benzimidazolyl, benzotriazolyl, cinnolinyl, indazolyl, indolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, purinyl, thienopyridinyl, pyrido[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl, quinolinyl, thieno[2,3-c]pyridinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-c]pyridinyl, pyrazolo[4,3-c]pyridine, pyrazolo[4,3-b]pyridinyl, tetrazolyl, chromane, 2,3-dihydrobenzo[b][1,4]dioxine, benzo[d][1,3]dioxole, 2,3-dihydrobenzofuran, tetrahydroquinoline, 2,3-dihydrobenzo[b][1,4]oxathiine, and others. In some embodiments, the heteroaryl is selected from thienyl, pyridinyl, furyl, pyrazolyl, imidazolyl, pyranyl, pyrazinyl, and pyrimidinyl.

As used herein, “halo”, “halide” or “halogen” is a chloro, bromo, fluoro, or iodo atom radical. In some embodiments, a halo is a chloro, bromo or fluoro. For example, a halide can be fluoro.

As used herein, “haloalkyl” means a hydrocarbon substituent, which is a linear or branched, alkyl, alkenyl or alkynyl substituted with one or more chloro, bromo, fluoro, and/or iodo atom(s). In some embodiments, a haloalkyl is a fluoroalkyls, wherein one or more of the hydrogen atoms have been substituted by fluoro. In some embodiments, haloalkyls are of 1 to about 3 carbons in length (e.g., 1 to about 2 carbons in length or 1 carbon in length). The term “haloalkylene” means a diradical variant of haloalkyl, and such diradicals may act as spacers between radicals, other atoms, or between a ring and another functional group.

As used herein, “heterocyclyl” means a nonaromatic cyclic ring system comprising at least one heteroatom in the ring system backbone. Heterocyclyls may include multiple fused rings. Heterocyclyls may be substituted or unsubstituted with one or more substituents. In some embodiments, heterocycles have 5-7 members. In six membered monocyclic heterocycles, the heteroatom(s) are selected from one to three of O, N or S, and wherein when the heterocycle is five membered, it can have one or two heteroatoms selected from O, N, or S. Examples of heterocyclyl include azirinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, 1,4,2-dithiazolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, morpholinyl, thiomorpholinyl, piperazinyl, pyranyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyridinyl, oxazinyl, thiazinyl, thiinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, piperidinyl, pyrazolidinyl imidazolidinyl, thiomorpholinyl, and others. In some embodiments, the heterocyclyl is selected from azetidinyl, morpholinyl, piperazinyl, pyrrolidinyl, and tetrahydropyridinyl.

As used herein, “monocyclic heterocyclyl” means a single nonaromatic cyclic ring comprising at least one heteroatom in the ring system backbone. Heterocyclyls may be substituted or unsubstituted with one or more substituents. In some embodiments, heterocycles have 5-7 members. In six membered monocyclic heterocycles, the heteroatom(s) are selected from one to three of O, N or S, and wherein when the heterocycle is five membered, it can have one or two heteroatoms selected from O, N, or S. Examples of heterocyclyl include azirinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, 1,4,2-dithiazolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, morpholinyl, thiomorpholinyl, piperazinyl, pyranyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyridinyl, oxazinyl, thiazinyl, thiinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, piperidinyl, pyrazolidinyl imidazolidinyl, thiomorpholinyl, and others.

The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more non-hydrogen atoms of the molecule. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. Substituents can include, for example, —(C_1-9 alkyl) optionally substituted with one or more of hydroxyl, —NH₂, —NH(C_1-3 alkyl), and —N(C_1-3 alkyl)₂; —(C_1-9 haloalkyl); a halide; a hydroxyl; a carbonyl [such as —C(O)OR, and —C(O)R]; a thiocarbonyl [such as —C(S)OR, —C(O)SR, and —C(S)R]; —(C_1-9 alkoxyl) optionally substituted with one or more of halide, hydroxyl, —NH₂, —NH(C_1-3 alkyl), and —N(C_1-3 alkyl)₂; —OPO(OH)₂; a phosphonate [such as —PO(OH)₂ and —PO(OR′)₂]; —OPO(OR′)R″; —NRR′; —C(O)NRR′; —C(NR)NR′R″; —C(NR′)R″; a cyano; a nitro; an azido; —SH; —S—R; —OSO₂(OR); a sulfonate [such as —SO₂(OH) and —SO₂(OR)]; —SO₂NR′R″; and —SO₂R; in which each occurrence of R, R′ and R″ are independently selected from H; —(C_1-9 alkyl); C_6-10 aryl optionally substituted with from 1-3R′″; 5-10 membered heteroaryl having from 1-4 heteroatoms independently selected from N, O, and S and optionally substituted with from 1-3 R′″; C_3-7 carbocyclyl optionally substituted with from 1-3 R′″; and 3-8 membered heterocyclyl having from 1-4 heteroatoms independently selected from N, O, and S and optionally substituted with from 1-3 R′″; wherein each R′″ is independently selected from —(C_1-6 alkyl), —(C_1-6 haloalkyl), a halide (e.g., F), a hydroxyl, —C(O)OR, —C(O)R, —(C_1-6 alkoxyl), —NRR′, —C(O)NRR′, and a cyano, in which each occurrence of R and R′ is independently selected from H and —(C_1-6 alkyl). In some embodiments, the substituent is selected from —(C_1-6 alkyl), —(C_1-6 haloalkyl), a halide (e.g., F), a hydroxyl, —C(O)OR, —C(O)R, —(C_1-6 alkoxyl), —NRR′, —C(O)NRR′, and a cyano, in which each occurrence of R and R′ is independently selected from H and —(C_1-6 alkyl).

As used herein, when two groups are indicated to be “linked” or “bonded” to form a “ring”, it is to be understood that a bond is formed between the two groups and may involve replacement of a hydrogen atom on one or both groups with the bond, thereby forming a carbocyclyl, heterocyclyl, aryl, or heteroaryl ring. The skilled artisan will recognize that such rings can and are readily formed by routine chemical reactions. In some embodiments, such rings have from 3-7 members, for example, 5 or 6 members.

The skilled artisan will recognize that some structures described herein may be resonance forms or tautomers of compounds that may be fairly represented by other chemical structures, even when kinetically, the artisan recognizes that such structures are only a very small portion of a sample of such compound(s). Such compounds are clearly contemplated within the scope of this disclosure, though such resonance forms or tautomers are not represented herein.

The compounds provided herein may encompass various stereochemical forms. The compounds also encompass diastereomers as well as optical isomers, e.g., mixtures of enantiomers including racemic mixtures, as well as individual enantiomers and diastereomers, which arise as a consequence of structural asymmetry in certain compounds. Separation of the individual isomers or selective synthesis of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art. Unless otherwise indicated, when a disclosed compound is named or depicted by a structure without specifying the stereochemistry and has one or more chiral centers, it is understood to represent all possible stereoisomers of the compound.

The term “administration” or “administering” refers to a method of providing a dosage of a compound or pharmaceutical composition to a vertebrate or invertebrate, including a mammal, a bird, a fish, or an amphibian, where the method is, e.g., orally, subcutaneously, intravenously, intralymphatic, intranasally, topically, transdermally, intraperitoneally, intramuscularly, intrapulmonarilly, vaginally, rectally, ontologically, neuro-otologically, intraocularly, subconjuctivally, via anterior eye chamber injection, intravitreally, intraperitoneally, intrathecally, intracystically, intrapleurally, via wound irrigation, intrabuccally, intra-abdominally, intra-articularly, intra-aurally, intrabronchially, intracapsularly, intrameningeally, via inhalation, via endotracheal or endobronchial instillation, via direct instillation into pulmonary cavities, intraspinally, intrasynovially, intrathoracically, via thoracostomy irrigation, epidurally, intratympanically, intracisternally, intravascularly, intraventricularly, intraosseously, via irrigation of infected bone, or via application as part of any admixture with a prosthetic device. The method of administration can vary depending on various factors, e.g., the components of the pharmaceutical composition, the site of the disease, the disease involved, and the severity of the disease.

A “diagnostic” as used herein is a compound, method, system, or device that assists in the identification or characterization of a health or disease state. The diagnostic can be used in standard assays as is known in the art.

The term “mammal” is used in its usual biological sense. Thus, it specifically includes humans, cattle, horses, monkeys, dogs, cats, mice, rats, cows, sheep, pigs, goats, and non-human primates, but also includes many other species.

The term “pharmaceutically acceptable carrier”, “pharmaceutically acceptable diluent” or “pharmaceutically acceptable excipient” includes any and all solvents, co-solvents, complexing agents, dispersion media, coatings, isotonic and absorption delaying agents and the like which are not biologically or otherwise undesirable. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. In addition, various adjuvants such as are commonly used in the art may be included. These and other such compounds are described in the literature, e.g., in the Merck Index, Merck & Company, Rahway, N.J. Considerations for the inclusion of various components in pharmaceutical compositions are described, e.g., in Gilman et al. (Eds.) (2010); Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 12th Ed., The McGraw-Hill Companies.

The term “pharmaceutically acceptable salt” refers to salts that retain the biological effectiveness and properties of the compounds provided herein and, which are not biologically or otherwise undesirable. In many cases, the compounds provided herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto. Many such salts are known in the art, for example, as described in WO 87/05297. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.

“Solvate” refers to the compound formed by the interaction of a solvent and a compound as provided herein or a salt thereof. Suitable solvates are pharmaceutically acceptable solvates including hydrates.

“Patient” as used herein, means a human or a non-human mammal, e.g., a dog, a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, a non-human primate, or a bird, e.g., a chicken, as well as any other vertebrate or invertebrate. In some embodiments, the patient is a human.

A “therapeutically effective amount” or “pharmaceutically effective amount” of a compound as provided herein is one which is sufficient to achieve the desired physiological effect and may vary according to the nature and severity of the disease condition, and the potency of the compound. “Therapeutically effective amount” is also intended to include one or more of the compounds of Formula I in combination with one or more other agents that are effective to treat the diseases and/or conditions described herein. The combination of compounds can be a synergistic combination. Synergy, as described, for example, by Chou and Talalay, Advances in Enzyme Regulation (1984), 22, 27-55, occurs when the effect of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at sub-optimal concentrations of the compounds. It will be appreciated that different concentrations may be employed for prophylaxis than for treatment of an active disease. This amount can further depend upon the patient's height, weight, sex, age and medical history.

A therapeutic effect relieves, to some extent, one or more of the symptoms of the disease.

“Treat,” “treatment,” or “treating,” as used herein refers to administering a compound or pharmaceutical composition as provided herein for therapeutic purposes. The term “therapeutic treatment” refers to administering treatment to a patient already suffering from a disease thus causing a therapeutically beneficial effect, such as ameliorating existing symptoms, ameliorating the underlying metabolic causes of symptoms, postponing or preventing the further development of a disorder, and/or reducing the severity of symptoms that will or are expected to develop.

“Drug-eluting” and/or controlled release as used herein refers to any and all mechanisms, e.g., diffusion, migration, permeation, and/or desorption by which the drug(s) incorporated in the drug-eluting material pass therefrom over time into the surrounding body tissue.

“Drug-eluting material” and/or controlled release material as used herein refers to any natural, synthetic or semi-synthetic material capable of acquiring and retaining a desired shape or configuration and into which one or more drugs can be incorporated and from which incorporated drug(s) are capable of eluting over time.

“Elutable drug” as used herein refers to any drug or combination of drugs having the ability to pass over time from the drug-eluting material in which it is incorporated into the surrounding areas of the body.

Compounds

The compounds and compositions described herein can be used as anti-proliferative agents, e.g., anti-cancer and anti-angiogenesis agents, and/or as inhibitors of the Wnt signaling pathway, e.g., for treating diseases or disorders associated with aberrant Wnt signaling. In addition, the compounds can be used as inhibitors of one or more kinases, kinase receptors, or kinase complexes. Such compounds and compositions are also useful for controlling cellular proliferation, differentiation, and/or apoptosis.

Some embodiments of the present disclosure include compounds of Formula I:

or salts, pharmaceutically acceptable salts, or prodrugs thereof.

In some embodiments, R¹, R², and R⁴ are independently selected from the group consisting of H and halide.

In some embodiments, R³ is selected from the group consisting of -pyridinyl(R⁶)_q and -pyrimidinyl(R⁷)_q.

In some embodiments, R³ is selected from the group consisting of -piperidinyl(R⁷)_h and -tetrahydropyridinyl(R⁷)_h.

In some embodiments, R³ is selected from the group consisting of -pyridinyl(R⁶), -pyrimidinyl(R⁶)_q, -pyrazinyl(R⁶)_q, -pyrazolyl(R⁶)_q, and -imidazolyl(R⁶)_q.

In some embodiments, R³ is selected from the group consisting of -heteroaryl(R⁶)_q and -heterocyclyl(R⁷)_h.

In some embodiments, R⁵ is selected from the group consisting of -heteroaryl(R⁸)_q, -heterocyclyl(R⁹)_h, and -aryl(R¹⁰)_k.

In some embodiments, R⁵ is selected from the group consisting of -pyridinyl(R⁸)_q, -imidazolyl(R⁸)_q, -furanyl(R⁸)_q, -thiophenyl(R⁸)_q, -piperidinyl(R⁹)_h, -piperazinyl(R⁹)_h, and -phenyl(R¹⁰)_k.

In some embodiments, each R⁶ is one substituent attached to the pyridinyl and is independently selected from the group consisting of H, halide, —(C_1-6 alkyl), —(C_1-4 alkylene)_pheterocyclyl(R¹¹)_h, —(C_1-4 alkylene)_pcarbocyclyl(R¹²)_j, —(C_1-4 alkylene)_paryl(R¹³)_k, —NHC(═O)R¹⁴, —NR¹⁵R¹⁶, —(C_1-6 alkylene)NR¹⁷R¹⁸, and —OR²⁴.

In some embodiments, each R⁶ is one substituent attached to the pyridinyl and is independently selected from the group consisting of halide, —(C_1-6 alkyl), —(C_1-4 alkylene)_pheterocyclyl(R¹¹)_h, —(C_1-4 alkylene)_pcarbocyclyl(R¹²)_j, —(C_1-4 alkylene)_paryl(R¹³)_k, —NHC(═O)R¹⁴, —NR¹⁵R¹⁶, —(C_1-6 alkylene)NR¹⁷R¹⁸, and —OR²⁴.

In some embodiments, each R⁶ is one substituent attached to the heteroaryl and is independently selected from the group consisting of H, halide, —(C_1-6 alkyl), —(C_1-4 alkylene)_pheterocyclyl(R¹¹)_h, —(C_1-4 alkylene)_pcarbocyclyl(R¹²)_j, —(C_1-4 alkylene)_paryl(R¹³)_k, —NHC(═O)R¹⁴, —NR¹⁵R¹⁶, —(C_1-6 alkylene)NR¹⁷R¹⁸, and —OR²⁴.

In some embodiments, each R⁶ is one substituent attached to the heteroaryl and is independently selected from the group consisting of halide, —(C_1-6 alkyl), —(C_1-4 alkylene)_pheterocyclyl(R¹¹)_h, —(C_1-4 alkylene)_pcarbocyclyl(R¹²)_j, —(C_1-4 alkylene)_paryl(R¹³)_k, —NHC(═O)R¹⁴, —NR¹⁵R¹⁶, —(C_1-6 alkylene)NR¹⁷R¹⁸, and —OR²⁴.

In some embodiments, each R⁶ is one substituent attached to the heteroaryl and is independently selected from the group consisting of F, -Me, -Et, —(CH₂)heterocyclyl(R¹¹)_h, -heterocyclyl(R¹¹)_h, —(CH₂)carbocyclyl(R¹²)_j, —(CH₂)aryl(R¹³)_k, —NHC(═O)(C_1-5 alkyl), —NHC(═O)phenyl(R²¹)_k, —NHC(═O)(CH₂)phenyl(R²¹)_k, —NHC(═O)carbocyclyl(R²²)_j, —NHC(═O)(CH₂)heterocyclyl(R²³)_h, —NH₂, —N(C_1-3 alkyl)₂, —NH(C_1-4 alkyl), —(CH₂)N(C_1-3 alkyl)₂, —(CH₂)NH(C_1-4 alkyl), —OH, —O(C_1-3 alkyl), —Ocarbocyclyl(R²²)_j, —Oheterocyclyl(R²³)_h, —O(CH₂CH₂)heterocyclyl(R²³)_h, —O(CH₂CH₂)N(C_1-3 alkyl)₂, and —O(CH₂)phenyl(R²¹)_k.

In some embodiments, each R⁷ is one substituent attached to the pyrimidinyl and is independently selected from the group consisting of H, halide, —(C_1-6 alkyl), —(C_1-4 alkylene)_pheterocyclyl(R¹¹)_h, —(C_1-4 alkylene)_pcarbocyclyl(R¹²)_j, —(C_1-4 alkylene)_paryl(R¹³)_k, —NHC(═O)R¹⁴, —NR¹⁵R¹⁶, —(C_1-6 alkylene)NR¹⁷R¹⁸, and —OR²⁴.

In some embodiments, each R⁷ is one substituent attached to the pyrimidinyl and is independently selected from the group consisting of halide, —(C_1-6 alkyl), —(C_1-4 alkylene)_pheterocyclyl(R¹¹)_h, —(C_1-4 alkylene)_pcarbocyclyl(R¹²)_j, —(C_1-4 alkylene)_paryl(R¹³)_k, —NHC(═O)R¹⁴, —NR¹⁵R¹⁶, —(C_1-6 alkylene)NR¹⁷R¹⁸, and —OR²⁴.

In some embodiments, each R⁷ is one substituent attached to the pyrimidinyl and is independently selected from the group consisting of H, —(C_1-4 alkyl), halide, —CF₃, and —CN.

In some embodiments, each R⁷ is one substituent attached to the heterocyclyl and is independently selected from the group consisting of —(C_1-4 alkyl), halide, —CF₃, and —CN.

In some embodiments, each R⁸ is one substituent attached to the heteroaryl and is independently selected from the group consisting of H, —(C_1-6 alkyl), halide, —CF₃, —OCH₃, —CN, and —C(═O)R⁹.

In some embodiments, each R⁸ is one substituent attached to the heteroaryl and is independently selected from the group consisting of —(C_1-6 alkyl), halide, —CF₃, —OCH₃, —CN, and —C(═O)R¹⁹.

In some embodiments, each R⁸ is one substituent attached to the heteroaryl and is independently selected from the group consisting of H, -Me, -Et, F, —CF₃, —OCH₃, —CN, and —C(═O)(C_1-3 alkyl).

In some embodiments, each R⁸ is one substituent attached to the heteroaryl and is independently selected from the group consisting of -Me, -Et, F, —CF₃, —OCH₃, —CN, and —C(═O)(C_1-3 alkyl).

In some embodiments, each R⁹ is one substituent attached to the heterocyclyl and is independently selected from the group consisting of H, —(C_1-6 alkyl), halide, —CF₃, —CN, and —OCH₃.

In some embodiments, each R⁹ is one substituent attached to the heterocyclyl and is independently selected from the group consisting of —(C_1-6 alkyl), halide, —CF₃, —CN, and —OCH₃.

In some embodiments, each R¹⁰ is one substituent attached to the aryl and is independently selected from the group consisting of H, —(C_1-6 alkyl), halide, —CF₃, —CN, —OCH₃, —(C_1-6 alkylene)_pNHSO₂R¹⁹, —NR¹⁵(C_1-6 alkylene)NR¹⁵R¹⁶, —(C_1-6 alkylene)_pNR¹⁵R¹⁶, and —OR²⁷.

In some embodiments, each R¹⁰ is one substituent attached to the aryl and is independently selected from the group consisting of —(C_1-6 alkyl), halide, —CF₃, —CN, —OCH₃, —(C_1-6 alkylene)_pNHSO₂R¹⁹, —NR¹⁵(C_1-6 alkylene)NR¹⁵R¹⁶, —(C_1-6 alkylene)_pNR¹⁵R¹⁶, and —OR²⁷.

In some embodiments, each R¹⁰ is one substituent attached to the aryl and is independently selected from the group consisting of H, -Me, -Et, F, —CF₃, —CN, —OCH₃, —(CH₂CH₂)NHSO₂(C_1-3 alkyl), —NH(CH₂CH₂)N(C_1-3 alkyl)₂, —OH, —O(C_1-3 alkyl), —O(CH₂CH₂)heterocyclyl(R²³)_h, and —O(CH₂CH₂)N(C_1-3 alkyl)₂.

In some embodiments, each R¹⁰ is one substituent attached to the aryl and is independently selected from the group consisting of -Me, -Et, F, —CF₃, —CN, —OCH₃, —(CH₂CH₂)NHSO₂(C_1-3 alkyl), —NH(CH₂CH₂)N(C_1-3 alkyl)₂, —OH, —O(C_1-3 alkyl), —O(CH₂CH₂)heterocyclyl(R²³)_h, and —O(CH₂CH₂)N(C_1-3 alkyl)₂.

In some embodiments, each R¹¹ is one substituent attached to the heterocyclyl and is independently selected from the group consisting of H, amino, —(C_1-4 alkyl), halide, —CF₃, and —CN.

In some embodiments, each R¹¹ is one substituent attached to the heterocyclyl and is independently selected from the group consisting of amino, —(C_1-4 alkyl), halide, —CF₃, and —CN.

In some embodiments, each R¹¹ is one substituent attached to the heterocyclyl and is independently selected from the group consisting of amino, Me, Et, F, Cl, and —CF₃.

In some embodiments, each R¹² is one substituent attached to the carbocyclyl and is independently selected from the group consisting of H, —(C_1-4 alkyl), halide, —CF₃, and —CN.

In some embodiments, each R¹² is one substituent attached to the carbocyclyl and is independently selected from the group consisting of —(C_1-4 alkyl), halide, —CF₃, and —CN.

In some embodiments, each R¹² is one substituent attached to the carbocyclyl and is independently selected from the group consisting of Me, Et, F, Cl, and —CF₃.

In some embodiments, each R¹³ is one substituent attached to the aryl and is independently selected from the group consisting of H, —(C_1-4 alkyl), halide, —CF₃, and —CN.

In some embodiments, each R¹³ is one substituent attached to the aryl and is independently selected from the group consisting of —(C_1-4 alkyl), halide, —CF₃, and —CN.

In some embodiments, each R¹³ is one substituent attached to the aryl and is independently selected from the group consisting of Me, Et, F, Cl, and —CF₃.

In some embodiments, each R¹⁴ is independently selected from the group consisting of —(C_1-9 alkyl), -heteroaryl(R²⁰)_q, -aryl(R²¹)_k, —CH₂aryl(R²¹)_k, -carbocyclyl(R²²)_j, and —CH₂carbocyclyl(R²²)_j.

In some embodiments, each R¹⁴ is independently selected from the group consisting of —(C_1-9 alkyl), -heteroaryl(R²⁰)_q, -aryl(R²¹)_k, —CH₂aryl(R²¹)_k, -carbocyclyl(R²²)_j, —CH₂carbocyclyl(R²²)_j, —(C_1-4 alkylene)_pNR²⁵R²⁶, -heterocyclyl(R²³)_h, and —CH₂heterocyclyl(R²³)_h.

In some embodiments, each R¹⁴ is independently selected from the group consisting of —(C_1-5 alkyl), -phenyl(R²¹)_k, —(CH₂)phenyl(R²¹)_k, -carbocyclyl(R²²)_j, —(CH₂)carbocyclyl(R²²)_j, —(CH₂)N(C_1-3 alkyl)₂, and —(CH₂)heterocyclyl(R²³)_h.

In some embodiments, each R¹⁵ is independently selected from the group consisting of H and —(C_1-6 alkyl).

In some embodiments, each R¹⁵ is independently selected from the group consisting of H and —(C_1-3 alkyl).

In some embodiments, each R¹⁶ is independently selected from the group consisting of H, —(C_1-6 alkyl), —CH₂aryl(R²¹)_k, and —CH₂carbocyclyl(R²²)_j.

In some embodiments, each R¹⁶ is independently selected from the group consisting of H, —(C_1-3 alkyl), —CH₂phenyl(R²¹)_k, and —CH₂carbocyclyl(R²²)_j.

In some embodiments, each R¹⁷ is independently selected from the group consisting of H and —(C_1-6 alkyl).

In some embodiments, each R¹⁷ is independently selected from the group consisting of H and —(C_1-3 alkyl).

In some embodiments, each R¹⁸ is independently selected from the group consisting of H, —(C_1-6 alkyl), —CH₂aryl(R²¹)_k, and —CH₂carbocyclyl(R²²)_j.

In some embodiments, each R¹⁸ is independently selected from the group consisting of H, —(C_1-3 alkyl), —CH₂phenyl(R²¹)_k, and —CH₂carbocyclyl(R²²)_j.

In some embodiments, each R¹⁹ is independently a —(C_1-6 alkyl).

In some embodiments, each R¹⁹ is independently a —(C_1-3 alkyl).

In some embodiments, each R²⁰ is one substituent attached to the heteroaryl and is independently selected from the group consisting of H, —(C_1-4 alkyl), halide, —CF₃, and —CN.

In some embodiments, each R²⁰ is one substituent attached to the heteroaryl and is independently selected from the group consisting of —(C_1-4 alkyl), halide, —CF₃, and —CN.

In some embodiments, each R²⁰ is one substituent attached to the heteroaryl and is independently selected from the group consisting of Me, Et, F, Cl, and —CF₃.

In some embodiments, each R²¹ is one substituent attached to the aryl and is independently selected from the group consisting of H, —(C_1-4 alkyl), halide, —CF₃, and —CN.

In some embodiments, each R²¹ is one substituent attached to the aryl and is independently selected from the group consisting of —(C_1-4 alkyl), halide, —CF₃, and —CN.

In some embodiments, each R²¹ is one substituent attached to the aryl and is independently selected from the group consisting of Me, Et, F, Cl, and —CF₃.

In some embodiments, each R²² is one substituent attached to the carbocyclyl and is independently selected from the group consisting of H, —(C_1-4 alkyl), halide, —CF₃, and —CN.

In some embodiments, each R²² is one substituent attached to the carbocyclyl and is independently selected from the group consisting of —(C_1-4 alkyl), halide, —CF₃, and —CN.

In some embodiments, each R²² is one substituent attached to the carbocyclyl and is independently selected from the group consisting of Me, Et, F, Cl, and —CF₃.

In some embodiments, each R²³ is one substituent attached to the heterocyclyl and is independently selected from the group consisting of H, —(C_1-4 alkyl), halide, —CF₃, and —CN.

In some embodiments, each R²³ is one substituent attached to the heterocyclyl and is independently selected from the group consisting of —(C_1-4 alkyl), halide, —CF₃, and —CN.

In some embodiments, each R²³ is one substituent attached to the heterocyclyl and is independently selected from the group consisting of Me, Et, F, Cl, and —CF₃.

In some embodiments, R²⁴ is selected from the group consisting of H, —(C_1-6 alkyl), —(C_1-4 alkylene)_pheterocyclyl(R²³)_h, —(C_1-4 alkylene)_pcarbocyclyl(R²²)_j, —(C_1-4 alkylene)_paryl(R²¹)_k, and —(C_1-6 alkylene)_pNR²⁵R²⁶.

In some embodiments, R²⁴ is selected from the group consisting of H, -Me, -Et, -iPr, -heterocyclyl(R²³)_h, —(CH₂CH₂)heterocyclyl(R²³)_h, -carbocyclyl(R²²)_j, —(CH₂)phenyl(R²¹)_k, and —(CH₂CH₂)N(C_1-3 alkyl)₂.

In some embodiments, each R²⁵ is independently selected from the group consisting of H and —(C_1-6 alkyl).

In some embodiments, each R²⁵ is independently selected from the group consisting of Me and Et.

In some embodiments, each R²⁶ is independently selected from the group consisting of H and —(C_1-6 alkyl).

In some embodiments, each R²⁶ is independently selected from the group consisting of Me and Et.

In some embodiments, R²⁷ is selected from the group consisting of H, —(C_1-6 alkyl), —(C_1-4 alkylene)_pheterocyclyl(R²³)_h, and —(C_1-6 alkylene)_pNR²⁵R²⁶.

In some embodiments, R²⁷ is selected from the group consisting of H, -Me, -Et, -iPr, —(CH₂CH₂)heterocyclyl(R²³)_h, and —(CH₂CH₂)N(C_1-3 alkyl)₂.

In some embodiments, each p is independently 0 or 1; in some embodiments, each p is 0; in some embodiments, each p is 1.

In some embodiments, each q is independently 0 to 4; in some embodiments, each q is 0; in some embodiments, each q is 1; in some embodiments, each q is 2; in some embodiments, each q is 3; in some embodiments, each q is 4.

In some embodiments, each h is independently 0 to 10; in some embodiments, each h is 0; in some embodiments, each h is 1; in some embodiments, each h is 2; in some embodiments, each h is 3; in some embodiments, each h is 4.

In some embodiments, each k is independently 0 to 5; in some embodiments, each k is 0; in some embodiments, each k is 1; in some embodiments, each k is 2; in some embodiments, each k is 3.

In some embodiments, each j is independently 0 to 12; in some embodiments, each j is 0; in some embodiments, each j is 1; in some embodiments, each j is 2; in some embodiments, each j is 3; in some embodiments, each j is 4.

In some embodiments, each R⁶ is one substituent attached to the heteroaryl and is selected from the group consisting of —(C_1-3 alkyl), —CH₂heterocyclyl(R¹¹)_h, —NHC(═O)R¹⁴, —NR¹⁵R¹⁶, and —CH₂NR¹⁷R¹⁸.

In some embodiments, at least one R¹¹ is halide.

In some embodiments, R¹⁴ is selected from the group consisting of —(C_1-5 alkyl), -phenyl(R²¹)_k, —CH₂phenyl(R²¹)_k, and -carbocyclyl(R²²)_j.

In some embodiments, each R¹⁵ and R¹⁶ are independently selected from H and —(C_1-5 alkyl).

In some embodiments, each R¹⁷ and R¹⁸ are independently selected from H and —(C_1-5 alkyl).

In some embodiments, k is 1 or 2 and each R¹⁰ is independently a halide.

In some embodiments, k is 2 and one R¹⁰ is halide and the other R¹⁰ is —CH₂NHSO₂R¹⁹.

In some embodiments, R¹⁹ is —(C_1-3 alkyl).

In some embodiments, k is 2 and one R¹⁰ is halide and the other R¹⁰ is —NHCH₂CH₂NR¹⁵R¹⁶.

In some embodiments, each R¹⁵ and R¹⁶ are independently selected from H and —(C_1-3 alkyl).

In some embodiments, R⁵ is selected from the group consisting of -pyridinyl(R⁸)_q, -imidazolyl(R⁸)_q, -furanyl(R⁸)_q, and -thiophenyl(R⁸)_q.

In some embodiments, q is 1, and R⁸ is selected from the group consisting of halide, —(C_1-3 alkyl), —C(═O)R¹⁹, and R¹⁹ is —(C_1-2 alkyl).

In some embodiments, R⁵ is selected from the group consisting of -piperidinyl(R⁹)_h and -piperazinyl(R⁹)_h.

In some embodiments, q is 1, and R⁹ is a —(C_1-3 alkyl).

In some embodiments, R¹ is H; in other embodiments, R¹ is halide, e.g. F.

In some embodiments, R² is H; in other embodiments, R² is halide, e.g. F.

In some embodiments, R⁴ is H; in other embodiments, R⁴ is halide, e.g. F.

In some embodiments, R² and R⁴ are H, and R¹ is F; in some embodiments, R¹ and R⁴ are H, and R² is F; in some embodiments, R¹ and R² are H, and R⁴ is F; in some embodiments, R² and R⁴ are F, and R¹ is H; in some embodiments, R¹ and R⁴ are F, and R² is H; in some embodiments, R¹ and R² are F, and R⁴ is H; in some embodiments, R¹, R², and R⁴ are H; in some embodiments, R¹, R², and R⁴ are F.

In some embodiments, R³ is -heteroaryl(R⁶)_q.

In some embodiments, R³ is -pyridinyl(R⁶)_q.

In some embodiments, R³ is -pyridin-3-yl(R⁶)_q.

In some embodiments, R³ is -pyrimidinyl(R⁶)_q.

In some embodiments, R³ is -pyrimidin-5-yl(R⁶)_q.

In some embodiments, R³ is -pyrimidin-5-yl(R⁶)_q and q is 0.

In some embodiments, R³ is -pyrazinyl(R⁶)_q.

In some embodiments, R³ is -pyrazolyl(R⁶)_q.

In some embodiments, R³ is -pyrazol-4-yl(R⁶)_q, q is 1, and R⁶ is Me.

In some embodiments, R³ is -pyrazol-4-yl(R⁶)_q and q is 0.

In some embodiments, R³ is -imidazolyl(R⁶)_q.

In some embodiments, R³ is -imidazol-5-yl(R⁶)_q, q is 1, and R⁶ is Me.

In some embodiments, R³ is -imidazol-5-yl(R⁶)_q, q is 2, and both R⁶ are Me.

In some embodiments, R³ is -heterocyclyl(R⁷)_h.

In some embodiments, R³ is -piperidinyl(R⁷)_h.

In some embodiments, R³ is -piperidin-4-yl(R⁷)_h.

In some embodiments, R³ is -piperidin-4-yl(R⁷)_h, and h is 0.

In some embodiments, R³ is -tetrahydropyridinyl(R⁷)_h.

In some embodiments, R³ is -1,2,3,6-tetrahydropyridinyl(R⁷)_h.

In some embodiments, R³ is -1,2,3,6-tetrahydropyridinyl(R⁷)_h, and h is 0.

In some embodiments, R⁵ is -heteroaryl(R⁸)_q.

In some embodiments, R⁵ is -heterocyclyl(R⁹)_h.

In some embodiments, R⁵ is -piperidinyl(R⁹)_h.

In some embodiments, R⁵ is -piperazinyl(R⁹)_h.

In some embodiments, R⁵ is -aryl(R¹⁰)_k.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k.

In some embodiments, R⁵ is -pyridinyl(R⁸)_q.

In some embodiments, R⁵ is -pyridin-3-yl(R⁸)_q.

In some embodiments, R⁵ is -pyridin-4-yl(R⁸)_q.

In some embodiments, R⁵ is -pyridin-5-yl(R⁸)_q.

In some embodiments, R⁵ is -pyridin-3-yl(R⁸)_q and q is 0.

In some embodiments, R⁵ is -pyridin-4-yl(R⁸)_q and q is 0.

In some embodiments, R⁵ is -pyridin-5-yl(R⁸)_q and q is 0.

In some embodiments, R⁵ is -imidazolyl(R⁸)_q.

In some embodiments, R⁵ is -imidazol-1-yl(R⁸)_q, q is 1, and R⁸ is —(C_1-3 alkyl).

In some embodiments, R⁵ is -imidazol-1-yl(R⁸)_q, q is 1, and R⁸ is methyl.

In some embodiments, R⁵ is -furanyl(R⁸)_q.

In some embodiments, R⁵ is -furan-2-yl(R⁸)_q.

In some embodiments, R⁵ is -furan-2-yl(R⁸)_q and q is 0.

In some embodiments, R⁵ is -furan-3-yl(R⁸)_q.

In some embodiments, R⁵ is -furan-3-yl(R⁸)_q and q is 0.

In some embodiments, R⁵ is -thiophenyl(R⁸)_q.

In some embodiments, R⁵ is -thiophen-2-yl(R⁸)_q.

In some embodiments, R⁵ is -thiophen-2-yl(R⁸)_q and q is 0.

In some embodiments, R⁵ is -thiophen-2-yl(R⁸)_q, q is 1 or 2, and each R⁸ is independently a halide.

In some embodiments, R⁵ is -thiophen-2-yl(R⁸)_q, q is 1 or 2, and R⁸ is F.

In some embodiments, R⁵ is -thiophen-2-yl(R⁸)_q, q is 1 or 2, and each R⁸ is independently a —(C_1-6 alkyl).

In some embodiments, R⁵ is -thiophen-2-yl(R⁸)_q, q is 1 or 2, and each R⁸ is independently a —(C_1-2 alkyl).

In some embodiments, R⁵ is -thiophen-2-yl(R⁸)_q, q is 1 or 2, and R⁸ is methyl.

In some embodiments, R⁵ is -thiophen-2-yl(R⁸)_q, q is 1 or 2, and R⁸ is —CF₃.

In some embodiments, R⁵ is -thiophen-2-yl(R⁸)_q, q is 1 or 2, and R⁸ is CN.

In some embodiments, R⁵ is -thiophen-2-yl(R⁸)_q, q is 1, and R⁸ is —C(═O)R¹⁹.

In some embodiments, R⁵ is -thiophen-2-yl(R⁸)_q, q is 1, R⁸ is —C(═O)R¹⁹, and R¹⁹ is —(C_1-6 alkyl).

In some embodiments, R⁵ is -thiophen-2-yl(R⁸)_q, q is 1, R⁸ is —C(═O)R⁹, and R¹⁹ is —(C_1-4 alkyl).

In some embodiments, R⁵ is -thiophen-2-yl(R⁸)_q, q is 1, R⁸ is —C(═O)R⁹, and R¹⁹ is —(C_1-2 alkyl).

In some embodiments, R⁵ is -thiophen-2-yl(R⁸)_q, q is 1, R⁸ is —C(═O)R⁹, and R¹⁹ is methyl.

In some embodiments, R⁵ is -thiophen-3-yl(R⁸)_q.

In some embodiments, R⁵ is -thiophen-3-yl(R⁸)_q and q is 0.

In some embodiments, R⁵ is -thiophen-3-yl(R⁸)_q, q is 1 or 2, and each R⁸ is independently a halide.

In some embodiments, R⁵ is -thiophen-3-yl(R⁸)_q, q is 1 or 2, and R⁸ is F.

In some embodiments, R⁵ is -thiophen-3-yl(R⁸)_q, q is 1 or 2, and each R⁸ is independently a —(C_1-6 alkyl).

In some embodiments, R⁵ is -thiophen-3-yl(R⁸)_q, q is 1 or 2, and each R⁸ is independently a —(C_1-2 alkyl).

In some embodiments, R⁵ is -thiophen-3-yl(R⁸)_q, q is 1 or 2, and R⁸ is methyl.

In some embodiments, R⁵ is -thiophen-3-yl(R⁸)_q, q is 1 or 2, and R⁸ is —CF₃.

In some embodiments, R⁵ is -thiophen-3-yl(R⁸)_q, q is 1 or 2, and R⁸ is CN.

In some embodiments, R⁵ is -thiophen-3-yl(R⁸)_q, q is 1, and R⁸ is —C(═O)R¹⁹.

In some embodiments, R⁵ is -thiophen-3-yl(R⁸)_q, q is 1, R⁸ is —C(═O)R⁹, and R¹⁹ is —(C_1-4 alkyl).

In some embodiments, R⁵ is -thiophen-3-yl(R⁸)_q, q is 1, R⁸ is —C(═O)R⁹, and R¹⁹ is —(C_1-2 alkyl).

In some embodiments, R⁵ is -thiophen-3-yl(R⁸)_q, q is 1, R⁸ is —C(═O)R⁹, and R¹⁹ is methyl.

In some embodiments, R⁵ is selected from the group consisting of:

In some embodiments, R⁵ is -phenyl(R¹⁰)_k.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k and k is 0.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 1 or 2, and each R¹⁰ is independently a halide.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 1 or 2, and R¹⁰ is F.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 1, and R¹⁰ is F.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is a halide and the other R¹⁰ is —(C_1-6 alkylene)_pNHSO₂R¹⁹.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is a halide and the other R¹⁰ is —(C_1-4 alkylene)_pNHSO₂R¹⁹, and p is 1.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is a halide and the other R¹⁰ is —(C_1-2 alkylene)_pNHSO₂R¹⁹, and p is 1.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is a halide and the other R¹⁰ is —CH₂NHSO₂R¹⁹.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is a halide and the other R¹⁰ is —CH₂NHSO₂R¹⁹, and R¹⁹ is —(C_1-4 alkyl).

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is a halide and the other R¹⁰ is —CH₂NHSO₂R¹⁹, and R¹⁹ is —(C_1-2 alkyl).

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is a halide and the other R¹⁰ is —CH₂NHSO₂R¹⁹, and R¹⁹ is methyl.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is F and the other R¹⁰ is —CH₂NHSO₂R¹⁹, and R¹⁹ is —(C_1-2 alkyl).

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is F and the other R¹⁰ is —CH₂NHSO₂R¹⁹, and R¹⁹ is methyl.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is halide and the other R¹⁰ is —NR¹⁵(C_1-6 alkylene)NR¹⁵R¹⁶.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is halide and the other R¹⁰ is —NR¹⁵(C_1-5 alkylene)NR¹⁵R¹⁶.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is halide and the other R¹⁰ is —NR¹⁵(C_1-4 alkylene)NR¹⁵R¹⁶.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is halide and the other R¹⁰ is —NR¹⁵(C_1-3 alkylene)NR¹⁵R¹⁶.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is halide and the other R¹⁰ is —NR⁵CH₂CH₂NR¹⁵R¹⁶.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is halide and the other R¹⁰ is —NHCH₂CH₂NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently a —(C_1-6 alkyl).

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is halide and the other R¹⁰ is —NHCH₂CH₂NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently a —(C_1-4 alkyl).

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is halide and the other R¹⁰ is —NHCH₂CH₂NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently a —(C_1-2 alkyl).

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is halide and the other R¹⁰ is —NHCH₂CH₂NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are both methyl.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is F and the other R¹⁰ is —NHCH₂CH₂NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently a —(C_1-2 alkyl).

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is F and the other R¹⁰ is —NHCH₂CH₂NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are both methyl.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is halide and the other R¹⁰ is —OCH₂CH₂NR²⁵R²⁶.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is halide and the other R¹⁰ is —OCH₂CH₂NR²⁵R²⁶, and R²⁵ and R²⁶ are independently a —(C_1-2 alkyl).

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is halide and the other R¹⁰ is —OCH₂CH₂NR²⁵R²⁶, and R²⁵ and R²⁶ are both methyl.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is F and the other R¹⁰ is —OCH₂CH₂NR²⁵R²⁶, and R²⁵ and R²⁶ are both methyl.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is halide and the other R¹⁰ is —CH₂NHSO₂R¹⁹, and R¹⁹ is —(C_1-4 alkyl).

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is halide and the other R¹⁰ is —CH₂NHSO₂R¹⁹, and R¹⁹ is —(C_1-2 alkyl).

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is halide and the other R¹⁰ is —CH₂NHSO₂R¹⁹, and R¹⁹ is methyl.

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is F and the other R¹⁰ is —CH₂NHSO₂R¹⁹, and R¹⁹ is —(C_1-2 alkyl).

In some embodiments, R⁵ is -phenyl(R¹⁰)_k, k is 2, one R¹⁰ is F and the other R¹⁰ is —CH₂NHSO₂R¹⁹, and R¹⁹ is methyl.

In some embodiments, R⁵ is selected from the group consisting of:

In some embodiments, R⁵ is -piperidinyl(R⁹)_h.

In some embodiments, R⁵ is -piperidin-1-yl(R⁹)_h.

In some embodiments, R⁵ is -piperidin-1-yl(R⁹)_h and h is 0.

In some embodiments, R⁵ is -piperidin-1-yl(R⁹)_h, h is 1 or 2, and each R⁹ is independently selected from a halide.

In some embodiments, R⁵ is -piperazinyl(R⁹)_h.

In some embodiments, R⁵ is -piperazin-1-yl(R⁹)_h.

In some embodiments, R⁵ is -piperazin-1-yl(R⁹)_h, h is 1, and R⁹ is C_1-3 alkyl.

In some embodiments, R⁵ is -piperazin-1-yl(R⁹)_h, h is 1, and R⁹ is methyl.

In some embodiments, R⁵ is -morpholinyl(R⁹)_h.

In some embodiments, R⁵ is -morpholin-1-yl(R⁹)_h.

In some embodiments, R⁵ is -morpholin-1-yl(R⁹)_h and h is 0.

In some embodiments, R⁵ is selected from the group consisting of:

In some embodiments, q is 0.

In some embodiments, at least one R⁶ is a halide.

In some embodiments, at least one R⁶ is a F.

In some embodiments, R⁶ is F.

In some embodiments, at least one R⁶ is —(C_1-6 alkyl).

In some embodiments, at least one R⁶ is —(C_1-5 alkyl).

In some embodiments, at least one R⁶ is —(C_1-4 alkyl).

In some embodiments, at least one R⁶ is —(C_1-3 alkyl).

In some embodiments, at least one R⁶ is —(C_1-2 alkyl).

In some embodiments, at least one R⁶ is methyl.

In some embodiments, R⁶ is a methyl.

In some embodiments, at least one R⁶ is —(C_1-4 alkylene)_pheterocyclyl(R¹¹)_h and p is 0 or 1.

In some embodiments, at least one R⁶ is —(C_1-3 alkylene)_pheterocyclyl(R¹¹)_h and p is 0 or 1.

In some embodiments, at least one R⁶ is —(C_1-2 alkylene)_pheterocyclyl(R¹¹)_h and p is 0 or 1.

In some embodiments, at least one R⁶ is —CH₂pyrrolidinyl(R⁷)_h.

In some embodiments, at least one R⁶ is —CH₂pyrrolidinyl(R⁷)_h and h is 0.

In some embodiments, R⁶ is a —CH₂pyrrolidinyl(R⁷)_h and h is 0.

In some embodiments, at least one R⁶ is —CH₂pyrrolidinyl(R¹¹)_h, h is 1 or 2, and at least one R¹¹ is a halide.

In some embodiments, at least one R⁶ is —CH₂pyrrolidinyl(R¹¹)_h, h is 1 or 2, and at least one R¹¹ is F.

In some embodiments, R⁶ is a —CH₂pyrrolidinyl(R⁷)_h, h is 1 or 2, and at least one R¹¹ is halide.

In some embodiments, R⁶ is —CH₂pyrrolidinyl(R⁷)_h, h is 1 or 2, and at least one R¹¹ is F.

In some embodiments, R⁶ is a —CH₂pyrrolidinyl(R⁷)_h, h is 1 or 2, and each R¹¹ is F.

In some embodiments, at least one R⁶ is —CH₂piperidinyl(R¹¹)_h.

In some embodiments, at least one R⁶ is —CH₂piperidinyl(R¹¹)_h and h is 0.

In some embodiments, R⁶ is a —CH₂piperidinyl(R¹¹)_h and h is 0.

In some embodiments, at least one R⁶ is —CH₂piperidinyl(R¹¹)_h and at least one R¹¹ is a halide.

In some embodiments, at least one R⁶ is —CH₂piperidinyl(R¹¹)_h and at least one R¹¹ is F.

In some embodiments, at least one R⁶ is —CH₂piperidinyl(R¹¹)_h, h is 1 or 2, and each R¹¹ is a halide.

In some embodiments, at least one R⁶ is —CH₂piperidinyl(R^U)_h, h is 1 or 2, and each R¹¹ is F.

In some embodiments, R⁶ is a —CH₂piperidinyl(R⁷)_h, h is 1 or 2, and each R¹¹ is a halide.

In some embodiments, R⁶ is a —CH₂piperidinyl(R⁷)_h, h is 1 or 2, and each R¹¹ is F.

In some embodiments, R⁶ is a

In some embodiments, at least one R⁶ is —(C_1-4 alkylene)_pcarbocyclyl(R¹²)_j.

In some embodiments, at least one R⁶ is —(C_1-4 alkylene)_pcarbocyclyl(R¹²)_j and j is 0 or 1.

In some embodiments, at least one R⁶ is —(C_1-3 alkylene)_pcarbocyclyl(R¹²)_j and j is 0 or 1.

In some embodiments, at least one R⁶ is —(C_1-2 alkylene)_pcarbocyclyl(R¹²)_j and j is 0 or 1.

In some embodiments, at least one R⁶ is —CH₂carbocyclyl(R²)_j.

In some embodiments, R⁶ is a —CH₂carbocyclyl(R²)_j.

In some embodiments, at least one R⁶ is —(C_1-4 alkylene)_paryl(R¹³)_k and k is 0 or 1.

In some embodiments, at least one R⁶ is —(C_1-3 alkylene)_paryl(R¹³)_k and k is 0 or 1.

In some embodiments, at least one R⁶ is —(C_1-2 alkylene)_paryl(R¹³)_k and k is 0 or 1.

In some embodiments, at least one R⁶ is —CH₂aryl(R¹³)_k.

In some embodiments, at least one R⁶ is —CH₂phenyl(R¹³)_k.

In some embodiments, R⁶ is a —CH₂phenyl(R¹³)_k.

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴.

In some embodiments, R⁶ is a —NHC(═O)R¹⁴.

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C_1-9 alkyl).

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C_1-8 alkyl).

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C_1-7 alkyl).

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C_1-6 alkyl).

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C_1-5 alkyl).

In some embodiments, R⁶ is a —NHC(═O)R¹⁴ and R¹⁴ is —(C_1-5 alkyl).

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C_1-4 alkyl).

In some embodiments, R⁶ is a —NHC(═O)R¹⁴ and R¹⁴ is —(C_1-4 alkyl).

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C_1-3 alkyl).

In some embodiments, R⁶ is a —NHC(═O)R⁴ and R¹⁴ is —(C_1-3 alkyl).

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C_1-2 alkyl).

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C_2-5 alkyl).

In some embodiments, R⁶ is a —NHC(═O)R⁴ and R¹⁴ is —(C_2-5 alkyl).

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C_3-4 alkyl).

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is -aryl(R²¹)_k.

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R¹⁴ is -phenyl(R²¹)_k, and k is 0.

In some embodiments, R⁶ is a —NHC(═O)R¹⁴, R¹⁴ is -phenyl(R²¹)_k, and k is 0.

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —CH₂aryl(R²¹)_k.

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R¹⁴ is —CH₂phenyl(R²¹)_k, and k is 0.

In some embodiments, R⁶ is a —NHC(═O)R¹⁴, R¹⁴ is —CH₂phenyl(R²¹)_k, and k is 0.

In some embodiments, at least one R⁶ is —NHC(═O)R⁴ and R¹⁴ is -heteroaryl(R²⁰)_q.

In some embodiments, at least one R⁶ is —NHC(═O)R⁴ and R¹⁴ is -carbocyclyl(R²²)_j.

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R¹⁴ is -carbocyclyl(R²²)_j, and j is 0.

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R¹⁴ is -cyclopropyl(R²²)_j, and j is 0.

In some embodiments, R⁶ is a —NHC(═O)R¹⁴, R¹⁴ is -cyclopropyl(R²²)_j, and j is 0.

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R¹⁴ is -cyclobutyl(R²²)_j, and j is 0.

In some embodiments, R⁶ is a —NHC(═O)R¹⁴, R¹⁴ is -cyclobutyl(R²²)_j, and j is 0.

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R¹⁴ is -cyclopentyl(R²²)_j, and j is 0.

In some embodiments, R⁶ is a —NHC(═O)R¹⁴, R¹⁴ is -cyclopentyl(R²²)_j, and j is 0.

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R¹⁴ is -cyclohexyl(R²²)_j, and j is 0.

In some embodiments, R⁶ is a —NHC(═O)R¹⁴, R¹⁴ is -cyclohexyl(R²²)_j, and j is 0.

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R¹⁴ is —CH₂carbocyclyl(R²²)_j, and j is 0.

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R¹⁴ is —CH₂cyclopropyl(R²²)_j, and j is 0.

In some embodiments, R⁶ is a —NHC(═O)R¹⁴, R¹⁴ is —CH₂cyclopropyl(R²²)_j, and j is 0.

In some embodiments, at least one R⁶ is —NR¹⁵R¹⁶.

In some embodiments, at least one R⁶ is —NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently selected from the group consisting of H and —(C_1-6 alkyl).

In some embodiments, at least one R⁶ is —NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently selected from the group consisting of H and —(C_1-5 alkyl).

In some embodiments, at least one R⁶ is —NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently selected from the group consisting of H and —(C_1-4 alkyl).

In some embodiments, at least one R⁶ is —NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently selected from the group consisting of H and —(C_1-3 alkyl).

In some embodiments, at least one R⁶ is —NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently selected from the group consisting of H and —(C_1-2 alkyl).

In some embodiments, at least one R⁶ is —NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently selected from the group consisting of H and methyl.

In some embodiments, R⁶ is a —NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently selected from the group consisting of H and methyl.

In some embodiments, at least one R⁶ is —NH₂.

In some embodiments, R⁶ is a —NH₂.

In some embodiments, at least one R⁶ is —NHR¹⁶ and R¹⁶ is —(C_1-4 alkyl).

In some embodiments, at least one R⁶ is —NHR¹⁶ and R¹⁶ is —(C_1-3 alkyl).

In some embodiments, R⁶ is —NHR¹⁶ and R¹⁶ is —(C_1-2 alkyl).

In some embodiments, at least one R⁶ is —NHR¹⁶ and R¹⁶ is —CH₂aryl(R²¹)_k.

In some embodiments, R⁶ is —NHR¹⁶, R¹⁶ is —CH₂phenyl(R²¹)_k, and k is 0.

In some embodiments, at least one R⁶ is —NHR¹⁶ and R¹⁶ is —CH₂carbocyclyl(R²²)_j.

In some embodiments, at least one R⁶ is —NHR¹⁶, R¹⁶ is —CH₂cyclopropyl(R²²)_j, and j is 0.

In some embodiments, R⁶ is a —NHR¹⁶, R¹⁶ is —CH₂cyclopropyl(R²²)_j, and j is 0.

In some embodiments, at least one R⁶ is —NHR¹⁶, R¹⁶ is —CH₂cyclobutyl(R²²)_j, and j is 0.

In some embodiments, R⁶ is a —NHR¹⁶, R¹⁶ is —CH₂cyclobutyl(R²²)_j, and j is 0.

In some embodiments, at least one R⁶ is —NHR¹⁶, R¹⁶ is —CH₂cyclopentyl(R²²)_j, and j is 0.

In some embodiments, R⁶ is a —NHR¹⁶, R¹⁶ is —CH₂cyclopentyl(R²²)_j, and j is 0.

In some embodiments, at least one R⁶ is —NHR¹⁶, R¹⁶ is —CH₂cyclohexyl(R²²)_j, and j is 0.

In some embodiments, R⁶ is a —NHR¹⁶, R¹⁶ is —CH₂cyclohexyl(R²²)_j, and j is 0.

In some embodiments, at least one R⁶ is —(C_1-6 alkylene)NR¹⁷R¹⁸.

In some embodiments, at least one R⁶ is —(C_1-5 alkylene)NR¹⁷R¹⁸.

In some embodiments, at least one R⁶ is —(C_1-4 alkylene)NR¹⁷R¹⁸.

In some embodiments, at least one R⁶ is —(C_1-3 alkylene)NR¹⁷R¹⁸.

In some embodiments, at least one R⁶ is —(C_1-2 alkylene)NR¹⁷R¹⁸.

In some embodiments, at least one R⁶ is —CH₂NR¹⁷R¹⁸.

In some embodiments, R⁶ is a —CH₂NR¹⁷R¹⁸.

In some embodiments, at least one R⁶ is —CH₂NR¹⁷R¹⁸, and R¹⁷ and R¹⁸ are independently selected from the group consisting of H and —(C_1-6 alkyl).

In some embodiments, at least one R⁶ is —CH₂NR¹⁷R¹⁸, and R¹⁷ and R¹⁸ are independently selected from the group consisting of H and —(C_1-5 alkyl).

In some embodiments, at least one R⁶ is —CH₂NR¹⁷R¹⁸, and R¹⁷ and R¹⁸ are independently selected from the group consisting of H and —(C_1-4 alkyl).

In some embodiments, at least one R⁶ is —CH₂NR¹⁷R¹⁸, and R¹⁷ and R¹⁸ are independently selected from the group consisting of H and —(C_1-3 alkyl).

In some embodiments, at least one R⁶ is —CH₂NR¹⁷R¹⁸, and R¹⁷ and R¹⁸ are independently selected from the group consisting of H and —(C_1-2 alkyl).

In some embodiments, at least one R⁶ is —CH₂NR¹⁷R¹⁸, and R¹⁷ and R¹⁸ are independently selected from the group consisting of H and methyl.

In some embodiments, R⁶ is a —CH₂NR¹⁷R¹⁸, R¹⁷ and R¹⁸ are independently selected from the group consisting of H and methyl.

In some embodiments, at least one R⁶ is —CH₂NH₂.

In some embodiments, R⁶ is a —CH₂NH₂.

In some embodiments, at least one R⁶ is —CH₂NMe₂.

In some embodiments, R⁶ is a —CH₂NMe₂.

In some embodiments, at least one R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —(C_1-4 alkyl).

In some embodiments, at least one R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —(C_1-3 alkyl).

In some embodiments, at least one R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —(C_1-2 alkyl).

In some embodiments, R⁶ is a —CH₂NHR¹⁸ and R¹⁸ is —(C_1-2 alkyl).

In some embodiments, at least one R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —CH₂aryl(R²¹)_k.

In some embodiments, at least one R⁶ is —CH₂NHR¹⁸, R¹⁸ is —CH₂phenyl(R²¹)_k, and k is 0.

In some embodiments, R⁶ is a —CH₂NHR¹⁸, R¹⁸ is —CH₂phenyl(R^Z1)_k, and k is 0.

In some embodiments, at least one R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —CH₂carbocyclyl(R²²)_j.

In some embodiments, at least one R⁶ is —CH₂NHR¹⁸, R¹⁸ is —CH₂cyclopropyl(R²²)_j, and j is 0.

In some embodiments, R⁶ is a —CH₂NHR¹⁸, R¹⁸ is —CH₂cyclopropyl(R²²)_j, and j is 0.

In some embodiments, at least one R⁶ is —CH₂NHR¹⁸, R¹⁸ is —CH₂cyclobutyl(R²²)_j, and j is 0.

In some embodiments, R⁶ is a —CH₂NHR¹⁸, R¹⁸ is —CH₂cyclobutyl(R²²)_j, and j is 0.

In some embodiments, at least one R⁶ is —CH₂NHR¹⁸, R¹⁸ is —CH₂cyclopentyl(R²²)_j, and j is 0.

In some embodiments, R⁶ is a —CH₂NHR¹⁸, R¹⁸ is —CH₂cyclopentyl(R²²)_j, and j is 0.

In some embodiments, at least one R⁶ is —CH₂NHR¹⁸, R¹⁸ is —CH₂cyclohexyl(R²²)_j, and j is 0.

In some embodiments, R⁶ is a —CH₂NHR¹⁸, R¹⁸ is —CH₂cyclohexyl(R²²)_j, and j is 0.

In some embodiments, at least one R⁶ is —OR²⁴.

In some embodiments, at least one R⁶ is —OH.

In some embodiments, R⁶ is a —OH.

In some embodiments, at least one R⁶ is —OR²⁴ and R²⁴ is —(C_1-3 alkyl).

In some embodiments, at least one R⁶ is —OR²⁴ and R²⁴ is —(C_1-2 alkyl).

In some embodiments, at least one R⁶ is —OMe.

In some embodiments, R⁶ is a —OMe.

In some embodiments, at least one R⁶ is —OR²⁴, R²⁴ is -heterocyclyl(R²³)_h, and h is 0.

In some embodiments, R⁶ is a —OR²⁴, R²⁴ is -heterocyclyl(R²³)_h, and h is 0.

In some embodiments, at least one R⁶ is —OR²⁴, R²⁴ is -carbocyclyl(R²²)_j, and j is 0.

In some embodiments, R⁶ is a —OR²⁴, R²⁴ is -carbocyclyl(R²²)_j, and j is 0.

In some embodiments, at least one R⁶ is —OR²⁴, R²⁴ is —(C_1-4 alkylene)heterocyclyl(R²³)_h, and h is 0.

In some embodiments, at least one R⁶ is —OR²⁴, R²⁴ is —(CH₂CH₂)heterocyclyl(R²³)_h, and h is 0.

In some embodiments, R⁶ is a —OR²⁴, R²⁴ is —(CH₂CH₂)heterocyclyl(R²³)_h, and h is 0.

In some embodiments, at least one R⁶ is —OR²⁴, R²⁴ is —(C_1-4 alkylene)NR²⁵R²⁶ and R²⁵ and R²⁶ are independently a —(C_1-4 alkyl).

In some embodiments, at least one R⁶ is —OR²⁴, R²⁴ is —(CH₂CH₂)NR²⁵R²⁶ and R²⁵ and R²⁶ are independently a —(C_1-2 alkyl).

In some embodiments, at least one R⁶ is —OR²⁴, and R²⁴ is —(CH₂CH₂)NMe₂.

In some embodiments, R⁶ is a —OR²⁴, and R²⁴ is —(CH₂CH₂)NMe₂.

In some embodiments, at least one R⁶ is —OR²⁴, R²⁴ is —(C_1-4 alkylene)aryl(R²¹)_k, k is 0 or 1 and R²¹ is halide.

In some embodiments, at least one R⁶ is —OR²⁴, R²⁴ is —(CH₂CH₂)phenyl(R²¹)_k, k is 0 or 1 and R²¹ is a halide.

In some embodiments, R⁶ is a —OR²⁴, R²⁴ is —(CH₂CH₂)phenyl(R²¹)_k, k is 0 or 1 and R²¹ is a halide.

In some embodiments, at least one R⁶ is —OR²⁴, R²⁴ is —(CH₂)phenyl(R²¹)_k, k is 0 or 1 and R²¹ is a halide.

In some embodiments, R⁶ is a —OR²⁴, R²⁴ is —(CH₂)phenyl(R²¹)_k, k is 0 or 1 and R²¹ is a halide.

In some embodiments, h is 0.

In some embodiments, at least one R⁷ is a halide.

In some embodiments, at least one R⁷ is a F.

In some embodiments, at least one R⁷ is —(C_1-6 alkyl).

In some embodiments, at least one R⁷ is —(C_1-5 alkyl).

In some embodiments, at least one R⁷ is —(C_1-4 alkyl).

In some embodiments, at least one R⁷ is —(C_1-3 alkyl).

In some embodiments, at least one R⁷ is —(C_1-2 alkyl).

In some embodiments, at least one R⁷ is methyl.

In some embodiments, at least one R⁸ is a halide.

In some embodiments, at least one R⁸ is a F.

In some embodiments, at least one R⁸ is —(C_1-4 alkyl).

In some embodiments, at least one R⁸ is —(C_1-3 alkyl).

In some embodiments, at least one R⁸ is —(C_1-2 alkyl).

In some embodiments, at least one R⁸ is methyl.

In some embodiments, R⁸ is a methyl.

In some embodiments, at least one R⁸ is —C(═O)(C_1-3 alkyl).

In some embodiments, at least one R⁸ is —C(═O)Me.

In some embodiments, R⁸ is a —C(═O)Me.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is —NHC(═O)R¹⁴; R¹⁴ is —(C_2-5 alkyl); R⁵ is -phenyl(R¹⁰)_k; k is 1 or 2; and R¹⁰ is F.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is —NHC(═O)R¹⁴; R¹⁴ is —(C_2-5 alkyl); R⁵ is -phenyl(R¹⁰)_k; k is 2; one R¹⁰ is F and the other R¹⁰ is —(C_1-2 alkylene)_pNHSO₂R¹⁹; p is 1; and R¹⁹ is —(C_1-3 alkyl).

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is —NHC(═O)R¹⁴; R¹⁴ is —(C_2-5 alkyl); R⁵ is -phenyl(R¹⁰)_k; k is 2; one R¹⁰ is F and the other R¹⁰ is —NH(C_1-6 alkylene)NR¹⁵R¹⁶; and R¹⁵ and R¹⁶ are independently selected from —(C_1-3 alkyl).

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q, wherein q is 1; R⁶ is —NHC(═O)R¹⁴; R¹⁴ is —(C_2-5 alkyl); R⁵ is -heteroaryl(R⁸)_q, wherein q is 1; R⁸ is selected from the group consisting of halide, —(C_1-2 alkyl), and —C(═O)R¹⁹; R¹⁹ is —(C_1-3 alkyl); and the heteroaryl is selected from the group consisting of pyridine, furan, thiophene, and imidazole.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is —NHC(═O)R¹⁴; R¹⁴ is —(C_2-5 alkyl); R⁵ is -heterocyclyl(R⁹)_h; h is 1 or 2; and R⁹ is selected from the group consisting of halide and —(C_1-2 alkyl).

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is —NHC(═O)R¹⁴; R¹⁴ is -carbocyclyl(R²²); j is 0; R is -phenyl(R¹⁰)_k; k is 1 or 2; R¹⁰ is F; and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is —NHC(═O)R¹⁴; R¹⁴ is -carbocyclyl(R²²)_j; j is 0; R⁵ is -phenyl(R¹⁰)_k; k is 2; one R¹⁰ is F and the other R¹⁰ is —(C_1-2 alkylene)_pNHSO₂R¹⁹; p is 1; R¹⁹ is —(C_1-3 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is —NHC(═O)R¹⁴; R¹⁴ is -carbocyclyl(R²²)_j; j is 0; R⁵ is -phenyl(R¹⁰)_k; k is 2; one R¹⁰ is F and the other R¹⁰ is —NH(C_1-6 alkylene)NR¹⁵R¹⁶; R¹⁵ and R¹⁶ are independently selected from —(C_1-3 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q, wherein q is 1; R⁶ is —NHC(═O)R¹⁴; R¹⁴ is -carbocyclyl(R²²)_j; j is 0; R is -heteroaryl(R⁸)_q, wherein q is 1; R⁸ is selected from the group consisting of halide, —(C_1-2 alkyl), and —C(═O)R¹⁹; R¹⁹ is C_1-3 alkyl; the heteroaryl is selected from the group consisting of pyridine, furan, thiophene, and imidazole; and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is —NHC(═O)R¹⁴; R¹⁴ is -carbocyclyl(R²)_j; j is 0; R⁵ is -heterocyclyl(R⁹)_h; h is 1 or 2; R⁹ is selected from the group consisting of halide and —(C_1-2 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is selected from the group consisting of —NR¹⁵R¹⁶ and —CH₂NR¹⁷R¹⁸; R¹⁵ and R¹⁷ are independently selected from the group consisting of H and —(C_1-3 alkyl); R¹⁶ and R¹⁸ are independently selected from the group consisting of H, —(C_1-3 alkyl), —CH₂phenyl(R²¹)_k, and —CH₂carbocyclyl(R²²)_j, wherein k and j are 0; R⁵ is -phenyl(R¹⁰)_k, wherein k is 1 or 2; R¹⁰ is F; and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is selected from the group consisting of —NR¹⁵R¹⁶ and —CH₂NR¹⁷R¹⁸; R¹⁵ and R¹⁷ are independently selected from the group consisting of H and —(C_1-3 alkyl); R¹⁶ and R¹⁸ are independently selected from the group consisting of H, —(C_1-3 alkyl), —CH₂phenyl(R²¹)_k, and —CH₂carbocyclyl(R²²)_j, wherein k and j are 0; R⁵ is -phenyl(R¹⁰)_k, wherein k is 2; one R¹⁰ is F and the other R¹⁰ is —(C_1-2 alkylene)_pNHSO₂R¹⁹; p is 1; R¹⁹ is —(C_1-3 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is selected from the group consisting of —NR¹⁵R¹⁶ and —CH₂NR¹⁷R¹⁸, wherein R¹⁵ and R¹⁷ are independently selected from the group consisting of H and —(C_1-3 alkyl), and R¹⁶ and R¹⁸ are independently selected from the group consisting of H, —(C_1-3 alkyl), —CH₂phenyl(R²¹)_k, and —CH₂carbocyclyl(R²²)_j, wherein k and j are 0; R⁵ is -phenyl(R¹⁰)_k, wherein k is 2; one R¹⁰ is F and the other R¹⁰ is —NH(C_1-6 alkylene)NR¹⁵R¹⁶, wherein R¹⁵ and R¹⁶ are independently selected from —(C_1-3 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q, wherein q is 1; R⁶ is selected from the group consisting of —NR¹⁵R¹⁶ and —CH₂NR¹⁷R¹⁸; R¹⁵ and R¹⁷ are independently selected from the group consisting of H and —(C_1-3 alkyl); R¹⁶ and R¹⁸ are independently selected from the group consisting of H, —(C_1-3 alkyl), —CH₂phenyl(R²¹)_k, and —CH₂carbocyclyl(R²²)_j; k and j are 0; R⁵ is -heteroaryl(R⁸)_q, wherein q is 1; R⁸ is selected from the group consisting of halide, —(C_1-2 alkyl), and —C(═O)R¹⁹; R¹⁹ is —(C_1-3 alkyl); the heteroaryl is selected from the group consisting of pyridine, furan, thiophene, and imidazole; and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is selected from the group consisting of —NR¹⁵R¹⁶ and —CH₂NR¹⁷R¹⁸; R¹⁵ and R¹⁷ are independently selected from the group consisting of H and —(C_1-3 alkyl); R¹⁶ and R¹⁸ are independently selected from the group consisting of H, —(C_1-3 alkyl), —CH₂phenyl(R²¹)_k, and —CH₂carbocyclyl(R²²)_j; k and j are 0; R⁵ is -heterocyclyl(R⁹)_h; h is 1 or 2; each R⁹ is independently selected from the group consisting of halide and —(C_1-2 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is —CH₂heterocyclyl(R¹¹)_h; h is 0-2; R¹¹ is F; R⁵ is -phenyl(R¹⁰)_k; k is 1 or 2; R¹⁰ is F; and the heterocyclyl is selected from the group consisting of pyrrolidine and piperidine.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is —CH₂heterocyclyl(R¹¹)_h; h is 0-2; R¹¹ is F; R⁵ is -phenyl(R¹⁰)_k; k is 2; one R¹⁰ is F and the other R¹⁰ is —(C_1-2 alkylene)_pNHSO₂R¹⁹; p is 1; R¹⁹ is —(C_1-3 alkyl); and the heterocyclyl is selected from the group consisting of pyrrolidine and piperidine.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is —CH₂heterocyclyl(R¹¹)_h; h is 0-2; R¹¹ is F; R⁵ is -phenyl(R¹⁰)_k; k is 2; one R¹⁰ is F and the other R¹⁰ is —NH(C_1-6 alkylene)NR^5SR⁶; R¹⁵ and R¹⁶ are independently selected from —(C_1-3 alkyl); and the heterocyclyl is selected from the group consisting of pyrrolidine and piperidine.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q, wherein q is 1; R⁶ is —CH₂heterocyclyl(R¹¹)_h; h is 0-2; R¹¹ is F; R⁵ is -heteroaryl(R⁸)_q, wherein q is 1; R⁸ is selected from the group consisting of halide, —(C_1-2 alkyl), and —C(═O)R¹⁹; R¹⁹ is —(C_1-3 alkyl); the heteroaryl is selected from the group consisting of pyridine, furan, thiophene, and imidazole; and the heterocyclyl is selected from the group consisting of pyrrolidine and piperidine.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is —CH₂heterocyclyl(R¹¹)_h, wherein h is 0-2; R¹¹ is F; R⁵ is -heterocyclyl(R⁹)_h, wherein h is 1 or 2; each R⁹ is independently selected from the group consisting of halide and —(C_1-2 alkyl); and the heterocyclyl is selected from the group consisting of pyrrolidine and piperidine.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyrimidinyl(R⁶)_q; q is 0; R⁵ is -phenyl(R¹⁰)_k; k is 1 or 2; and R¹⁰ is F.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyrimidinyl(R⁶); q is 0; R⁵ is -phenyl(R¹⁰)_k; k is 2; one R¹⁰ is F and the other R¹⁰ is —(C_1-2 alkylene)_pNHSO₂R¹⁹; p is 1; and R¹⁹ is —(C_1-3 alkyl).

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyrimidinyl(R⁶)_q; q is 0; R⁵ is -phenyl(R¹⁰)_k; k is 2; one R¹⁰ is F and the other R¹⁰ is —NH(C_1-6 alkylene)NR¹⁵R¹⁶; and R¹⁵ and R¹⁶ are independently a —(C_1-3 alkyl).

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyrimidinyl(R⁷)_q, wherein q is 0; R⁵ is -heteroaryl(R⁸)_q, wherein q is 1; R⁸ is selected from the group consisting of halide, —(C_1-2 alkyl), and —C(═O)R¹⁹; R¹⁹ is —(C_1-3 alkyl); and the heteroaryl is selected from the group consisting of pyridine, furan, thiophene, and imidazole.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyrimidinyl(R⁶)_q; q is 0; R⁵ is -heterocyclyl(R⁹)_h; h is 1 or 2; each R⁹ is independently selected from the group consisting of halide and —(C_1-2 alkyl).

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyridin-3-yl(R⁸)_q; q is 1; R⁶ is —NHC(═O)R¹⁴; R¹⁴ is —(C_2-5 alkyl); R⁵ is -phenyl(R¹⁰)_k; k is 1 or 2; and R¹⁰ is F.

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyridin-3-yl(R⁸)_q; q is 1; R⁶ is —NHC(═O)R¹⁴; R¹⁴ is —(C_2-5 alkyl); R⁵ is -phenyl(R¹⁰)_k; k is 2; one R¹⁰ is F and the other R¹⁰ is —(C_1-2 alkylene)_pNHSO₂R¹⁹; p is 1; and R¹⁹ is —(C_1-3 alkyl).

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyridin-3-yl(R⁸)_q; q is 1; R⁶ is —NHC(═O)R¹⁴; R¹⁴ is —(C_2-5 alkyl); R⁵ is -phenyl(R¹⁰)_k; k is 2; one R¹⁰ is F and the other R¹⁰ is —NH(C_1-6 alkylene)NR¹⁵R¹⁶; and R¹⁵ and R¹⁶ are independently a —(C_1-3 alkyl).

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyridin-3-yl(R⁸)_q, wherein q is 1; R⁶ is —NHC(═O)R¹⁴; R¹⁴ is —(C_2-5 alkyl); R⁵ is -heteroaryl(R⁸)_q, wherein q is 1; R⁸ is selected from the group consisting of halide, —(C_1-2 alkyl), and —C(═O)R¹⁹; R¹⁹ is —(C_1-3 alkyl); and the heteroaryl is selected from the group consisting of pyridine, furan, thiophene, and imidazole.

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyridin-3-yl(R⁸)_q; q is 1; R⁶ is —NHC(═O)R⁴; R¹⁴ is —(C_2-5 alkyl); R⁵ is -heterocyclyl(R⁹)_h; h is 1 or 2; and each R⁹ is independently selected from the group consisting of halide and —(C_1-2 alkyl).

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is —NHC(═O)R⁴; R¹⁴ is -carbocyclyl(R²²)); j is 0; R⁵ is -phenyl(R¹⁰)_k; k is 1 or 2; R¹⁰ is F; and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is —NHC(═O)R¹⁴; R¹⁴ is -carbocyclyl(R²²)_j; j is 0; R⁵ is -phenyl(R¹⁰)_k; k is 2; one R¹⁰ is F and the other R¹⁰ is —(C_1-2 alkylene)_pNHSO₂R¹⁹; p is 1; R¹⁹ is —(C_1-3 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is —NHC(═O)R¹⁴; R¹⁴ is -carbocyclyl(R²²)_j; j is 0; R⁵ is -phenyl(R¹⁰)_k; k is 2; one R¹⁰ is F and the other R¹⁰ is —NH(C_1-6 alkylene)NR¹⁵R¹⁶; R¹⁵ and R¹⁶ are independently a —(C_1-3 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q, wherein q is 1; R⁶ is —NHC(═O)R¹⁴; R¹⁴ is -carbocyclyl(R²²)_j; j is 0; R⁵ is -heteroaryl(R⁸)_q, wherein q is 1; R⁸ is selected from the group consisting of halide, —(C_1-2 alkyl), and —C(═O)R¹⁹; R¹⁹ is —(C_1-3 alkyl); the heteroaryl is selected from the group consisting of pyridine, furan, thiophene, and imidazole; and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is —NHC(═O)R¹⁴; R¹⁴ is -carbocyclyl(R²)_j; j is 0; R⁵ is -heterocyclyl(R⁹)_h; h is 1 or 2; each R⁹ is independently selected from the group consisting of halide and —(C_1-2 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is selected from the group consisting of —NR¹⁵R¹⁶ and —CH₂NR¹⁷R¹⁸; R¹⁵ and R¹⁷ are independently selected from the group consisting of H and —(C_1-3 alkyl); R¹⁶ and R¹⁸ are independently selected from the group consisting of H, —(C_1-3 alkyl), —CH₂phenyl(R²¹)_k, and —CH₂carbocyclyl(R²)_j, wherein k and j are 0; R⁵ is -phenyl(R¹⁰)_k, wherein k is 1 or 2; R¹⁰ is F; and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is selected from the group consisting of —NR¹⁵R¹⁶ and —CH₂NR¹⁷R¹⁸; R¹⁵, R¹⁶, R¹⁷, and R¹⁸ are independently selected from the group consisting of H, —(C_1-3 alkyl), —CH₂phenyl(R²¹)_k, and —CH₂carbocyclyl(R²)_j, wherein k and j are 0; R⁵ is -phenyl(R¹⁰)_k, wherein k is 2; one R¹⁰ is F and the other R¹⁰ is —(C_1-2 alkylene)_pNHSO₂R¹⁹; p is 1; R¹⁹ is —(C_1-3 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is selected from the group consisting of —NR¹⁵R¹⁶ and —CH₂NR¹⁷R¹⁸, wherein R¹⁵ and R¹⁷ are independently selected from the group consisting of H and —(C_1-3 alkyl), and R¹⁶ and R¹⁸ are independently selected from the group consisting of H, —(C_1-3 alkyl), —CH₂phenyl(R²¹)_k, and —CH₂carbocyclyl(R²²)), wherein k and j are 0; R⁵ is -phenyl(R¹⁰)_k, wherein k is 2; one R¹⁰ is F and the other R¹⁰ is —NH(C_1-6 alkylene)NR¹⁵R¹⁶, wherein R¹⁵ and R¹⁶ are independently selected from —(C_1-3 alkyl); and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q, wherein q is 1; R⁶ is selected from the group consisting of —NR¹⁵R¹⁶ and —CH₂NR¹⁷R¹⁸; R¹⁵ and R¹⁷ are independently selected from the group consisting of H and —(C_1-3 alkyl); R¹⁶ and R¹⁸ are independently selected from the group consisting of H, —(C_1-3 alkyl), —CH₂phenyl(R²¹)_k, and —CH₂carbocyclyl(R²²)); k and j are 0; R⁵ is -heteroaryl(R⁸)_q, wherein q is 1; R⁸ is selected from the group consisting of halide, —(C_1-2 alkyl), and —C(═O)R¹⁹; R¹⁹ is —(C_1-3 alkyl); the heteroaryl is selected from the group consisting of pyridine, furan, thiophene, and imidazole; and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyridin-3-yl(R⁸)_q; q is 1; R⁶ is selected from the group consisting of —NR¹⁵R¹⁶ and —CH₂NR¹⁷R¹⁸; R¹⁵ and R¹⁷ are independently selected from the group consisting of H and —(C_1-3 alkyl); R¹⁶ and R¹⁸ are independently selected from the group consisting of H, —(C_1-3 alkyl), —CH₂phenyl(R²¹)_k, and —CH₂carbocyclyl(R²²)); k and j are 0; R⁵ is -heterocyclyl(R⁹)_h; h is 1 or 2; each R⁹ is independently selected from the group consisting of halide and C_1-2 alkyl; and the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyridin-3-yl(R⁸)_q; q is 1; R⁶ is —CH₂heterocyclyl(R¹¹)_h; h is 0-2; R¹¹ is F; R⁵ is -phenyl(R¹⁰)_k; k is 1 or 2; R¹⁰ is F; and the heterocyclyl is selected from the group consisting of pyrrolidine and piperidine.

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyridin-3-yl(R⁸)_q; q is 1; R⁶ is —CH₂heterocyclyl(R¹¹)_h; h is 0-2; R¹¹ is F; R⁵ is -phenyl(R¹⁰)_k; k is 2; one R¹⁰ is F and the other R¹⁰ is —(C_1-2 alkylene)_pNHSO₂R¹⁹; p is 1; R¹⁹ is —(C_1-3 alkyl); and the heterocyclyl is selected from the group consisting of pyrrolidine and piperidine.

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyridin-3-yl(R⁸)_q; q is 1; R⁶ is —CH₂heterocyclyl(R¹¹)_h; h is 0-2; R¹¹ is F; R⁵ is -phenyl(R¹⁰)_k; k is 2; one R¹⁰ is F and the other R¹⁰ is —NH(C_1-6 alkylene)NR¹⁵R¹⁶; R¹⁵ and R¹⁶ are independently selected from —(C_1-3 alkyl); and the heterocyclyl is selected from the group consisting of pyrrolidine and piperidine.

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q, wherein q is 1; R⁶ is —CH₂heterocyclyl(R¹¹)_h; h is 0-2; R¹¹ is F; R⁵ is -heteroaryl(R⁸)_q, wherein q is 1; R⁸ is selected from the group consisting of halide, —(C_1-2 alkyl), and —C(═O)R¹⁹; R¹⁹ is —(C_1-3 alkyl); the heteroaryl is selected from the group consisting of pyridine, furan, thiophene, and imidazole; and the heterocyclyl is selected from the group consisting of pyrrolidine and piperidine.

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is —CH₂heterocyclyl(R¹¹)_h, wherein h is 0-2; R¹¹ is F; R⁵ is -heterocyclyl(R⁹)_h, wherein h is 1 or 2; R⁹ is selected from the group consisting of halide and —(C_1-2 alkyl); and the heterocyclyl is selected from the group consisting of pyrrolidine and piperidine.

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyrimidinyl(R⁶)_q; q is 0; R⁵ is -phenyl(R¹⁰)_k; k is 1 or 2; and R¹⁰ is F.

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyrimidinyl(R⁶)_q; q is 0; R⁵ is -phenyl(R¹⁰)_k; k is 2; one R¹⁰ is F and the other R¹⁰ is —(C_1-2 alkylene)_pNHSO₂R¹⁹; p is 1; and R¹⁹ is —(C_1-3 alkyl).

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyrimidinyl(R⁶)_q; q is 0; R is -phenyl(R¹⁰)_k; k is 2; one R¹⁰ is F and the other R¹⁰ is —NH(C_1-6 alkylene)NR¹⁵R¹⁶; and R¹⁵ and R¹⁶ are independently selected from —(C_1-3 alkyl).

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyrimidinyl(R⁶)_q, wherein q is 0; R⁵ is -heteroaryl(R⁸)_q, wherein q is 1; R⁸ is selected from the group consisting of halide, —(C_1-2 alkyl), and —C(═O)R¹⁹; R¹⁹ is —(C_1-3 alkyl); and the heteroaryl is selected from the group consisting of pyridine, furan, thiophene, and imidazole.

In some embodiments, R² is F; R¹ and R⁴ are H; R³ is -pyrimidinyl(R⁶)_q; q is 0; R is -heterocyclyl(R⁹)_h; h is 1 or 2; R⁹ is selected from the group consisting of halide and —(C_1-2 alkyl).

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyrazol-4-yl(R⁶)_q; q is 0 or 1; R⁶ is —(C_1-3 alkyl); R⁵ is -phenyl(R¹⁰)_k; k is 1 or 2; and R¹⁰ is F.

In some embodiments, R¹, R², and R⁴ are H; R³ is -imidazol-5-yl(R⁶)_q; q is 1 or 2; each R⁶ is independently selected from —(C_1-3 alkyl); R⁵ is -phenyl(R¹⁰)_k; k is 1 or 2; and R¹⁰ is F.

In some embodiments, R¹, R², and R⁴ are H; R³ is -pyridin-3-yl(R⁶)_q; q is 1; R⁶ is —OR²⁴; R²⁴ is selected from the group consisting of H and —(C_1-3 alkyl); R⁵ is -phenyl(R¹⁰)_k; k is 1 or 2; and R¹⁰ is F.

Illustrative compounds of Formula (I) are shown in Table 1.

TABLE 1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
2220
2221
2222
2223
2224
2225
2226
2227
2228
2229
2230
2231
2232
2233
2234
2235
2236
2237
2238
2239
2240
2241
2242
2243
2244
2245
2246
2247
2248
2249
2250
2251
2252
2253
2254
2255
2256
2257
2258
2259
2260
2261
2262
2263
2264
2265
2266
2267
2268
2269
2270
2271
2272
2273
2274
2275
2276
2277
2278
2279
2280
2281
2282
2283
2284
2285
2286
2287
2288
2289
2290

Administration and Pharmaceutical Compositions

Some embodiments include pharmaceutical compositions comprising: (a) a therapeutically effective amount of a compound provided herein, or its corresponding enantiomer, diastereoisomer or tautomer, or pharmaceutically acceptable salt; and (b) a pharmaceutically acceptable carrier.

The compounds provided herein may also be useful in combination (administered together or sequentially) with other known agents.

Non-limiting examples of diseases which can be treated with a combination of a compound of Formula (I) and other known agents are colorectal cancer, ovarian cancer, retinitis pigmentosa, macular degeneration, diabetic retinopathy, idiopathic pulmonary fibrosis/pulmonary fibrosis, and osteoarthritis.

In some embodiments, colorectal cancer can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: 5-Fluorouracil (5-FU), which can be administered with the vitamin-like drug leucovorin (also called folinic acid); capecitabine (XELODA®), irinotecan (CAMPOSTAR®), oxaliplatin (ELOXATIN®). Examples of combinations of these drugs which could be further combined with a compound of Formula (I) are FOLFOX (5-FU, leucovorin, and oxaliplatin), FOLFIRI (5-FU, leucovorin, and irinotecan), FOLFOXIRI (leucovorin, 5-FU, oxaliplatin, and irinotecan) and CapeOx (Capecitabine and oxaliplatin). For rectal cancer, chemo with 5-FU or capecitabine combined with radiation may be given before surgery (neoadjuvant treatment).

In some embodiments, ovarian cancer can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: Topotecan, Liposomal doxorubicin (DOXIL®), Gemcitabine (GEMZAR®), Cyclophosphamide (CYTOXAN®), Vinorelbine (NAVELBINE®), Ifosfamide (IFEX®), Etoposide (VP-16), Altretamine (HEXALEN®), Capecitabine (XELODA®), Irinotecan (CPT-11, CAMPTOSAR®), Melphalan, Pemetrexed (ALIMTA®) and Albumin bound paclitaxel (nab-paclitaxel, ABRAXANE®). Examples of combinations of these drugs which could be further combined with a compound of Formula (I) are TIP (paclitaxel [Taxol], ifosfamide, and cisplatin), VeIP (vinblastine, ifosfamide, and cisplatin) and VIP (etoposide [VP-16], ifosfamide, and cisplatin).

In some embodiments, a compound of Formula (I) can be used to treat cancer in combination with any of the following methods: (a) Hormone therapy such as aromatase inhibitors, LHRH [luteinizing hormone-releasing hormone] analogs and inhibitors, and others; (b) Ablation or embolization procedures such as radiofrequency ablation (RFA), ethanol (alcohol) ablation, microwave thermotherapy and cryosurgery (cryotherapy); (c) Chemotherapy using alkylating agents such as cisplatin and carboplatin, oxaliplatin, mechlorethamine, cyclophosphamide, chlorambucil and ifosfamide; (d) Chemotherapy using anti-metabolites such as azathioprine and mercaptopurine; (e) Chemotherapy using plant alkaloids and terpenoids such as vinca alkaloids (i.e. Vincristine, Vinblastine, Vinorelbine and Vindesine) and taxanes; (f) Chemotherapy using podophyllotoxin, etoposide, teniposide and docetaxel; (g) Chemotherapy using topoisomerase inhibitors such as irinotecan, topotecan, amsacrine, etoposide, etoposide phosphate, and teniposide; (h) Chemotherapy using cytotoxic antibiotics such as actinomycin, anthracyclines, doxorubicin, daunorubicin, valrubicin, idarubicin, epirubicin, bleomycin, plicamycin and mitomycin; (i) Chemotherapy using tyrosine-kinase inhibitors such as Imatinib mesylate (GLEEVEC®, also known as STI-571), Gefitinib (Iressa, also known as ZD1839), Erlotinib (marketed as TARCEVA®), Bortezomib (VELCADE®), tamoxifen, tofacitinib, crizotinib, Bcl-2 inhibitors (e.g. obatoclax in clinical trials, ABT-263, and Gossypol), PARP inhibitors (e.g. Iniparib, Olaparib in clinical trials), PI3K inhibitors (e.g. perifosine in a phase III trial), VEGF Receptor 2 inhibitors (e.g. Apatinib), AN-152, (AEZS-108), Braf inhibitors (e.g. vemurafenib, dabrafenib and LGX818), MEK inhibitors (e.g. trametinib and MEK162), CDK inhibitors, (e.g. PD-0332991), salinomycin and Sorafenib; (j) Chemotherapy using monoclonal antibodies such as Rituximab (marketed as MABTHERA® or RITUXAN®), Trastuzumab (Herceptin also known as ErbB2), Cetuximab (marketed as ERBITUX®), and Bevacizumab (marketed as AVASTIN®); and (k) radiation therapy.

In some embodiments, diabetic retinopathy can be treated with a combination of a compound of Formula (I) and one or more of the following natural supplements: Bilberry, Butcher's broom, Ginkgo, Grape seed extract, and Pycnogenol (Pine bark).

In some embodiments, idiopathic pulmonary fibrosis/pulmonary fibrosis can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: pirfenidone (pirfenidone was approved for use in 2011 in Europe under the brand name Esbriet®), prednisone, azathioprine, N-acetylcysteine, interferon-γ 1b, bosentan (bosentan is currently being studied in patients with IPF, [The American Journal of Respiratory and Critical Care Medicine (2011), 184(1), 92-9]), Nintedanib (BIBF 1120 and Vargatef), QAX576 [British Journal of Pharmacology (2011), 163(1), 141-172], and anti-inflammatory agents such as corticosteroids.

In some embodiments, a compound of Formula (I) can be used to treat idiopathic pulmonary fibrosis/pulmonary fibrosis in combination with any of the following methods: oxygen therapy, pulmonary rehabilitation and surgery.

In some embodiments, a compound of Formula (I) can be used to treat osteoarthritis in combination with any of the following methods: (a) Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, aspirin and acetaminophen; (b) physical therapy; (c) injections of corticosteroid medications; (d) injections of hyaluronic acid derivatives (e.g. Hyalgan, Synvisc); (e) narcotics, like codeine; (f) in combination with braces and/or shoe inserts or any device that can immobilize or support your joint to help you keep pressure off it (e.g., splints, braces, shoe inserts or other medical devices); (g) realigning bones (osteotomy); (h) joint replacement (arthroplasty); and (i) in combination with a chronic pain class.

In some embodiments, macular degeneration can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: Bevacizumab (Avastin®), Ranibizumab (Lucentis®), Pegaptanib (Macugen), Aflibercept (Eylea®), verteporfin (Visudyne®) in combination with photodynamic therapy (PDT) or with any of the following methods: (a) in combination with laser to destroy abnormal blood vessels (photocoagulation); and (b) in combination with increased vitamin intake of antioxidant vitamins and zinc.

In some embodiments, retinitis pigmentosa can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: UF-021 (Ocuseva™), vitamin A palmitate and pikachurin or with any of the following methods: (a) with the Argus® II retinal implant; and (b) with stem cell and/or gene therapy.

Administration of the compounds disclosed herein or the pharmaceutically acceptable salts thereof can be via any of the accepted modes of administration, including, but not limited to, orally, subcutaneously, intravenously, intranasally, topically, transdermally, intraperitoneally, intramuscularly, intrapulmonarilly, vaginally, rectally, ontologically, neuro-otologically, intraocularly, subconjuctivally, via anterior eye chamber injection, intravitreally, intraperitoneally, intrathecally, intracystically, intrapleurally, via wound irrigation, intrabuccally, intra-abdominally, intra-articularly, intra-aurally, intrabronchially, intracapsularly, intrameningeally, via inhalation, via endotracheal or endobronchial instillation, via direct instillation into pulmonary cavities, intraspinally, intrasynovially, intrathoracically, via thoracostomy irrigation, epidurally, intratympanically, intracisternally, intravascularly, intraventricularly, intraosseously, via irrigation of infected bone, or via application as part of any admixture with a prosthetic devices. In some embodiments, the administration method includes oral or parenteral administration.

Compounds provided herein intended for pharmaceutical use may be administered as crystalline or amorphous products. Pharmaceutically acceptable compositions may include solid, semi-solid, liquid, solutions, colloidal, liposomes, emulsions, suspensions, complexes, coacervates and aerosols. Dosage forms, such as, e.g., tablets, capsules, powders, liquids, suspensions, suppositories, aerosols, implants, controlled release or the like. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, milling, grinding, supercritical fluid processing, coacervation, complex coacervation, encapsulation, emulsification, complexation, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose. The compounds can also be administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, pills (tablets and or capsules), transdermal (including electrotransport) patches, implants and the like, for prolonged and/or timed, pulsed administration at a predetermined rate.

The compounds can be administered either alone or in combination with a conventional pharmaceutical carrier, excipient or the like. Pharmaceutically acceptable excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-α-tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens, poloxamers or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, tris, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium-chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, and wool fat. Cyclodextrins such as α-, β, and γ-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-β-cyclodextrins, or other solubilized derivatives can also be used to enhance delivery of compounds described herein. Dosage forms or compositions containing a compound as described herein in the range of 0.005% to 100% with the balance made up from non-toxic carrier may be prepared. The contemplated compositions may contain 0.001%-100% of a compound provided herein, in one embodiment 0.1-95%, in another embodiment 75-85%, in a further embodiment 20-80%. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington: The Science and Practice of Pharmacy, 22^nd Edition (Pharmaceutical Press, London, U K. 2012).

In one embodiment, the compositions will take the form of a unit dosage form such as a pill or tablet and thus the composition may contain, along with a compound provided herein, a diluent such as lactose, sucrose, dicalcium phosphate, or the like; a lubricant such as magnesium stearate or the like; and a binder such as starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose, cellulose derivatives or the like. In another solid dosage form, a powder, marume, solution or suspension (e.g., in propylene carbonate, vegetable oils, PEG's, poloxamer 124 or triglycerides) is encapsulated in a capsule (gelatin or cellulose base capsule). Unit dosage forms in which one or more compounds provided herein or additional active agents are physically separated are also contemplated; e.g., capsules with granules (or tablets in a capsule) of each drug; two-layer tablets; two-compartment gel caps, etc. Enteric coated or delayed release oral dosage forms are also contemplated.

Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. a compound provided herein and optional pharmaceutical adjuvants in a carrier (e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol or the like) to form a solution, colloid, liposome, emulsion, complexes, coacervate or suspension. If desired, the pharmaceutical composition can also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, co-solvents, solubilizing agents, pH buffering agents and the like (e.g., sodium acetate, sodium citrate, cyclodextrin derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, and the like).

In some embodiments, the unit dosage of compounds of Formula (I) is about 0.25 mg/Kg to about 50 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 0.25 mg/Kg to about 20 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 0.50 mg/Kg to about 19 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 0.75 mg/Kg to about 18 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 1.0 mg/Kg to about 17 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 1.25 mg/Kg to about 16 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 1.50 mg/Kg to about 15 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 1.75 mg/Kg to about 14 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 2.0 mg/Kg to about 13 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 3.0 mg/Kg to about 12 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 4.0 mg/Kg to about 11 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 5.0 mg/Kg to about 10 mg/Kg in humans.

In some embodiments, the compositions are provided in unit dosage forms suitable for single administration.

In some embodiments, the compositions are provided in unit dosage forms suitable for twice a day administration.

In some embodiments, the compositions are provided in unit dosage forms suitable for three times a day administration.

Injectables can be prepared in conventional forms, either as liquid solutions, colloid, liposomes, complexes, coacervate or suspensions, as emulsions, or in solid forms suitable for reconstitution in liquid prior to injection. The percentage of a compound provided herein contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the patient. However, percentages of active ingredient of 0.01% to 10% in solution are employable, and could be higher if the composition is a solid or suspension, which could be subsequently diluted to the above percentages.

In some embodiments, the composition will comprise about 0.1-10% of the active agent in solution.

In some embodiments, the composition will comprise about 0.1-5% of the active agent in solution.

In some embodiments, the composition will comprise about 0.1-4% of the active agent in solution.

In some embodiments, the composition will comprise about 0.15-3% of the active agent in solution.

In some embodiments, the composition will comprise about 0.2-2% of the active agent in solution.

In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-96 hours.

In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-72 hours.

In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-48 hours.

In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-24 hours.

In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-12 hours.

In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-6 hours.

In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m² to about 300 mg/m².

In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m² to about 200 mg/m².

In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m² to about 100 mg/m².

In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 10 mg/m² to about 50 mg/m².

In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 50 mg/m² to about 200 mg/m².

In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 75 mg/m² to about 175 mg/m².

In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 100 mg/m² to about 150 mg/m².

It is to be noted that concentrations and dosage values may also vary depending on the specific compound and the severity of the condition to be alleviated. It is to be further understood that for any particular patient, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.

In one embodiment, the compositions can be administered to the respiratory tract (including nasal and pulmonary) e.g., through a nebulizer, metered-dose inhalers, atomizer, mister, aerosol, dry powder inhaler, insufflator, liquid instillation or other suitable device or technique.

In some embodiments, aerosols intended for delivery to the nasal mucosa are provided for inhalation through the nose. For optimal delivery to the nasal cavities, inhaled particle sizes of about 5 to about 100 microns are useful, with particle sizes of about 10 to about 60 microns being preferred. For nasal delivery, a larger inhaled particle size may be desired to maximize impaction on the nasal mucosa and to minimize or prevent pulmonary deposition of the administered formulation. In some embodiments, aerosols intended for delivery to the lung are provided for inhalation through the nose or the mouth. For delivery to the lung, inhaled aerodynamic particle sizes of about less than 10 μm are useful (e.g., about 1 to about 10 microns). Inhaled particles may be defined as liquid droplets containing dissolved drug, liquid droplets containing suspended drug particles (in cases where the drug is insoluble in the suspending medium), dry particles of pure drug substance, drug substance incorporated with excipients, liposomes, emulsions, colloidal systems, coacervates, aggregates of drug nanoparticles, or dry particles of a diluent which contain embedded drug nanoparticles.

In some embodiments, compounds of Formula (I) disclosed herein intended for respiratory delivery (either systemic or local) can be administered as aqueous formulations, as non-aqueous solutions or suspensions, as suspensions or solutions in halogenated hydrocarbon propellants with or without alcohol, as a colloidal system, as emulsions, coacervates, or as dry powders. Aqueous formulations may be aerosolized by liquid nebulizers employing either hydraulic or ultrasonic atomization or by modified micropump systems (like the soft mist inhalers, the Aerodose® or the AERx® systems). Propellant-based systems may use suitable pressurized metered-dose inhalers (pMDIs). Dry powders may use dry powder inhaler devices (DPIs), which are capable of dispersing the drug substance effectively. A desired particle size and distribution may be obtained by choosing an appropriate device.

In some embodiments, the compositions of Formula (I) disclosed herein can be administered to the ear by various methods. For example, a round window catheter (e.g., U.S. Pat. Nos. 6,440,102 and 6,648,873) can be used.

Alternatively, formulations can be incorporated into a wick for use between the outer and middle ear (e.g., U.S. Pat. No. 6,120,484) or absorbed to collagen sponge or other solid support (e.g., U.S. Pat. No. 4,164,559).

If desired, formulations of the invention can be incorporated into a gel formulation (e.g., U.S. Pat. Nos. 4,474,752 and 6,911,211).

In some embodiments, compounds of Formula (I) disclosed herein intended for delivery to the ear can be administered via an implanted pump and delivery system through a needle directly into the middle or inner ear (cochlea) or through a cochlear implant stylet electrode channel or alternative prepared drug delivery channel such as but not limited to a needle through temporal bone into the cochlea.

Other options include delivery via a pump through a thin film coated onto a multichannel electrode or electrode with a specially imbedded drug delivery channel (pathways) carved into the thin film for this purpose. In other embodiments the acidic or basic solid compound of Formula (I) can be delivered from the reservoir of an external or internal implanted pumping system.

Formulations of the invention also can be administered to the ear by intratympanic injection into the middle ear, inner ear, or cochlea (e.g., U.S. Pat. No. 6,377,849 and Ser. No. 11/337,815).

Intratympanic injection of therapeutic agents is the technique of injecting a therapeutic agent behind the tympanic membrane into the middle and/or inner ear. In one embodiment, the formulations described herein are administered directly onto the round window membrane via transtympanic injection. In another embodiment, the ion channel modulating agent auris-acceptable formulations described herein are administered onto the round window membrane via a non-transtympanic approach to the inner ear. In additional embodiments, the formulation described herein is administered onto the round window membrane via a surgical approach to the round window membrane comprising modification of the crista fenestrae cochleae.

In some embodiments, the compounds of Formula (I) are formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG (like PEG ointments), and the like.

Suppositories for rectal administration of the drug (either as a solution, colloid, suspension or a complex) can be prepared by mixing a compound provided herein with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt or erode/dissolve in the rectum and release the compound. Such materials include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, poloxamers, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol. In suppository forms of the compositions, a low-melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter, is first melted.

Solid compositions can be provided in various different types of dosage forms, depending on the physicochemical properties of the compound provided herein, the desired dissolution rate, cost considerations, and other criteria. In one of the embodiments, the solid composition is a single unit. This implies that one unit dose of the compound is comprised in a single, physically shaped solid form or article. In other words, the solid composition is coherent, which is in contrast to a multiple unit dosage form, in which the units are incoherent.

Examples of single units which may be used as dosage forms for the solid composition include tablets, such as compressed tablets, film-like units, foil-like units, wafers, lyophilized matrix units, and the like. In one embodiment, the solid composition is a highly porous lyophilized form. Such lyophilizates, sometimes also called wafers or lyophilized tablets, are particularly useful for their rapid disintegration, which also enables the rapid dissolution of the compound.

On the other hand, for some applications the solid composition may also be formed as a multiple unit dosage form as defined above. Examples of multiple units are powders, granules, microparticles, pellets, mini-tablets, beads, lyophilized powders, and the like. In one embodiment, the solid composition is a lyophilized powder. Such a dispersed lyophilized system comprises a multitude of powder particles, and due to the lyophilization process used in the formation of the powder, each particle has an irregular, porous microstructure through which the powder is capable of absorbing water very rapidly, resulting in quick dissolution. Effervescent compositions are also contemplated to aid the quick dispersion and absorption of the compound.

Another type of multiparticulate system which is also capable of achieving rapid drug dissolution is that of powders, granules, or pellets from water-soluble excipients which are coated with a compound provided herein so that the compound is located at the outer surface of the individual particles. In this type of system, the water-soluble low molecular weight excipient may be useful for preparing the cores of such coated particles, which can be subsequently coated with a coating composition comprising the compound and, for example, one or more additional excipients, such as a binder, a pore former, a saccharide, a sugar alcohol, a film-forming polymer, a plasticizer, or other excipients used in pharmaceutical coating compositions.

Also provided herein are kits. Typically, a kit includes one or more compounds or compositions as described herein. In certain embodiments, a kit can include one or more delivery systems, e.g., for delivering or administering a compound as provided herein, and directions for use of the kit (e.g., instructions for treating a patient). In another embodiment, the kit can include a compound or composition as described herein and a label that indicates that the contents are to be administered to a patient with cancer. In another embodiment, the kit can include a compound or composition as described herein and a label that indicates that the contents are to be administered to a patient with one or more of hepatocellular carcinoma, colon cancer, leukemia, lymphoma, sarcoma, ovarian cancer, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, mycotic and viral infections, bone and cartilage diseases, Alzheimer's disease, lung disease, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), polyposis coli, bone density and vascular defects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG) and other eye diseases or syndromes associated with defects and/or damaged photoreceptors, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Müllerian-duct regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease, and Rett syndrome.

Methods of Treatment

The compounds and compositions provided herein can be used as inhibitors and/or modulators of one or more components of the Wnt pathway, which may include one or more Wnt proteins, and thus can be used to treat a variety of disorders and diseases in which aberrant Wnt signaling is implicated, such as cancer and other diseases associated with abnormal angiogenesis, cellular proliferation, and cell cycling. Accordingly, the compounds and compositions provided herein can be used to treat cancer, to reduce or inhibit angiogenesis, to reduce or inhibit cellular proliferation, to correct a genetic disorder, and/or to treat a neurological condition/disorder/disease due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Non-limiting examples of diseases which can be treated with the compounds and compositions provided herein include a variety of cancers, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, scleroderma, mycotic and viral infections, bone and cartilage diseases, neurological conditions/diseases such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), motor neuron disease, multiple sclerosis or autism, lung disease, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, polyposis coli, bone density and vascular defects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG) and other eye diseases or syndromes associated with defects and/or damaged photoreceptors, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Müllerian-duct regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease and Rett syndrome.

In some embodiments, non-limiting examples of eye diseases which can be treated with the compounds and compositions provided herein include age-related macular degeneration (AMD or ARMD), rod cone dystrophy, retinitis pigmentosa (RP), acute idiopathic blind spot enlargement (AIBSE), acute zonal occult outer retinopathy (AZOOR), acute macular neuroretinopathy (AMN), multiple evanescent white dot syndrome (MEWDS), multifocal choroiditis, opticneuropathy. Further causes of photoreceptor damage that can be treated with the compounds and compositions provided herein include retinal detachment, vascular disturbance, eye tumors or extreme light damage.

With respect to cancer, the Wnt pathway is known to be constitutively activated in a variety of cancers including, for example, colon cancer, hepatocellular carcinoma, lung cancer, ovarian cancer, prostate cancer, pancreatic cancer and leukemias such as CML, CLL and T-ALL. Accordingly, the compounds and compositions described herein may be used to treat these cancers in which the Wnt pathway is constitutively activated. In certain embodiments, the cancer is chosen from hepatocellular carcinoma, colon cancer, leukemia, lymphoma, sarcoma and ovarian cancer.

Other cancers can also be treated with the compounds and compositions described herein.

More particularly, cancers that may be treated by the compounds, compositions and methods described herein include, but are not limited to, the following:

1) Breast cancers, including, for example ER⁺ breast cancer, ER⁻ breast cancer, her2⁻ breast cancer, her2⁺ breast cancer, stromal tumors such as fibroadenomas, phyllodes tumors, and sarcomas, and epithelial tumors such as large duct papillomas; carcinomas of the breast including in situ (noninvasive) carcinoma that includes ductal carcinoma in situ (including Paget's disease) and lobular carcinoma in situ, and invasive (infiltrating) carcinoma including, but not limited to, invasive ductal carcinoma, invasive lobular carcinoma, medullary carcinoma, colloid (mucinous) carcinoma, tubular carcinoma, and invasive papillary carcinoma; and miscellaneous malignant neoplasms. Further examples of breast cancers can include luminal A, luminal B, basal A, basal B, and triple negative breast cancer, which is estrogen receptor negative (ER⁻), progesterone receptor negative, and her2 negative (her2⁻). In some embodiments, the breast cancer may have a high risk Oncotype score.

2) Cardiac cancers, including, for example sarcoma, e.g., angiosarcoma, fibrosarcoma, rhabdomyosarcoma, and liposarcoma; myxoma; rhabdomyoma; fibroma; lipoma and teratoma.

3) Lung cancers, including, for example, bronchogenic carcinoma, e.g., squamous cell, undifferentiated small cell, undifferentiated large cell, and adenocarcinoma; alveolar and bronchiolar carcinoma; bronchial adenoma; sarcoma; lymphoma; chondromatous hamartoma; and mesothelioma.

4) Gastrointestinal cancer, including, for example, cancers of the esophagus, e.g., squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, and lymphoma; cancers of the stomach, e.g., carcinoma, lymphoma, and leiomyosarcoma; cancers of the pancreas, e.g., ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, and vipoma; cancers of the small bowel, e.g., adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, and fibroma; cancers of the large bowel, e.g., adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, and leiomyoma.

5) Genitourinary tract cancers, including, for example, cancers of the kidney, e.g., adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, and leukemia; cancers of the bladder and urethra, e.g., squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma; cancers of the prostate, e.g., adenocarcinoma, and sarcoma; cancer of the testis, e.g., seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, and lipoma.

6) Liver cancers, including, for example, hepatoma, e.g., hepatocellular carcinoma; cholangiocarcinoma; hepatoblastoma; angiosarcoma; hepatocellular adenoma; and hemangioma.

7) Bone cancers, including, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochrondroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors.

8) Nervous system cancers, including, for example, cancers of the skull, e.g., osteoma, hemangioma, granuloma, xanthoma, and osteitis deformans; cancers of the meninges, e.g., meningioma, meningiosarcoma, and gliomatosis; cancers of the brain, e.g., astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, and congenital tumors; and cancers of the spinal cord, e.g., neurofibroma, meningioma, glioma, and sarcoma.

9) Gynecological cancers, including, for example, cancers of the uterus, e.g., endometrial carcinoma; cancers of the cervix, e.g., cervical carcinoma, and pre tumor cervical dysplasia; cancers of the ovaries, e.g., ovarian carcinoma, including serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma, granulosa theca cell tumors, Sertoli Leydig cell tumors, dysgerminoma, and malignant teratoma; cancers of the vulva, e.g., squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, and melanoma; cancers of the vagina, e.g., clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma, and embryonal rhabdomyosarcoma; and cancers of the fallopian tubes, e.g., carcinoma.

10) Hematologic cancers, including, for example, cancers of the blood, e.g., acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, and myelodysplastic syndrome, Hodgkin's lymphoma, non-Hodgkin's lymphoma (malignant lymphoma) and Waldenstrom's macroglobulinemia.

11) Skin cancers and skin disorders, including, for example, malignant melanoma and metastatic melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, and scleroderma.

12) Adrenal gland cancers, including, for example, neuroblastoma.

Cancers may be solid tumors that may or may not be metastatic. Cancers may also occur, as in leukemia, as a diffuse tissue. Thus, the term “tumor cell,” as provided herein, includes a cell afflicted by any one of the above identified disorders.

A method of treating cancer using a compound or composition as described herein may be combined with existing methods of treating cancers, for example by chemotherapy, irradiation, or surgery (e.g., oophorectomy). In some embodiments, a compound or composition can be administered before, during, or after another anticancer agent or treatment.

The compounds and compositions described herein can be used as anti-angiogenesis agents and as agents for modulating and/or inhibiting the activity of protein kinases, thus providing treatments for cancer and other diseases associated with cellular proliferation mediated by protein kinases. For example, the compounds described herein can inhibit the activity of one or more kinases. Accordingly, provided herein is a method of treating cancer or preventing or reducing angiogenesis through kinase inhibition.

In addition, and including treatment of cancer, the compounds and compositions described herein can function as cell-cycle control agents for treating proliferative disorders in a patient. Disorders associated with excessive proliferation include, for example, cancers, scleroderma, immunological disorders involving undesired proliferation of leukocytes, and restenosis and other smooth muscle disorders. Furthermore, such compounds may be used to prevent de-differentiation of post-mitotic tissue and/or cells.

Diseases or disorders associated with uncontrolled or abnormal cellular proliferation include, but are not limited to, the following:

• • a variety of cancers, including, but not limited to, carcinoma, hematopoietic tumors of lymphoid lineage, hematopoietic tumors of myeloid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system and other tumors including melanoma, seminoma and Kaposi's sarcoma.
  • a disease process which features abnormal cellular proliferation, e.g., benign prostatic hyperplasia, familial adenomatosis polyposis, neurofibromatosis, atherosclerosis, arthritis, glomerulonephritis, restenosis following angioplasty or vascular surgery, inflammatory bowel disease, transplantation rejection, endotoxic shock, and fungal infections. Fibrotic disorders such as skin fibrosis; scleroderma; progressive systemic fibrosis; lung fibrosis; muscle fibrosis; kidney fibrosis; glomerulosclerosis; glomerulonephritis; hypertrophic scar formation; uterine fibrosis; renal fibrosis; cirrhosis of the liver, liver fibrosis; fatty liver disease (FLD); adhesions, such as those occurring in the abdomen, pelvis, spine or tendons; chronic obstructive pulmonary disease; fibrosis following myocardial infarction; pulmonary fibrosis; fibrosis and scarring associated with diffuse/interstitial lung disease; central nervous system fibrosis, such as fibrosis following stroke; fibrosis associated with neuro-degenerative disorders such as Alzheimer's Disease or multiple sclerosis; fibrosis associated with proliferative vitreoretinopathy (PVR); restenosis; endometriosis; ischemic disease and radiation fibrosis.
  • defective apoptosis-associated conditions, such as cancers (including but not limited to those types mentioned herein), viral infections (including but not limited to herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus), prevention of AIDS development in HIV-infected individuals, autoimmune diseases (including but not limited to systemic lupus erythematosus, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, autoimmune mediated glomerulonephritis, inflammatory bowel disease and autoimmune diabetes mellitus), neuro-degenerative disorders (including but not limited to Alzheimer's disease, lung disease, amyotrophic lateral sclerosis, retinitis pigmentosa, Parkinson's disease, AIDS-related dementia, spinal muscular atrophy and cerebellar degeneration), myelodysplastic syndromes, aplastic anemia, ischemic injury associated with myocardial infarctions, stroke and reperfusion injury, arrhythmia, atherosclerosis, toxin-induced or alcohol related liver diseases, hematological diseases (including but not limited to chronic anemia and aplastic anemia), degenerative diseases of the musculoskeletal system (including but not limited to osteoporosis and arthritis), tendinopathies such as tendinitis and tendinosis, aspirin-sensitive rhinosinusitis, cystic fibrosis, multiple sclerosis, kidney diseases and cancer pain.
  • genetic diseases due to mutations in Wnt signaling components, such as polyposis coli, bone density and vascular defects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG) and other eye diseases or syndromes associated with defects and/or damaged photoreceptors, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Müllerian-duct regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease and Rett syndrome.

The compounds and compositions described herein can be used to treat neurological conditions, disorders and/or diseases caused by dysfunction in the Wnt signaling pathway. Non-limiting examples of neurological conditions/disorders/diseases which can be treated with the compounds and compositions provided herein include Alzheimer's disease, aphasia, apraxia, arachnoiditis, ataxia telangiectasia, attention deficit hyperactivity disorder, auditory processing disorder, autism, alcoholism, Bell's palsy, bipolar disorder, brachial plexus injury, Canavan disease, carpal tunnel syndrome, causalgia, central pain syndrome, central pontine myelinolysis, centronuclear myopathy, cephalic disorder, cerebral aneurysm, cerebral arteriosclerosis, cerebral atrophy, cerebral gigantism, cerebral palsy, cerebral vasculitis, cervical spinal stenosis, Charcot-Marie-Tooth disease, Chiari malformation, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic pain, Coffin-Lowry syndrome, complex regional pain syndrome, compression neuropathy, congenital facial diplegia, corticobasal degeneration, cranial arteritis, craniosynostosis, Creutzfeldt-Jakob disease, cumulative trauma disorder, Cushing's syndrome, cytomegalic inclusion body disease (CIBD), Dandy-Walker syndrome, Dawson disease, de Morsier's syndrome, Dejerine-Klumpke palsy, Dejerine-Sottas disease, delayed sleep phase syndrome, dementia, dermatomyositis, developmental dyspraxia, diabetic neuropathy, diffuse sclerosis, Dravet syndrome, dysautonomia, dyscalculia, dysgraphia, dyslexia, dystonia, empty sella syndrome, encephalitis, encephalocele, encephalotrigeminal angiomatosis, encopresis, epilepsy, Erb's palsy, erythromelalgia, essential tremor, Fabry's disease, Fahr's syndrome, familial spastic paralysis, febrile seizure, Fisher syndrome, Friedreich's ataxia, fibromyalgia, Foville's syndrome, Gaucher's disease, Gerstmann's syndrome, giant cell arteritis, giant cell inclusion disease, globoid cell leukodystrophy, gray matter heterotopia, Guillain-Barre syndrome, HTLV-1 associated myelopathy, Hallervorden-Spatz disease, hemifacial spasm, hereditary spastic paraplegia, heredopathia atactica polyneuritiformis, herpes zoster oticus, herpes zoster, Hirayama syndrome, holoprosencephaly, Huntington's disease, hydranencephaly, hydrocephalus, hypercortisolism, hypoxia, immune-mediated encephalomyelitis, inclusion body myositis, incontinentia pigmenti, infantile phytanic acid storage disease, infantile Refsum disease, infantile spasms, inflammatory myopathy, intracranial cyst, intracranial hypertension, Joubert syndrome, Karak syndrome, Kearns-Sayre syndrome, Kennedy disease, Kinsbourne syndrome, Klippel Feil syndrome, Krabbe disease, Kugelberg-Welander disease, kuru, Lafora disease, Lambert-Eaton myasthenic syndrome, Landau-Kleffner syndrome, lateral medullary (Wallenberg) syndrome, Leigh's disease, Lennox-Gastaut syndrome, Lesch-Nyhan syndrome, leukodystrophy, Lewy body dementia, lissencephaly, locked-in syndrome, Lou Gehrig's disease, lumbar disc disease, lumbar spinal stenosis, Lyme disease, Machado-Joseph disease (Spinocerebellar ataxia type 3), macrencephaly, macropsia, megalencephaly, Melkersson-Rosenthal syndrome, Meniere's disease, meningitis, Menkes disease, metachromatic leukodystrophy, microcephaly, micropsia, Miller Fisher syndrome, misophonia, mitochondrial myopathy, Mobius syndrome, monomelic amyotrophy, motor neuron disease, motor skills disorder, Moyamoya disease, mucopolysaccharidoses, multi-infarct dementia, multifocal motor neuropathy, multiple sclerosis, multiple system atrophy, muscular dystrophy, myalgic encephalomyelitis, myasthenia gravis, myelinoclastic diffuse sclerosis, myoclonic Encephalopathy of infants, myoclonus, myopathy, myotubular myopathy, myotonia congenital, narcolepsy, neurofibromatosis, neuroleptic malignant syndrome, lupus erythematosus, neuromyotonia, neuronal ceroid lipofuscinosis, Niemann-Pick disease, O'Sullivan-McLeod syndrome, occipital Neuralgia, occult Spinal Dysraphism Sequence, Ohtahara syndrome, olivopontocerebellar atrophy, opsoclonus myoclonus syndrome, optic neuritis, orthostatic hypotension, palinopsia, paresthesia, Parkinson's disease, paramyotonia Congenita, paraneoplastic diseases, paroxysmal attacks, Parry-Romberg syndrome, Pelizaeus-Merzbacher disease, periodic paralyses, peripheral neuropathy, photic sneeze reflex, phytanic acid storage disease, Pick's disease, polymicrogyria (PMG), polymyositis, porencephaly, post-polio syndrome, postherpetic neuralgia (PHN), postural hypotension, Prader-Willi syndrome, primary lateral sclerosis, prion diseases, progressive hemifacial atrophy, progressive multifocal leukoencephalopathy, progressive supranuclear palsy, pseudotumor cerebri, Ramsay Hunt syndrome type I, Ramsay Hunt syndrome type II, Ramsay Hunt syndrome type III, Rasmussen's encephalitis, reflex neurovascular dystrophy, Refsum disease, restless legs syndrome, retrovirus-associated myelopathy, Rett syndrome, Reye's syndrome, rhythmic movement disorder, Romberg syndrome, Saint Vitus dance, Sandhoff disease, schizophrenia, Schilder's disease, schizencephaly, sensory integration dysfunction, septo-optic dysplasia, Shy-Drager syndrome, Sjögren's syndrome, snatiation, Sotos syndrome, spasticity, spina bifida, spinal cord tumors, spinal muscular atrophy, spinocerebellar ataxia, Steele-Richardson-Olszewski syndrome, Stiff-person syndrome, stroke, Sturge-Weber syndrome, subacute sclerosing panencephalitis, subcortical arteriosclerotic encephalopathy, superficial siderosis, Sydenham's chorea, syncope, synesthesia, syringomyelia, tarsal tunnel syndrome, tardive dyskinesia, tardive dysphrenia, Tarlov cyst, Tay-Sachs disease, temporal arteritis, tetanus, tethered spinal cord syndrome, Thomsen disease, thoracic outlet syndrome, tic douloureux, Todd's paralysis, Tourette syndrome, toxic encephalopathy, transient ischemic attack, transmissible spongiform encephalopathies, transverse myelitis, tremor, trigeminal neuralgia, tropical spastic paraparesis, trypanosomiasis, tuberous sclerosis, ubisiosis, Von Hippel-Lindau disease (VHL), Viliuisk Encephalomyelitis (VE), Wallenberg's syndrome, Werdnig, Hoffman disease, west syndrome, Williams syndrome, Wilson's disease and Zellweger syndrome.

The compounds and compositions may also be useful in the inhibition of the development of invasive cancer, tumor angiogenesis and metastasis.

In some embodiments, the disclosure provides a method for treating a disease or disorder associated with aberrant cellular proliferation by administering to a patient in need of such treatment an effective amount of one or more of the compounds of Formula (I), in combination (simultaneously or sequentially) with at least one other agent.

In some embodiments, the disclosure provides a method of treating or ameliorating in a patient a disorder or disease selected from the group consisting of: cancer, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), degenerative disc disease, bone/osteoporotic fractures, bone or cartilage disease, and osteoarthritis, the method comprising administering to the patient a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

In some embodiments, the method of treats a disorder or disease in which aberrant Wnt signaling is implicated in a patient, the method comprises administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

In some embodiments, the disorder or disease is cancer.

In some embodiments, the disorder or disease is systemic inflammation.

In some embodiments, the disorder or disease is metastatic melanoma.

In some embodiments, the disorder or disease is fatty liver disease.

In some embodiments, the disorder or disease is liver fibrosis.

In some embodiments, the disorder or disease is tendonitis.

In some embodiments, the disorder or disease is damage to a tendon requiring tendon regeneration.

In some embodiments, the disorder or disease is diabetes.

In some embodiments, the disorder or disease is degenerative disc disease.

In some embodiments, the disorder or disease is osteoarthritis.

In some embodiments, the disorder or disease is diabetic retinopathy.

In some embodiments, the disorder or disease is pulmonary fibrosis.

In some embodiments, the disorder or disease is idiopathic pulmonary fibrosis (IPF).

In some embodiments, the disorder or disease is degenerative disc disease.

In some embodiments, the disorder or disease is rheumatoid arthritis.

In some embodiments, the disorder or disease is scleroderma.

In some embodiments, the disorder or disease is a mycotic or viral infection.

In some embodiments, the disorder or disease is a bone or cartilage disease.

In some embodiments, the disorder or disease is Alzheimer's disease.

In some embodiments, the disorder or disease is osteoarthritis.

In some embodiments, the disorder or disease is lung disease

In some embodiments, the disorder or disease is a genetic disease caused by mutations in Wnt signaling components, wherein the genetic disease is selected from: polyposis coli, osteoporosis-pseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia syndrome, Müllerian-duct regression and virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease and Rett syndrome.

In some embodiments, the patient is a human.

In some embodiments, the cancer is chosen from: hepatocellular carcinoma, colon cancer, breast cancer, pancreatic cancer, chronic myeloid leukemia (CML), chronic myelomonocytic leukemia, chronic lymphocytic leukemia (CLL), acute myeloid leukemia, acute lymphocytic leukemia, Hodgkin lymphoma, lymphoma, sarcoma and ovarian cancer.

In some embodiments, the cancer is chosen from: lung cancer—non-small cell, lung cancer—small cell, multiple myeloma, nasopharyngeal cancer, neuroblastoma, osteosarcoma, penile cancer, pituitary tumors, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer—basal and squamous cell, skin cancer—melanoma, small intestine cancer, stomach (gastric) cancers, testicular cancer, thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, laryngeal or hypopharyngeal cancer, kidney cancer, Kaposi sarcoma, gestational trophoblastic disease, gastrointestinal stromal tumor, gastrointestinal carcinoid tumor, gallbladder cancer, eye cancer (melanoma and lymphoma), Ewing tumor, esophagus cancer, endometrial cancer, colorectal cancer, cervical cancer, brain or spinal cord tumor, bone metastasis, bone cancer, bladder cancer, bile duct cancer, anal cancer and adrenal cortical cancer.

In some embodiments, the cancer is hepatocellular carcinoma.

In some embodiments, the cancer is colon cancer.

In some embodiments, the cancer is colorectal cancer.

In some embodiments, the cancer is breast cancer.

In some embodiments, the cancer is pancreatic cancer.

In some embodiments, the cancer is chronic myeloid leukemia (CML).

In some embodiments, the cancer is chronic myelomonocytic leukemia.

In some embodiments, the cancer is chronic lymphocytic leukemia (CLL).

In some embodiments, the cancer is acute myeloid leukemia.

In some embodiments, the cancer is acute lymphocytic leukemia.

In some embodiments, the cancer is Hodgkin lymphoma.

In some embodiments, the cancer is lymphoma.

In some embodiments, the cancer is sarcoma.

In some embodiments, the cancer is ovarian cancer.

In some embodiments, the cancer is lung cancer—non-small cell.

In some embodiments, the cancer is lung cancer—small cell.

In some embodiments, the cancer is multiple myeloma.

In some embodiments, the cancer is nasopharyngeal cancer.

In some embodiments, the cancer is neuroblastoma.

In some embodiments, the cancer is osteosarcoma.

In some embodiments, the cancer is penile cancer.

In some embodiments, the cancer is pituitary tumors.

In some embodiments, the cancer is prostate cancer.

In some embodiments, the cancer is retinoblastoma.

In some embodiments, the cancer is rhabdomyosarcoma.

In some embodiments, the cancer is salivary gland cancer.

In some embodiments, the cancer is skin cancer—basal and squamous cell.

In some embodiments, the cancer is skin cancer—melanoma.

In some embodiments, the cancer is small intestine cancer.

In some embodiments, the cancer is stomach (gastric) cancers.

In some embodiments, the cancer is testicular cancer.

In some embodiments, the cancer is thymus cancer.

In some embodiments, the cancer is thyroid cancer.

In some embodiments, the cancer is uterine sarcoma.

In some embodiments, the cancer is vaginal cancer.

In some embodiments, the cancer is vulvar cancer.

In some embodiments, the cancer is Wilms tumor.

In some embodiments, the cancer is laryngeal or hypopharyngeal cancer.

In some embodiments, the cancer is kidney cancer.

In some embodiments, the cancer is Kaposi sarcoma.

In some embodiments, the cancer is gestational trophoblastic disease.

In some embodiments, the cancer is gastrointestinal stromal tumor.

In some embodiments, the cancer is gastrointestinal carcinoid tumor.

In some embodiments, the cancer is gallbladder cancer.

In some embodiments, the cancer is eye cancer (melanoma and lymphoma).

In some embodiments, the cancer is Ewing tumor.

In some embodiments, the cancer is esophagus cancer.

In some embodiments, the cancer is endometrial cancer.

In some embodiments, the cancer is colorectal cancer.

In some embodiments, the cancer is cervical cancer.

In some embodiments, the cancer is brain or spinal cord tumor.

In some embodiments, the cancer is bone metastasis.

In some embodiments, the cancer is bone cancer.

In some embodiments, the cancer is bladder cancer.

In some embodiments, the cancer is bile duct cancer.

In some embodiments, the cancer is anal cancer.

In some embodiments, the cancer is adrenal cortical cancer.

In some embodiments, the disorder or disease is a neurological condition, disorder or disease, wherein the neurological condition/disorder/disease is selected from: Alzheimer's disease, frontotemporal dementias, dementia with lewy bodies, prion diseases, Parkinson's disease, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, amyotrophic lateral sclerosis (ALS), inclusion body myositis, autism, degenerative myopathies, diabetic neuropathy, other metabolic neuropathies, endocrine neuropathies, orthostatic hypotension, multiple sclerosis and Charcot-Marie-Tooth disease.

In some embodiments, the compound of Formula (I) inhibits one or more proteins in the Wnt pathway.

In some embodiments, the compound of Formula (I) inhibits signaling induced by one or more Wnt proteins.

In some embodiments, the Wnt proteins are chosen from: WNT1, WNT2, WNT2B, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, and WNT16.

In some embodiments, the method inhibits one or more proteins in the Wnt pathway, the method comprises contacting a cell with an effective amount of a compound of Formula (I).

In some embodiments, the cell is a human cell.

In some embodiments, the human cell is a cancerous cell.

In some embodiments, the cancerous cell is a colon cancer cell.

In some embodiments, the contacting is in vitro.

In some embodiments, the compound of Formula (I) inhibits a kinase activity.

In some embodiments, the method treats a disease or disorder mediated by the Wnt pathway in a patient, the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula (I) inhibits one or more Wnt proteins.

In some embodiments, the method treats a disease or disorder mediated by kinase activity in a patient, the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.

In some embodiments, the disease or disorder comprises tumor growth, cell proliferation, or angiogenesis.

In some embodiments, the method inhibits the activity of a protein kinase receptor, the method comprises contacting the receptor with an effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.

In some embodiments, the method treats a disease or disorder associated with aberrant cellular proliferation in a patient; the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.

In some embodiments, the method prevents or reduces angiogenesis in a patient; the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.

In some embodiments, the method prevents or reduces abnormal cellular proliferation in a patient; the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.

In some embodiments, the method treats a disease or disorder associated with aberrant cellular proliferation in a patient, the method comprises administering to the patient a pharmaceutical composition comprising one or more of the compounds of claim 1 in combination with a pharmaceutically acceptable carrier and one or more other agents.

Moreover, the compounds and compositions, for example, as inhibitors of the cyclin-dependent kinases (CDKs), can modulate the level of cellular RNA and DNA synthesis and therefore are expected to be useful in the treatment of viral infections such as HIV, human papilloma virus, herpes virus, Epstein-Barr virus, adenovirus, Sindbis virus, pox virus and the like.

Compounds and compositions described herein can inhibit the kinase activity of, for example, CDK/cyclin complexes, such as those active in the G₀. or G.₁ stage of the cell cycle, e.g., CDK2, CDK4, and/or CDK6 complexes.

Evaluation of Biological Activity

The biological activity of the compounds described herein can be tested using any suitable assay known to those of skill in the art, see, e.g., WO 2001/053268 and WO 2005/009997. For example, the activity of a compound may be tested using one or more of the test methods outlined below.

In one example, tumor cells may be screened for Wnt independent growth. In such a method, tumor cells of interest are contacted with a compound (i.e. inhibitor) of interest, and the proliferation of the cells, e.g. by uptake of tritiated thymidine, is monitored. In some embodiments, tumor cells may be isolated from a candidate patient who has been screened for the presence of a cancer that is associated with a mutation in the Wnt signaling pathway. Candidate cancers include, without limitation, those listed above.

In another example, one may utilize in vitro assays for Wnt biological activity, e.g. stabilization of β-catenin and promoting growth of stem cells. Assays for biological activity of Wnt include stabilization of β-catenin, which can be measured, for example, by serial dilutions of a candidate inhibitor composition. An exemplary assay for Wnt biological activity contacts a candidate inhibitor with cells containing constitutively active Wnt/β-catenin signaling. The cells are cultured for a period of time sufficient to stabilize β-catenin, usually at least about 1 hour, and lysed. The cell lysate is resolved by SDS PAGE, then transferred to nitrocellulose and probed with antibodies specific for β-catenin.

In a further example, the activity of a candidate compound can be measured in a Xenopus secondary axis bioassay (Leyns, L. et al. Cell (1997), 88(6), 747-756).

To further illustrate this invention, the following examples are included. The examples should not, of course, be construed as specifically limiting the invention. Variations of these examples within the scope of the claims are within the purview of one skilled in the art and are considered to fall within the scope of the invention as described, and claimed herein. The reader will recognize that the skilled artisan, armed with the present disclosure, and skill in the art is able to prepare and use the invention without exhaustive examples.

EXAMPLES

Compound Preparation

The starting materials used in preparing the compounds of the invention are known, made by known methods, or are commercially available. It will be apparent to the skilled artisan that methods for preparing precursors and functionality related to the compounds claimed herein are generally described in the literature. The skilled artisan given the literature and this disclosure is well equipped to prepare any of the compounds.

It is recognized that the skilled artisan in the art of organic chemistry can readily carry out manipulations without further direction, that is, it is well within the scope and practice of the skilled artisan to carry out these manipulations. These include reduction of carbonyl compounds to their corresponding alcohols, oxidations, acylations, aromatic substitutions, both electrophilic and nucleophilic, etherifications, esterification and saponification and the like. These manipulations are discussed in standard texts such as March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure 7^th Ed., John Wiley & Sons (2013), Carey and Sundberg, Advanced Organic Chemistry 5^th Ed., Springer (2007), Comprehensive Organic Transformations: A Guide to Functional Group Transformations, 2nd Ed., John Wiley & Sons (1999) (incorporated herein by reference in its entirety) and the like.

The skilled artisan will readily appreciate that certain reactions are best carried out when other functionality is masked or protected in the molecule, thus avoiding any undesirable side reactions and/or increasing the yield of the reaction. Often the skilled artisan utilizes protecting groups to accomplish such increased yields or to avoid the undesired reactions. These reactions are found in the literature and are also well within the scope of the skilled artisan. Examples of many of these manipulations can be found for example in T. Greene and P. Wuts Protective Groups in Organic Synthesis, 4th Ed., John Wiley & Sons (2007), incorporated herein by reference in its entirety.

Trademarks used herein are examples only and reflect illustrative materials used at the time of the invention. The skilled artisan will recognize that variations in lot, manufacturing processes, and the like, are expected. Hence the examples, and the trademarks used in them are non-limiting, and they are not intended to be limiting, but are merely an illustration of how a skilled artisan may choose to perform one or more of the embodiments of the invention.

(¹H) nuclear magnetic resonance spectra (NMR) were measured in the indicated solvents on a Bruker NMR spectrometer (Avance™ DRX300, 300 MHz for ¹H or Avance™ DRX500, 500 MHz for ¹H) or Varian NMR spectrometer (Mercury 400BB, 400 MHz for ¹H). Peak positions are expressed in parts per million (ppm) downfield from tetramethylsilane. The peak multiplicities are denoted as follows, s, singlet; d, doublet; t, triplet; q, quartet; ABq, AB quartet; quin, quintet; sex, sextet; sep, septet; non, nonet; dd, doublet of doublets; ddd, doublet of doublets of doublets; d/ABq, doublet of AB quartet; dt, doublet of triplets; td, triplet of doublets; dq, doublet of quartets; m, multiplet.

• • The following abbreviations have the indicated meanings:
  • BH₃-Me₂S=borane dimethyl sulfide complex
  • (Boc)₂O=di-tert-butyl dicarbonate
  • brine=saturated aqueous sodium chloride
  • CDCl₃=deuterated chloroform
  • CD₃OD=deuterated methanol
  • DCAD=di-(4-chlorobenzyl)azodicarboxylate
  • DCE=dichloroethane
  • DCM=dichloromethane
  • DEAD=diethyl azodicarboxylate
  • DHP=dihydropyran
  • DMAP=4-dimethylaminopyridine
  • DMF=N,N-dimethylformamide
  • DMSO-d₆=deuterated dimethylsulfoxide
  • ESIMS=electron spray mass spectrometry
  • Et=ethyl

EtOAc=ethyl acetate

• • EtOH=ethanol
  • HCl=hydrochloric acid
  • HOAc=acetic acid
  • K₂CO₃=potassium carbonate
  • KOAc=potassium acetate
  • LC/MS=liquid chromatography-mass spectrometry
  • Me=methyl
  • MeOH=methanol
  • MgSO₄=magnesium sulfate
  • MsCl=methanesulfonyl chloride or mesyl chloride
  • MW=microwave
  • NaBH₄=sodium borohydride
  • NaBH(OAc)₃=sodium triacetoxyborohydride
  • NaCNBH₃=sodium cyanoborohydride
  • NaHCO₃=sodium bicarbonate
  • NaOH=sodium hydroxide
  • Na₂S₂O₅=sodium metabisulfite or sodium pyrosulfite
  • NBS=N-bromosuccinimide
  • NH₄OH=ammonium hydroxide
  • NMR=nuclear magnetic resonance
  • ON=overnight
  • Pd/C=palladium(0) on carbon
  • Pd(dppf)Cl₂=1,1′-bis(diphenylphosphino)ferrocene]palladium(II) chloride
  • Pd(PPh₃)₄=tetrakis(triphenylphosphine)palladium(0)
  • Pd(PPh₃)₂Cl₂=bis(triphenylphosphine)palladium(II) dichloride
  • PE=petroleum ether
  • Pin₂B₂=bis(pinacolato)diboron
  • PPh₃=triphenylphosphine
  • PPTS=pyridinium p-toluenesulfonate
  • r.t=room temperature
  • SEM-Cl=2-(trimethylsilyl)ethoxymethyl chloride
  • TBME=methyl tert-butyl ether
  • TEA=triethylamine
  • TFA=trifluoroacetic acid
  • THF=tetrahydrofuran

THP=tetrahydropyran

• • TLC=thin layer chromatography
  • p-TsOH=p-toluenesulfonic acid

The following example schemes are provided for the guidance of the reader, and collectively represent an example method for making the compounds provided herein. Furthermore, other methods for preparing compounds of the invention will be readily apparent to the person of ordinary skill in the art in light of the following reaction schemes and examples. The skilled artisan is thoroughly equipped to prepare these compounds by those methods given the literature and this disclosure. The compound numberings used in the synthetic schemes depicted below are meant for those specific schemes only, and should not be construed as or confused with same numberings in other sections of the application. Unless otherwise indicated, all variables are as defined above.

General Procedure

Compounds of Formula (I) of the present invention can be prepared as depicted in Scheme 1.

Scheme 1 describes an alternative method for preparation of indazole derivatives (X) by first formylating 5-bromo-1H-indole (II) to produce 5-bromo-1H-indazole-3-carbaldehyde (III) followed by protection with either SEM-Cl or DHP to give the protected aldehyde (IV). Aldehyde (IV) is then reacted with bis(pinacolato)diboron to form the borate ester (V). Suzuki coupling with various bromides (VI) yields indazole derivatives (VII). Aldehyde (VII) is reacted with various 1,2-diamines (VIII) to produce (IX). Final deprotection of the pyrazole nitrogen yields the desired indazole derivatives (X).

Illustrative Compound Examples

Preparation of SEM protected intermediate (XII) is depicted below in Scheme 2.

Step 1

A solution of NaNO₂ (110.4 g, 1.6 mol, 8 eq) in water (200 mL) was added dropwise to a solution of 5-bromoindole (XI) (39.2 g, 0.2 mol, 1 eq) in acetone (1000 mL) stirred at −10→0° C., while adding NaNO₂ the solution temperature was maintained below 20° C. An aqueous 2N HCl solution (480 mL) was added slowly to the solution with vigorously stirring while keeping the internal temperature between 0 and 20° C. The solution was further stirred at 20° C. for 3 h after the addition. The solution was concentrated under reduced pressure to remove acetone while keeping the temperature below 35° C. The solid was collected by filtration and transferred to a flask. Cold (−10° C.) DCM (200 mL) was added and stirred for 30 min at −5° C., the solids were filtered and dried under vacuum at 40° C. to get 5-bromo-1H-indazole-3-carbaldehyde (XII) (34.0 g, 151 mmol, 76% yield) as a brown solid. ESIMS found for C₈H₅BrN₂O m/z 225 (M+H).

Step 2

To a suspension of NaH (6.6 g, 166 mmol, 1.10 eq) in DMF (500 mL) was added a solution of 5-bromo-1H-indazole-3-carbaldehyde (XII) (34.0 g, 151 mmol, 1.0 eq) in DMF (50 mL) dropwise at 0° C. over a period of 30 min. The mixture was stirred at room temperature for 2 h, then SEM-Cl (26.4 g, 159 mmol, 1.08 eq) was added dropwise and the mixture was stirred at room temperature for another 3 h. Then the mixture was poured into an ice-water mixture (1000 mL) and extracted with EtOAc (300 mL×3), the organic phases were combined, dried over Na₂SO₄, filtered and concentrated in vacuo, the resultant residue was purified by flash chromatography on silica gel (PE:EtOAc=20:1→10:1) to afford 5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-3-carbaldehyde (XIII) as a mixture of regioisomers (53.0 g, 151 mmol, 100% yield) as a yellow oil. ESIMS found for C₁₄H₁₉BrN₂O₂Si m/z 355 (M+H).

Step 3

To a solution of the mixed 5-bromo-1-((2-(trimethylsilyl)ethoxy) methyl)-1H-indazole-3-carbaldehyde (XIII) (53.0 g, 151 mmol, 1.0 eq), bis(pinacolato)diboron (38.0 g, 150 mmol, 1.0 eq) and KOAc (44.0 g, 450 mmol, 3.0 eq) in DMF (1000 mL) was added Pd(dppf)Cl₂ (7.7 g, 10.5 mmol, 0.07 eq). The mixture was stirred at 90° C. under nitrogen for 10 h. The mixture was filtered; the filtrate was poured onto water (1000 mL) and extracted with EtOAc (500 mL×3). The combined organic phases were dried, filtered and concentrated in vacuo. The resultant residue was purified by flash chromatography on silica gel (PE:EtOAc=10:1→1:1) to give the 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-3-carbaldehyde (XIV) as a mixture of regioisomers (42.9 g, 106 mmol, 71% yield) as a yellow oil. ESIMS found for C₂₀H₃₁BN₂O₄Si m/z 403 (M+H).

Preparation of THP protected intermediate (XIII) is depicted below in Scheme 3.

Step 1

Procedure can be found in Scheme 2, Step 1.

Step 2

A mixture of 5-bromo-1H-indazole-3-carbaldehyde (XII) (29.9 g, 133 mmol), 3,4-dihydro-2H-pyran (27.4 mL, 300 mmol) and PPTS (352 mg, 1.4 mmol) in DCM was heated to reflux for 5 hours. The solution was poured into a saturated NaHCO₃ solution, the layers were separated, and the aqueous layer was extracted with DCM. The combined organic layers were washed with 5% aqueous citric acid and brine, dried over MgSO₄, and concentrated. The crude product was purified on a silica gel column (100% EtOAc→3:97 MeOH:DCM) to provide 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-3a,7a-dihydro-1H-indazole-3-carbaldehyde (XV) was isolated as a white solid (16.4 g, 52.7 mmol, 39.6% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.57-1.65 (m, 2H), 1.72-1.83 (m, 1H), 2.02-2.11 (m, 2H), 2.33-2.44 (m 1H), 3.76-3.83 (m, 1H), 3.84-3.93 (m, 1H), 6.08 (dd, J=2.5 Hz, 9 Hz, 1H), 7.72 (dd, J=1.5 Hz, J=8.5 Hz, 1H), 7.92 (d, J=9 Hz, 1H), 8.28 (d, J=2 Hz, 1H), 10.17 (s, 1H); ESIMS found C₁₃H₁₅BrN₂O₂ m/z 311.0 (M+H).

Preparation of 6-fluoro-substituted indazole intermediate (XXII) is depicted below in Scheme 4.

Step 1

A solution of 5-fluoro-2-methylaniline (XVI) (100 g, 799 mmol, 1.0 eq) and Ac₂O (89 g, 879 mmol, 1.1 eq) in toluene (4.0 L) was stirred at 110° C. for 4 h. TLC (PE:EtOAc=2:1) showed (XVI) was consumed. The reaction mixture was cooled to 25° C. The precipitated solid was filtered, washed with petro ether. The solid was dried in vacuo to give N-(5-fluoro-2-methylphenyl)acetamide (XVII) as a white solid (120 g, 717.8 mmol, 89.8% yield), which was used in step 2 without further purification. ESIMS found C₉H₁₀FNO m/z 168.1 (M+1).

Step 2

To a solution of N-(5-fluoro-2-methylphenyl)acetamide (XVII) (120 g, 717 mmol, 1.0 eq) in HOAc (3 L) was added a solution of Br₂ (140 g, 876 mmol, 1.2 eq) in HOAc (1 L) dropwise. The mixture was stirred at 25° C. for 3 h. LC/MS showed compound 2 was (XVII) completely consumed. The reaction mixture was quenched with water (8 L). The solid was filtered, washed with water and petroleum ether. The solid was dried in vacuo to give N-(4-bromo-5-fluoro-2-methylphenyl)acetamide (XVIII) as a white solid (155 g, 629.9 mmol, 87.8% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 2.20 (s, 6H), 7.07 (brs, 1H), 7.32 (d, J=7.2 Hz, 1H), 7.85 (d, J 10.8 Hz, 1H); ESIMS found C₉H₉BrFNO m/z 247.2 (M+1).

Step 3

A solution of N-(4-bromo-5-fluoro-2-methylphenyl)acetamide (XVIII) (155 g, 629.9 mmol, 1.0 eq), Ac₂O (192 g, 1.8 mol, 3.0 eq), KOAc (123 g, 1.26 mol, 2.0 eq), 18-CROWN-6 (8.3 g, 31 mmol, 0.05 eq) and isoamyl nitrite (147 g, 1.2 mol, 2.0 eq) in CHCl₃ (7.0 L) was stirred at 65° C. for 12 h. TLC (PE:EtOAc=5:1, Rf=0.2) showed (XVIII) was consumed completely. The solvent was removed under reduced pressure. The residue was extracted with EtOAc (1.5 L) and water (1.5 L). The organic layer was dried over anhydrous Na₂SO₄, concentrated under reduced pressure to give 1-(5-bromo-6-fluoro-1H-indazol-1-yl)ethan-1-one (XIX) as a white solid (170 g, crude, quantitative yield), which was used in step 4 without further purification. ESIMS found C₉H₆BrFN₂O m/z 258.1 (M+1).

Step 4

A solution of 1-(5-bromo-6-fluoro-1H-indazol-1-yl)ethan-1-one (XIX) (170 g, 629.9 mmol, 1.0 eq) in 3 N HCl (6.6 mol, 10 eq) and MeOH (900 mL) was stirred at 60° C. for 12 h. TLC (PE:EtOAc=5:1, Rf=0.8) showed (XIX) was consumed completely. The reaction mixture was cooled to room temperature and basified with 1N aq. NaOH to pH=10. The precipitated solid was filtered and dried in vacuo to afford 5-bromo-6-fluoro-1H-indazole (XX) as a yellow solid (100 g, 465.1 mmol, 73.8% yield). ESIMS found C₇H₄BrFN₂ m/z 215.1 (M+1).

Step 5

To solution of a mixture of 5-bromo-6-fluoro-1H-indazole (XX) (90 g, 418 mmol, 1.0 eq) and 3,4-dihydro-2H-pyran (70 g, 837 mmol, 2.0 eq) in DCM (2.0 L) was added p-TsOH (3.6 g, 20 mmol, 0.05 eq) at 25° C. The resulting mixture was stirred at 25° C. for 12 h. TLC (PE:EtOAc=5:1, Rf=0.7) showed (XX) was completely consumed. To the reaction mixture was added saturated aqueous NaHCO₃ (4 L). The organic layer was separated, dried over Na₂SO₄, concentrated in vacuo to give a residue, which was further purified by silica gel column (EtOAc:PE=20:1) to give 5-bromo-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (XXI) as a brown oil (120 g, 401.1 mmol, 96.0% yield), which was used in step 6 without further purification. ESIMS found C₁₂H₁₂BrFN₂O m/z 299.2 (M+1).

Step 6

A solution of 5-bromo-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (XXI) (30 g, 100 mmol, 1.0 eq), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (25 g, 100 mmol, 1.0 eq), Pd(dppf)Cl₂ (3.6 g, 5.0 mmol, 0.05 eq), KOAc (19.6 g, 200 mmol, 2.0 eq) in dioxane (550 mL) was stirred at 100° C. for 12 h under N₂. LC/MS showed (XXI) was completely consumed. The reaction mixture was concentrated and then extracted with EtOAc (300 mL) and water (100 mL). The mixture was filtered and separated. The organic layer was dried over anhydrous Na₂SO₄, concentrated to give crude product, which was further purified by silica gel column (EtOAc:PE=20/1) to give 6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (XXII) as a green solid (13 g, 37.5 mmol, 37.4% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.37 (s, 12H), 1.73-1.43 (m, 3H), 2.58-2.50 (m, 1H), 3.79-3.73 (m, 1H), 4.06-4.04 (m, 1H), 5.66-5.63 (m, 1H), 7.28-7.21 (m, 1H), 8.00 (s, 1H), 8.19 (d, J=5.6 Hz, 1H); ESIMS found C₁₈H₂₄BFN₂O₃ m/z 347.2 (M+1).

Preparation of 7-fluoro-substituted indazole intermediate (XXVIII) is depicted below in Scheme 5.

Step 1

To a stirred solution of 2,3-difluorobenzaldehyde (XXIII) (75.0 g, 528 mmol, 1.0 eq) in H₂SO₄ (565 mL) was added NBS (113 g, 633 mmol, 1.2 eq) in portions at 60° C. The resulting mixture was stirred at 60° C. for 12 hr. LC/MS showed the reaction was completed. The reaction mixture was poured into ice water and petroleum ether (500 mL) and stirred for 10 min, the organic layer was separated and concentrated under vacuum to give crude product. The residue was purified column chromatography silica gel (100% petroleum ether) to give 5-bromo-2,3-difluorobenzaldehyde (XXIV) (120 g, 543.0 mmol, quantitative yield). ESIMS found C₇H₃BrF₂O m/z 221.1 (M+1).

Step 2

To a solution of 5-bromo-2,3-difluorobenzaldehyde (XXIV) (115 g, 520 mmol, 1.0 eq), MeONH₂ HCl (47.8 g, 572 mmol, 1.1 eq) and K₂CO₃ (86.3 g, 624 mmol, 1.20 eq) was in DME (1.30 L) was heated to 40° C. for 15 h. TLC (petroleum ether) showed (XXIV) was consumed. The reaction was filtered and the filtrate was concentrated under vacuum to give crude product. The residue was purified by column chromatography on silica gel (100% petroleum ether) to give (E)-5-bromo-2,3-difluorobenzaldehyde O-methyl oxime (XXV) (74 g, 56.9% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 4.04 (s, 3H), 7.37-7.32 (m, 1H), 7.77 (s, 1H), 8.23 (s, 1H); ESIMS found C₈H₆BrF₂NO m/z 250.2 (M+1).

Step 3

A solution of (E)-5-bromo-2,3-difluorobenzaldehyde O-methyl oxime (XXV) (150 g, 600 mmol, 1.0 eq), NH₂NH₂—H₂O (600 mL) in dry THF (600 mL) was heated to 90° C. for 84 h. LC/MS showed the reaction was completed. The solvent was evaporated and the resulting mixture was diluted with EtOAc, washed with water, dried over Na₂SO₄ and concentrated under vacuum to give crude product. The residue was purified by column chromatography on silica gel (PE:EtOAc=10:1) to give 5-bromo-7-fluoro-1H-indazole (XXVI) as a white solid (78 g, 362.7 mmol, 60.5% yield). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 7.44 (d, J=9.6 Hz, 1H), 7.87 (d, J=1.6 Hz, 1H), 8.17 (s, 1H), 13.90 (s, 1H); ESIMS found C₇H₄BrFN₂ m/z 215 (M+1).

Step 4

Preparation of 5-bromo-7-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (XXVII) was performed following the procedure listed in Scheme 4, Step 5. Light yellow solid (98 g, 327.6 mmol, 93.9% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.78-1.62 (m, 3H), 2.17-2.09 (m, 2H), 2.63-2.58 (m, 1H), 3.76 (t, J=11.6 Hz, 1H), 4.05 (d, J=9.6 Hz, 1H), 5.85 (d, J=9.6 Hz, 1H), 7.22 (d, J=12.0 Hz, 1H), 7.65 (s, 1H), 8.00 (s, 1H); ESIMS found C₁₂H₁₂BrFN₂O m/z 299.2 (M+1).

Step 5

Preparation of 7-fluoro-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (XXVIII) was performed following the procedure listed in Scheme 4, Step 6. White solid (45 g, 130.0 mmol, 86.7% yield). ESIMS found C₁₈H₂₄BFN₂O₃ m/z 347.1 (M+1).

Preparation of 4-fluoro-substituted indazole intermediate (XXXIII) is depicted below in Scheme 6.

Step 1

To a stirred solution of 3-fluoro-2-methylaniline (XXIX) (50 g, 399 mmol, 1.0 eq) in CH₃CN (1.2 L) was added NBS (78 g, 439 mmol, 1.1 eq) in portions at 10° C., the resulting mixture was stirred at 25° C. for 1 h. LC/MS showed the reaction was completed. Saturated Na₂S₂O₃ (1.2 L) was then added slowly to the reaction mixture at 10° C., extracted with EtOAc (2 L) and the organic layer was concentrated under vacuum to give crude product. The residue was washed with PE (1 L), the solid was filtered, washed again with PE (500 mL) and dried under vacuum to give 4-bromo-3-fluoro-2-methylaniline (XXX) as a white solid (163.0 g, 798.9 mmol, 66.7% yield). ESIMS found C₇H₇BrFN m/z 204.1 (M+1).

Step 2

To a stirred solution of 4-bromo-3-fluoro-2-methylaniline (XXX) (40 g, 196 mmol, 1.0 eq) in HOAc (1.2 L) was added NaNO₂ (16 g, 235 mmol, 1.2 eq) in portions at 10° C., the resulting mixture was stirred at 25° C. for 4 h. LC/MS showed the reaction was completed. Upon completion, aqueous NaOH (50%) was added to the reaction mixture until pH 7-8, then the mixture was extracted with EtOAc (1.6 L), the organic layer was dried over Na₂SO₄, filtered; filtrate was concentrated under vacuum to give crude 5-bromo-4-fluoro-1H-indazole (XXXI) (40 g, 186.0 mmol, 94.9% yield), which was used in step 3 without further purification. ¹H NMR (CDCl₃, 400 MHz) δ ppm 7.47-7.42 (m, 1H), 7.56-7.53 (m, 1H), 8.23 (s, 1H); ESIMS found C₇H₄BrFN₂ m/z 215 (M+1).

Step 3

Preparation of 5-bromo-4-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (XXXII) was performed following the procedure listed in Scheme 4, Step 5. Brown oil (9.9 g, 33.1 mmol, 71.9% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.75-1.67 (m, 3H), 2.10-1.76 (m, 2H), 2.52-2.14 (m, 1H), 3.76-3.71 (m, 1H), 4.01-3.97 (m, 1H), 5.70-5.69 (m, 1H), 7.30-7.26 (m, 1H), 7.47-7.45 (m, 1H), 8.06 (s, 1H); ESIMS found C₁₂H₁₂BrFN₂O m/z 299 (M+1).

Step 4

Preparation of 4-fluoro-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (XXXIII) was performed following the procedure listed in Scheme 4, Step 6. Red oil (25 g, 72.2 mmol, 72.2% yield). ¹H NMR (CD₃OD, 400 MHz) δ ppm 1.72 (s, 12H), 2.12-1.74 (m, 5H), 2.52-2.16 (m, 1H), 3.85-3.80 (m, 1H), 4.12-4.00 (m, 1H), 5.84-5.81 (m, 1H), 7.48 (d, J=8.0 Hz, 1H), 7.71-7.67 (m, 1H), 8.15 (s, 1H); ESIMS found C₁₈H₂₄BFN₂O₃ m/z 347 (M+1).

Preparation of intermediate N-(5-bromopyridin-3-yl)pivalamide (XXXVI) is depicted below in Scheme 7.

Step 1

To a solution of 3-amino-5-bromo pyridine (XXXIV) (1.0 g, 5.78 mmol) in dry pyridine (10 mL) was added pivaloyl chloride (XXXV) (769 mg, 6.38 mmol). The reaction mixture was stirred at room temperature for 3 h. The reaction was poured into an ice water/saturated aqueous NaHCO₃ mixture and stirred for 30 min. The precipitate was filtered, washed with cold water and dried at room temperature to yield N-(5-bromopyridin-3-yl)pivalamide (XXXVI) as an off-white solid (1.082 g, 4.22 mmol, 73.1% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.23 (s, 9H), 8.37 (d, J=2 Hz, 1H), 8.39 (t, J=2 Hz, 1H), 8.80 (d, J=2 Hz, 1H), 9.58 (brs, 1H); ESIMS found C₁₀H₁₃BrN₂O m/z 258.9 (Br⁸¹M+H).

The following intermediates were prepared in accordance with the procedure described in the above Scheme 7.

N-(5-Bromopyridin-3-yl)isobutyramide (XXXVII): Off-white solid, (71% yield). ¹H NMR (CDC₃) δ ppm 8.55-8.35 (m, 3H), 7.32 (s, 1H), 2.59-2.48 (m, 1H), 1.28-1.27 (d, 6H); ESIMS found C₉H₁₁BrN₂O m/z 242.9 (Br⁷⁹M+H).

N-(5-Bromopyridin-3-yl)propionamide (XXXVIII): Off white solid (92% yield). ¹H NMR (DMSO-d₆) δ ppm 1.09 (t, J=7.54 Hz, 3H), 2.36 (q, J=7.54 Hz, 2H), 8.36 (m, 2H), 8.65 (d, J=2.07 Hz, 1H), 10.26 (s, 1H); ESIMS found C₈H₉BrN₂O m/z 231.1 (Br⁸¹M+H).

N-(5-Bromopyridin-3-yl)butyramide (XXXIX): Yellow solid (2.1 g, 8.64 mmol, 88.8% yield). ¹H NMR (CD₃OD, 400 MHz) δ ppm 1.02 (t, J=7.2 Hz, 3H), 1.74 (sxt, J=7.2 Hz, 2H), 2.40 (t, J=7.2 Hz, 2H), 8.35 (d, J=2 Hz, 1H), 8.46 (t, J=2 Hz, 1H), 8.63 (d, J=2 Hz, 1H); ESIMS found C₉H₁₁BrN₂O m/z 243.1 (Br⁷⁹M+H).

N-(5-Bromopyridin-3-yl)pentanamide (XL): Yellow solid (2.0 g, 7.78 mmol, 85.3% yield). ¹H NMR (CD₃OD, 400 MHz) δ ppm 0.98 (t, J=7.4 Hz, 3H), 1.43 (sxt, J=7.4 Hz, 2H), 1.70 (quin, J=7.4 Hz, 2H), 2.43 (t, J=7.6 Hz, 2H), 8.35 (s, 1H), 8.45 (d, J=2 Hz, 1H), 8.64 (d, J=2 Hz, 1H); ESIMS found C₁₀H₁₃BrN₂O m/z 256.9 (Br⁷⁹M+H).

N-(5-Bromopyridin-3-yl)-3-methylbutanamide (XLI): Off white solid, (67% yield), ¹H NMR (CDCl₃, 500 MHz) δ ppm 8.55-8.42 (m, 3H), 7.62 (s, 1H), 2.31-2.18 (m, 3H), 1.02-1.01 (d, J=6 Hz, 6H); ESIMS found C₁₀H₁₃BrN₂O m/z 258.9 (Br⁸¹M+H).

N-(5-Bromopyridin-3-yl)-3,3-dimethylbutanamide (XLII): Yellow solid (1.7 g, 6.27 mmol, 78.6% yield). ¹H NMR (CD₃OD, 400 MHz) δ ppm 1.10 (s, 9H), 2.29 (s, 2H), 8.36 (d, J=1.6 Hz, 1H), 8.46 (d, J=2.0 Hz, 1H), 8.64 (d, J=2.0 Hz, 1H); ESIMS found C₁₁H₁₅BrN₂O m/z 273.1 ((Br^s8M+H).

N-(5-Bromopyridin-3-yl)-2-phenylacetamide (XLIII): White solid (2.5 g, 8.59 mmol, 77.9% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 3.76 (s, 2H), 7.26-7.45 (m, 5H), 7.57 (brs, 1H), 8.33 (s, 1H), 8.37 (s, 2H); ESIMS found C₁₃H₁₁BrN₂O m/z 292.8 (Br⁸¹M+H).

N-(5-Bromopyridin-3-yl)benzamide (XLIV): White solid (2.7 g, 9.74 mmol, 60% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 7.40-7.52 (m, 2H), 7.52-7.62 (m, 1H), 7.86 (d, J=7.2 Hz, 2H), 8.39 (d, J=1.6 Hz, 1H), 8.46 (s, 1H), 8.55 (d, J=1.6 Hz, 1H), 8.57 (d, J=2.0 Hz, 1H); ESIMS found C₁₂H₉BrN₂O m/z 278.8 (Br⁸′M+H).

N-(5-Bromopyridin-3-yl)cyclopropanecarboxamide (XLV): Off-white solid, (83% yield), ¹H NMR (CDCl₃, 500 MHz) δ ppm 8.46-8.39 (m, 3H), 7.54 (bs, 1H), 1.56-1.50 (m, 1H), 1.13-1.07 (m, 2H), 0.96-0.90 (m, 2H); ESIMS found for C₉H₉BrN₂O m/z 240.9 (Br⁷⁹M+H).

N-(5-Bromopyridin-3-yl)cyclobutanecarboxamide (XLVI): Yellow solid (2.1 g, 6.27 mmol, 86.6% yield). ¹H NMR (CD₃OD, 400 MHz) δ ppm 1.80-1.99 (m, 1H), 1.99-2.15 (m, 1H), 2.16-2.30 (m, 2H), 2.30-2.45 (m, 2H), 3.25-3.35 (m, 1H), 8.34 (d, J=2.0 Hz, 1H), 8.47 (s, 1H), 8.64 (d, J=2.0 Hz, 1H); ESIMS found C₁₀H₁₁BrN₂O m/z 257.1 (Br^s8M+H).

N-(5-Bromopyridin-3-yl)cyclopentanecarboxamide (XLVII): Yellow solid (1.9 g, 7.06 mmol, 80.2% yield). ¹H NMR (CD₃OD, 400 MHz) δ ppm 1.57-1.74 (m, 2H), 1.74-1.91 (m, 4H), 1.91-2.07 (m, 2H), 2.77-2.92 (m, 1H), 8.34 (d, J=1.6 Hz, 1H), 8.45 (s, 1H), 8.65 (d, J=2.0 Hz, 1H); ESIMS found C₁₀H₁₃BrN₂O m/z 271.1 (Br^s8M+H).

N-(5-bromopyridin-3-yl)cyclohexanecarboxamide (XLVIII): Yellow solid (2.0 g, 7.06 mmol, 84.3% yield). ¹H NMR (CD₃OD, 400 MHz) δ ppm 1.19-1.46 (m, 3H), 1.46-1.63 (m, 2H), 1.74 (d, J=11.6 Hz, 1H), 1.88 (t, J=14.0 Hz, 4H), 2.40 (tt, J=11.6 Hz, J=3.6 Hz, 1H), 8.34 (d, J=2.0 Hz, 1H), 8.44 (t, J=2.0 Hz, 1H), 8.64 (d, J=2.0 Hz, 1H); ESIMS found C₁₂H₁₅BrN₂O m/z 285.1 (Br⁸¹M+H).

N-(5-bromopyridin-3-yl)-2-cyclohexylacetamide (XLIX): Yellow solid (261 mg, 0.878 mmol, 84.4% yield). ESIMS found C₁₃H₁₇BrN₂O m/z 297.1 (Br⁸¹M+H).

Preparation of intermediate 5-bromo-N,N-dimethylpyridin-3-amine (LI) is depicted below in Scheme 8.

Step 1

To a solution of 3,5-dibromopyridine (L) (2.37 g, 10.0 mmol) in dry DMF (20.0 mL) was added K₂CO₃ (4.5 g, 33 mmol) and dimethylamino hydrochloride (1.79 g, 22 mmol). The mixture was heated overnight at 200° C. in a sealed tube. The solution was cooled to room temperature and excess DMF was removed under vacuum. The residue was partitioned between EtOAc and water. The organic phase was separated. The aqueous phase was washed with EtOAc and the combined organic phases were dried over MgSO₄, and concentrated to afford 5-bromo-N,N-dimethylpyridin-3-amine (LI) as an off-white solid (1.78 g, 8.85 mmol, 88% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.94 (s, 6H), 7.25 (t, J=2 Hz, 1H), 7.91 (d, J=2 Hz, 1H), 8.07 (d, J=2 Hz, 1H); ESIMS found C₇H₉BrN₂ m/z 201.1 (M+H).

Preparation of intermediate 5-bromo-N-isopropylpyridin-3-amine (LII) is depicted below in Scheme 9.

Steps 1

To a solution of 5-bromopyridin-3-amine (XXXIV) (535 mg, 3.09 mmol) in MeOH (62 mL) was added acetone (296 μL, 4.02 mL). The pH was adjusted to 4 using HOAc and stirred for 30 min. NaCNBH₃ (272 mg, 4.33 mmol) was added and stirred at room temperature overnight. The MeOH was removed under vacuum and the residue was partitioned between EtOAc and saturated aqueous NaHCO₃. The organic layer was dried over MgSO₄ and evaporated under vacuum. The crude product was purified on a silica gel column (100% hexane→90:10 hexane:EtOAc) to produce 5-bromo-N-isopropylpyridin-3-amine (LII) as an oil which slowly solidified into an off-white solid (309 mg, 1.44 mmol, 47% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.12 (d, J=6.3 Hz, 6H), 3.55-3.59 (m, 1H), 6.03 (d, J=7.9 Hz, 1H), 7.05-7.06 (m, 1H), 7.75 (d, J=2 Hz, 1H), 7.90 (d, J=2 Hz, 1H); ESIMS found C₈H_IIBrN₂ m/z 215.1 (M+H).

Preparation of intermediate 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine (LIV) is depicted below in Scheme 10.

Steps 1

Preparation of 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine (LIV) was performed following the procedure listed in Scheme 9, Step 1. Brown oil (1.20 g, 5.59 mmol, 45% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.15 (s, 6H), 3.43 (s, 2H), 7.94 (s, 1H), 8.47 (d, J=1.1 Hz, 1H), 8.59 (d, J=2.2 Hz, 1H); ESIMS found C₈H₁₁BrN₂ m/z 215 (M^Br79+H) and 217 (M^Br81+H).

Preparation of intermediate 3-bromo-5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridine (LV) is depicted below in Scheme 11.

Steps 1

To a mixture of 5-bromopyridine-3-carbaldehyde (LIII) (6.00 g, 32.26 mmol, 1.0 eq), 3,3-difluoropyrrolidine (5.56 g, 38.71 mmol, 1.20 eq) and TEA (5.39 mL, 38.71 mmol, 1.2 Eq) in DCE (200 mL) was stirred at room temperature for 30 min, then added sodium triacetoxyborohydride (10.25 g, 48.38 mmol, 1.50 eq) in one portion at room temperature under N₂. The mixture was stirred at room temperature for 6 hours. TLC showed the reaction was complete. The reaction was quenched with 1N NaOH (100 mL), extracted with DCE (100 mL×2). The combined organic layers were washed with brine (100 mL), dried and concentrated. The residue was purified by silica gel chromatography (column height: 50 mm, diameter: 50 mm, 300-400 mesh silica gel, DCM/MeOH=30/1→20/1) to give 3-bromo-5-((3,3-difluoropyrrolidin-1-yl)methyl) pyridine (LV): Yellow oil (8.00 g, 28.9 mmol, 89.5% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 2.30 (spt, J=7.2 Hz. 2H), 2.75 (t, J=6.8 Hz, 2H), 2.91 (t, J=13.2 Hz, 2H), 7.85 (s, 1H), 8.45 (s, 1H), 8.59 (d, J=2 Hz, 1H); ESIMS found for C₁₀H₁₁BrF₂N₂ m/z 277.0 (M+H).

The following intermediates were prepared in accordance with the procedure described in the above Scheme 10 or Scheme 11.

3-Bromo-5-(pyrrolidin-1-ylmethyl)pyridine (LVI): Golden liquid (1.35 g, 97% yield). ¹H NMR (DMSO-d₆) 1.68-1.71 (m, 4H), 2.42-2.44 (m, 4H), 3.60 (s, 2H), 7.96 (s, 1H), 8.48 (d, J=2 Hz, 1H), 8.58 (d, J=3 Hz, 1H); ESIMS found for C₁₀H₁₃BrN₂ m/z 242.2 (M+H).

3-Bromo-5-(piperidin-1-ylmethyl)pyridine (LVII): Brown liquid (13.1 g, 94% yield). ¹H NMR (DMSO-d₆) 1.36-1.39 (m, 2H), 1.46-1.51 (m, 4H), 2.31-2.32 (m, 4H), 3.46 (s, 2H), 7.94 (s, 1H), 8.47 (d, J=2 Hz, 1H), 8.58 (d, J=3 Hz, 1H); ESIMS found for C₁₁H₁₅BrN₂ m/z 257.0 (M+H).

N-((5-Bromopyridin-3-yl)methyl)ethanamine (LVIII): Golden liquid (1.29 g, 6.00 mmol, 60% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.14 (t, J=7.2 Hz, 3H), 2.67 (q, J=7.2 Hz, 2H), 3.79 (s, 2H), 7.85 (t, J=2 Hz, 1H), 8.46 (d, J=1.6 Hz, 1H), 8.56 (d, J=2.4 Hz, 1H); ESIMS found for C₈H_IIBrN₂ m/z 215.1 (M+H).

N-Benzyl-1-(5-bromopyridin-3-yl)methanamine (LIX): Yellow oil (8.0 g, 28.9 mmol, 89.5% yield). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 3.71 (s, 2H), 3.74 (s, 2H), 7.18-7.28 (m, 1H), 7.28-7.40 (m, 4H), 8.04 (s, 1H), 8.52 (s, 1H), 8.58 (s, 1H); ESIMS found for Cl₃H₁₃BrN₂ m/z 277.1 (M+H).

Preparation of intermediate tert-butyl (5-bromopyridin-3-yl)methyl (cyclopentylmethyl)carbamate (LXIV) is depicted below in Scheme 12.

Step 1

To a solution of 5-bromonicotinaldehyde (LIII) (2.0 g, 10.8 mmol, 1 eq) in MeOH (20 mL) was added NaBH₄ (2.4 g, 64.9 mmol, 6 eq) and the reaction mixture was stirred at room temperature for 3 h. The mixture was concentrated in vacuo and the residue was diluted in water (15 mL), the aqueous phase was extracted with DCM (10 mL×3). The combined organic layers were dried over MgSO₄, filtered and concentrated in vacuo to afford (5-bromopyridin-3-yl)methanol (LX) (1.8 g, 9.57 mmol, 90.0% yield) as a colorless oil. ¹H NMR (CDCl₃, 500 MHz) δ ppm 4.73 (s, 2H), 7.90 (s, 1H), 8.47 (s, 1H), 8.57 (s, 1H). ESIMS found for C₆H₆BrNO m/z 188.0 (M+H).

Step 2

To a stirred solution of (5-bromopyridin-3-yl)methanol (LX) (1.60 g, 8.5 mmol, 1 eq), phthalimide (1.24 g, 8.5 mmol, 1 eq) and PPh₃ (3.33 g, 12.75 mmol, 1.5 eq) in anhydrous THF (15 mL) was added DEAD (2.21 g, 12.75 mmol, 1.5 eq) dropwise at 0° C. under N₂. Then the reaction mixture was stirred at room temperature for 6 h. The mixture was washed with saturated NaHCO₃ solution (15 mL), water (15 mL) and brine (15 mL) subsequently. The organic layers were dried over MgSO₄, concentrated under reduced pressure, the resultant residue was purified by flash chromatography on silica gel (PE:EtOAc=4:1) to give 2-((5-bromopyridin-3-yl)methyl)isoindoline-1,3-dione (LXI) (2.5 g, 7.88 mmol, 82.3% yield) as a white solid. ESIMS found for C₁₄H₉BrN₂O₂ m/z 317.1 (M+H).

Step 3

A solution of 2-((5-bromopyridin-3-yl)methyl)isoindoline-1,3-dione (LXI) (1.9 g, 6.0 mmol, 1 eq) and hydrazine hydrate (2.0 g, 40 mmol, 6 eq) in EtOH (20 mL) was heated at 70° C. for 3 h. The mixture was filtered through a Celite® pad and the filtrate was concentrated in vacuo, the crude product was dissolved in 1N HCl solution (15 mL) and concentrated to dryness, then it was washed with acetone (10 mL×3), the precipitate was collected by filtration, dried in vacuo to give (5-bromopyridin-3-yl)methanamine (LXII) (1.3 g, 6.95 mmol, 97.7% yield) as a white solid. ¹H NMR (D₂O, 500 MHz) δ ppm 4.34 (s, 2H), 8.56 (s, 1H), 8.75 (d, J=1.2 Hz, 1H), 8.91 (d, J=1.6 Hz, 1H). ESIMS found for C₆H₇BrN₂ m/z 187.0 (M+H).

Step 4

A solution of (5-bromopyridin-3-yl)methanamine (LXII) (1.30 g, 5.8 mmol, 1.0 eq), cyclopentanecarbaldehyde (0.57 g, 5.8 mmol, 1.0 eq) and TEA (0.60 g, 5.8 mmol, 1.0 eq) in MeOH (15 mL) was stirred at room temperature for 2 h. Then NaBH₃CN (1.98 g, 34.6 mmol, 6.0 eq) was added and the mixture was stirred at the same temperature for another 3 h. The solvent was removed under reduced pressure and the residue was diluted in water (20 mL) and extracted with DCM (10 mL×3), combined organic layers were dried over MgSO₄ and concentrated in vacuo to give 1-(5-bromopyridin-3-yl)-N-(cyclopentylmethyl)methanamine (LXIII) (1.23 g, 4.57 mmol, 79.3% yield) as a yellow oil. ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.07-1.23 (m, 2H), 1.47-1.67 (m, 4H), 1.70-1.84 (m, 2H), 2.02 (spt, J=7.6 Hz. 1H), 2.53 (d, J=7.2 Hz, 2H), 3.80 (s, 2H), 7.86 (s, 1H), 8.47 (s, 1H), 8.56 (d, J=2.0 Hz, 1H); ESIMS found for C₁₂H₁₇BrN₂ m/z 269.1 (M+H).

Step 5

To a solution of 1-(5-bromopyridin-3-yl)-N-(cyclopentylmethyl) methanamine (LXIII) (1.00 g, 3.7 mmol, 1 eq) and TEA (0.93 g, 9.2 mmol, 2.5 eq) in DCM (20 mL) was added portionwise (Boc)₂O (0.85 g, 4.0 mmol, 1.1 eq) at 0° C., the reaction mixture was stirred at room temperature for 1 h. The mixture was washed with water (10 mL), brine (10 mL), the organic layer was separated, dried over MgSO₄ and concentrated in vacuo to give tert-butyl (5-bromopyridin-3-yl)methyl (cyclopentylmethyl)carbamate (LXIV) (1.25 g, 3.38 mmol, 91.9% yield) as a white solid. ESIMS found for C₁₇H₂₅BrN₂O₂ m/z 369.1 (M+H).

Preparation of intermediate 3-bromo-5-(cyclohexyloxy)pyridine (LXVII) is depicted below in Scheme 13.

Step 1

To a solution of 5-bromopyridin-3-ol (LXV) (523 mg, 3.01 mmol) in THF (30 mL) cooled to 0° C. were added triphenylphosphine (867 mg, 3.31 mmol) and cyclohexanol (LXVI) (331 mg, 3.31 mmol) followed by (E)-bis(4-chlorobenzyl) diazene-1,2-dicarboxylate (1.21 g, 3.31 mmol), added portionwise. The reaction mixture was then stirred at 25° C. overnight. The reaction was worked-up with a EtOAc-NaHCO₃ extraction and the solid filtered off. The solvent was removed and the residue was purified by Isco (20% EtOAc-Hexanes) to give 3-bromo-5-(cyclohexyloxy)pyridine (LXVII) (209 mg, 0.82 mmol, 27.2% yield) as a yellow oil. ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.21-1.31 (m, 1H) 1.34-1.48 (m, 4H) 1.49-1.57 (m, 1H) 1.70 (br dd, J=9.74, 4.25 Hz, 2H) 1.88-1.96 (m, 2H) 2.50 (dt, J=3.70, 1.72 Hz, 5H) 4.46-4.54 (m, 1H) 7.72 (t, J=2.20 Hz, 1H) 8.24 (d, J=1.92 Hz, 1H) 8.27 (d, J=2.47 Hz, 1H).

The following intermediate was prepared in accordance with the procedure described in the above Scheme 13.

tert-Butyl 4-((5-bromopyridin-3-yl)oxy)piperidine-1-carboxylate (LXVIII): Yellow oil (244 mg, 0.683 mmol, 23.2% yield). ESIMS found for C₁₅H₂₁BrN₂O₃ m/z 358.3 (M+H).

Preparation of intermediate 3-(benzyloxy)-5-bromopyridine (LXX) is depicted below in Scheme 14.

Step 1

To a solution of 5-bromopyridin-3-ol (LXV) (174 mg, 1.0 mmol) in DMF (3 mL) was added potassium carbonate (415 mg, 3.0 mmol). The slurry was heated at 90° C. for 1 hour and then cooled to 25° C. The (bromomethyl)benzene (LXIX) (171 mg, 1.0 mmol) was added and the mixture was stirred at 25° C. overnight. The reaction was worked-up using a saturated sodium bicarbonate and ethyl acetate extraction. The product was purified by ISCO column eluted with 40-100% EtOAc-Hexanes. The 3-(benzyloxy)-5-bromopyridine (LXX) (105 mg, 0.398 mmol, 39.8% yield) was obtained as yellow oil. MS: 266.1. ESIMS found for C₁₂H₁₀BrNO m/z 266.1 (M+H).

The following intermediates were prepared in accordance with the procedure described in the above Scheme 14.

3-Bomo-5-(2-(pyrrolidin-1-yl)ethoxy)pyridine (LXXI): Yellow oil ((97 mg, 0.358 mmol, 15.56% yield). ESIMS found for C₁₁H₁₅BrN₂O m/z 272.2 (M+H).

2-((5-bromopyridin-3-yl)oxy)-N,N-dimethylethan-1-amine (LXXII): Yellow oil (97 mg, 0.396 mmol, 28.9% yield). ESIMS found for C₉H₁₃BrN₂O m/z 245.1 (M+H).

1-(2-(3-bromo-5-fluorophenoxy)ethyl)pyrrolidine (LXXIII): Yellow oil (370 mg, 1.284 mmol, 85.8% yield). ESIMS found for C₁₂H₁₅BrFNO m/z 289.0 (M+H).

2-(3-bromo-5-fluorophenoxy)-N,N-dimethylethan-1-amine (LXXIV): Yellow oil (364 mg, 1.389 mmol, 50.2% yield). ESIMS found for C₁₀H₁₃BrFNO m/z 263.9 (M+H).

Preparation of intermediate tert-butyl 4-(2-((5-bromopyridin-3-yl)amino)-2-oxoethyl)piperidine-1-carboxylate (LXXVI) is depicted below in Scheme 15.

Step 1

To a solution of 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)acetic acid (LXXV) (3.4 g, 13.97 mmol) in DCM (10 mL) was added DMF (1 mL). The solution was cooled in ice-water to 0° C. Oxalyl chloride (1.835 mL, 20.96 mmol) was then added dropwise. The mixture was stirred for one hour at 25° C. The organic volatile was then removed under vacuum. The residue was dissolved in DCM (10 mL). DMAP (0.171 g, 1.397 mmol) and 5-bromopyridin-3-amine (XXXIV) (2.418 g, 13.97 mmol) were added to the solution and cooled to 0° C. DIEA (4.88 ml, 27.9 mmol) was then added dropwise and the mixture was stirred for 2 hours at 25° C. The reaction was worked-up with DCM and saturated NaHCO3. The product was purified by ISCO eluted with 0-100% EtOAc-Hexanes. The tert-butyl 4-(2-((5-bromopyridin-3-yl)amino)-2-oxoethyl)piperidine-1-carboxylate (LXXVI) (2.82 g, 7.08 mmol, 50.7% yield) was obtained as yellow oil. ESIMS found for C₁₇H₂₄BrN₃O₃ m/z 343.1 (M-56).

The following intermediate was prepared in accordance with the procedure described in the above Scheme 15.

N-(5-Bromopyridin-3-yl)-2-(dimethylamino)acetamide (LXXVII): Yellow oil (528 mg, 2.05 mmol, 19.0% yield). ESIMS found for C₉H₁₂BrN₃O m/z 259.3 (M+H).

Preparation of tert-butyl (1-(6-chloropyrazin-2-yl)azetidin-3-yl)carbamate (LXXX) is depicted below in Scheme 16.

Step 1

To a solution of tert-butyl azetidin-3-ylcarbamate hydrochloride (LXXVIII) (2 g, 9.58 mmol) in dry DMF (19.2 mL) was added DIPEA (8.37 ml, 47.9 mmol). To this mixture was added 2,6-dichloropyrazine (LXXIX) (1.428 g, 9.58 mmol) and the reaction was stirred at 95° C. for 3 hours. The reaction was quenched with water (20 mL) and extracted with EtOAc. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel column chromatography (40 g) (100% hexanes→hexanes:EtOAc 1:1) to yield tert-butyl (1-(6-chloropyrazin-2-yl)azetidin-3-yl)carbamate (LXXX) (2.2882 g, 8.04 mmol, 84% yield) as a white solid. ESIMS found for C₁₂H₁₇ClN₄O₂ m/z 285.1 (M+H).

Preparation of intermediate 2-(3-fluorophenyl)pyridine-3,4-diamine (LXXXIV) is depicted below in Scheme 17.

Step 1

A solution of 2-chloro-3-nitropyridin-4-amine (LXXXI) (2.0 g, 11.5 mmol, 1.0 eq), (3-fluorophenyl)boronic acid (LXXXII) (1.93 g, 13.8 mmol, 1.2 eq), Pd(PPh₃)₄ (0.40 g, 0.34 mmol, 0.03 eq), Na₂CO₃ (2.44 g, 23.05 mmol, 2.0 eq) in a mixed solvent of toluene (20 mL), H₂O (10 mL) and EtOH (4 mL) was stirred at 75° C. for 15 h under nitrogen atmosphere. Then the reaction mixture was washed with brine (30 mL) and dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo, the resultant residue was purified by chromatography on silica gel (PE:EtOAc=1:1) to afford 2-(3-fluorophenyl)-3-nitropyridin-4-amine (LXXXIII) (1.91 g, 8.2 mmol, 71.2% yield) as a yellow solid. ESIMS found for C₁₁H₈FN₃O₂ m/z 234.2 (M+H).

Step 2

To a solution of 2-(3-fluorophenyl)-3-nitropyridin-4-amine (LXXXIII) (1.91 g, 8.19 mmol, 1.0 eq) in MeOH (100 mL) was added Pd/C (0.8 g) under nitrogen atmosphere. The mixture was stirred under 50 psi of H₂ for 6 h at room temperature. The mixture was then filtered and concentrated in vacuo to afford 2-(3-fluorophenyl)pyridine-3,4-diamine (LXXXIV) as a black solid (1.52 g, 7.48 mmol, 91.3% yield). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 4.30 (s, 2H), 5.55 (s, 2H), 6.44 (d, J=4.8 Hz, 1H), 7.07-7.19 (m, 1H), 7.33 (dd, J=4.4 Hz, J=2 Hz, 1H), 7.38-7.49 (m, 2H), 7.57 (d, J=4.8 Hz, 1H); ESIMS found C₁₁H₁₀FN₃ m/z 204.0 (M+H).

The following intermediates were prepared in accordance with the procedure described in the above Scheme 17.

2-(4-Fluorophenyl)pyridine-3,4-diamine (LXXXV): White Solid (1.56 g, 7.67 mmol, 92.0% yield). ¹H NMR (CDCl₃, 400 MHz) 3.38 (brs, 2H), 4.02 (brs, 2H), 6.57 (d, J=4.8 Hz, 1H), 7.15 (t, J=4.8 Hz, 2H), 7.59 (dd, J=8.4 Hz, J=5.6 Hz, 2H), 7.94 (d, J=5.2 Hz, 1H); ESIMS found for C₁₁H₁₀FN₃ m/z 204.0 (M+H).

2-(2-Fluorophenyl)pyridine-3,4-diamine (LXXXVI): Yellow Solid (1.45 g, 7.14 mmol, 89.2% yield). ¹H NMR (CDCl₃, 400 MHz) 3.23 (brs, 2H), 4.12 (brs, 2H), 6.62 (d, J=4.89 Hz, 1H), 7.19 (t, J=9.03 Hz, 1H), 7.24-7.33 (m, 1H), 7.42 (d, J=6.02 Hz, 1H), 7.45-7.61 (m, 1H), 8.00 (d, J=4.89 Hz, 1H); ESIMS found for C₁₁H₁₀FN₃ m/z 204.0 (M+H).

[2,3′-Bipyridine]-3,4-diamine (LXXXVII): Black Solid (1.19 g, 6.39 mmol, 86.4% yield). ESIMS found for C₁₀H₁₀N₄ m/z 187.1 (M+H).

2-(Thiophen-3-yl)pyridine-3,4-diamine (LXXXVIII): Yellow oil (1.12 g, 5.86 mmol, 96.7% yield). ¹H NMR (CDCl₃, 400 MHz) 3.53 (brs, 2H), 3.99 (brs, 2H), 6.55 (d, J=5.14 Hz, 1H), 7.40-7.49 (m, 2H), 7.56-7.62 (m, 1H), 7.93 (d, J=5.14 Hz, 1H); ESIMS found for C₉H₉N₃S m/z 192.0 (M+H).

2-(Furan-3-yl)pyridine-3,4-diamine (LXXXIX): Yellow oil (1.32 g, 7.53 mmol, 95.2% yield). ESIMS found for C₉H₉N₃O m/z 176.0 (M+H).

2-(Thiophen-2-yl)pyridine-3,4-diamine (XC): Yellow oil (1.04 g, 5.44 mmol, 98.3% yield). ¹H NMR (CDCl₃, 400 MHz) 3.22 (brs, 2H), 4.11 (brs, 2H), 6.61 (d, J=4.8 Hz, 1H), 7.18 (t, J=9.0 Hz, 1H), 7.50 (d, J=6.8 Hz, 1H), 7.44-7.58 (m, 1H), 7.99 (d, J=4.8 Hz, 1H); ESIMS found for C₉H₉N₃S m/z 192.0 (M+H).

2-(5-Fluorothiophen-2-yl)pyridine-3,4-diamine (XCI): Yellow oil (1.2 g, 5.74 mmol, 91.5% yield). ESIMS found for C₉H₈FN₃S m/z 210.1 (M+H).

2-(5-Methylthiophen-2-yl)pyridine-3,4-diamine (XCII): Yellow oil (1.20 g, 5.85 mmol, 86.0% yield). ¹H NMR (CD₃OD, 400 MHz) 2.55 (s, 3H), 6.62 (d, J=6 Hz, 1H), 6.87 (d, J=1.2 Hz, 1H), 7.23 (d, J=3.2 Hz, 1H), 7.63 (d, J=5.6 Hz, 1H); ESIMS found for C₁₀H₁₁N₃S m/z 206.0 (M+H).

1-(5-(3,4-Diaminopyridin-2-yl)thiophen-2-yl)ethan-1-one (XCIII): Yellow oil (1.20 g, 5.85 mmol, 86.0% yield). ¹H NMR (DMSO-d₆, 400 MHz) 2.52 (s, 3H), 4.84 (s, 2H), 5.83 (s, 2H), 6.46 (d, J=4.8 Hz, 1H), 7.57 (d, J=4.8 Hz, 1H), 7.66 (d, J=4 Hz, 1H), 7.88 (d, J=4 Hz, 1H); ESIMS found for C₁₁H₁₁N₃OS m/z 234.0 (M+H).

3-(3,4-Diaminopyridin-2-yl)-5-fluorophenol (XCIV): White solid (320 mg, 1.46 mmol, 84.6% yield). ESIMS found for C₁₁H₁₀FN₃O m/z 220.1 (M+H).

2-(3-Fluoro-5-methoxyphenyl)pyridine-3,4-diamine (XCV): White solid (501 mg, 2.148 mmol, 93.1% yield). ESIMS found for C₁₂H₁₂FN₃O m/z 234.1 (M+H).

2-(3-Fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)pyridine-3,4-diamine (XCVI): Black oil (167 mg, 0.528 mmol, 80.9% yield). ESIMS found for C₁₇H₂₁FN₄O m/z 317.1 (M+H).

2-(3-(2-(Dimethylamino)ethoxy)-5-fluorophenyl)pyridine-3,4-diamine (XCVII): Black oil (88 mg, 0.303 mmol, 20.83% yield). ¹H NMR (DMSO-d₆, 400 MHz); ESIMS found for C₁₅H₁₉FN₄O m/z 291.1 (M+H).

Preparation of intermediate [2,4′-bipyridine]-3,4-diamine (C) is depicted below in Scheme 18.

Step 1

To a solution of pyridin-4-ylboronic acid (XCVIII) (2.00 g, 16.3 mmol), 2-chloro-3-nitropyridin-4-amine (LXXXI) (2.35 g, 13.6 mmol), Na₂CO₃ (5.03 g, 47.5 mmol) and Pd(dppf)Cl₂ (502.87 mg, 677.92 μmol) in dioxane (40 mL) and H₂O (8 mL) was de-gassed and then heated to 80° C. overnight under N₂. TLC (100% EtOAc) showed the starting material was consumed completely. The reaction mixture was poured into H₂O (300 mL). The mixture was extracted with EtOAc (3×250 mL). The organic phase was washed with brine (300 mL), dried over anhydrous MgSO₄, concentrated in vacuum to give a residue, which was purified by silica gel column chromatography (DCM/MeOH=20/1) to afford 3-nitro-[2,4′-bipyridin]-4-amine (XCIX) (1.60 g, 7.4 mmol, 54.6% yield) as yellow solid. ESIMS found for C₁₀H₈N₄O₂ m/z 217.1 (M+H).

Step 2

To a solution of 3-nitro-[2,4′-bipyridin]-4-amine (XCIX) (1.60 g, 7.4 mmol) in MeOH (30 mL), was added Fe (1.65 g, 29.6 mmol) and NH₄Cl (3.10 g, 59.2 mmol) in one portion at rt. The mixture was stirred at rt. for 10 min. Then heated to 80° C. and stirred for 16 hours. TLC showed the reaction was completed. The mixture was cooled to rt. and concentrated in reduced pressure at 60° C. The combined organic phase was washed with saturated brine (100 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The to give crude [2,4′-bipyridine]-3,4-diamine (C) (1.20 g, 6.44 mmol, 87.1% yield) as a yellow solid. ¹H NMR (DMSO-d₆, 400 MHz) 4.52 (s, 2H), 5.69 (s, 2H), 6.50 (d, J=4.8 Hz, 1H), 7.62 (d, J=6 Hz, 2H), 7.63 (d, J=4.8 Hz, 1H), 8.61 (d, J=6 Hz, 2H); ESIMS found for C₁₀H₁₀N₄ m/z 187.0 (M+H).

Preparation of intermediate [2,2′-bipyridine]-3,4-diamine (CIII) is depicted below in Scheme 19.

Step 1

To a solution of 2-(tributylstannyl)pyridine (CI) (9.00 g, 24.5 mmol, 1.0 eq), 2-chloro-3-nitropyridin-4-amine (LXXXI) (4.24 g, 24.5 mmol, 1.0 eq), Pd(PPh₃)₄ (28.25 g, 24.5 mmol, 1.0 eq) in dioxane (40 mL) was de-gassed and then heated to 100° C. for 1 h under N₂. LC/MS showed that half of the starting material was consumed. The mixture was filtered and concentrated in vacuum to give a residue, which was purified by prep-HPLC (Base) to afford the 3-nitro-[2,2′-bipyridin]-4-amine (CII) (0.70 g, 3.24 mmol, 13.2% yield) as a light yellow oil. ESIMS found for C₁₀H₈N₄O₂ m/z 217.1 (M+H).

Step 2

To a solution of 3-nitro-[2,2′-bipyridin]-4-amine (CII) (700 mg, 3.24 mmol, 1.0 eq) in MeOH (15 mL) was added Pd/C (200 mg, 3.24 mmol, 1.0 eq). The mixture was stirred at 25° C. for 4 h. LC/MS showed that the starting material was completely consumed. The mixture was filtered and concentrated to give [2,2′-bipyridine]-3,4-diamine (CIII) (450.0 mg, 2.42 mmol, 74.6% yield) as a light brown solid. ¹H NMR (DMSO-d₆, 400 MHz) 5.73 (brs, 2H), 6.52 (d, J=4.8 Hz, 1H), 6.76 (brs, 2H), 7.31 (dt, J=5.6 Hz, J=1.2 Hz, 1H), 7.52-7.58 (m, 1H), 7.82 (dt, J=8 Hz, J=1.2 Hz, 1H), 8.44 (d, J=8 Hz, 1H), 8.60 (d, J=6 Hz, 1H); ESIMS found for C₁₀H₁₀N₄ m/z 187.1 (M+H).

Preparation of intermediate 2-(piperidin-1-yl)pyridine-3,4-diamine (CV) is depicted below in Scheme 20.

Step 1

To a solution of 2-chloro-3-nitropyridin-4-amine (LXXXI) (4.00 g, 23.5 mmol, 1.0 eq) and piperidine (5.89 g, 69.1 mmol, 3.0 eq) in DMF (60 mL) was added K₂CO₃ (9.56 g, 69.1 mmol, 3.0 eq) in one portion and the mixture was stirred at 120° C. under nitrogen overnight. The reaction mixture was diluted with EtOAc (30 mL) and washed with aqueous saturated NaHCO₃ solution (80 mL). The organic phases were dried over Na₂SO₄ and concentrated in vacuo, the resultant residue was purified by silica gel column chromatography (PE:EtOAc=5:1→1:1) to give 3-nitro-2-(piperidin-1-yl)pyridin-4-amine (CIV) (3.87 g, 5.42 mmol, 75.6% yield) as a black oil. ESIMS found for C₁₀H₁₄N₄O₂ m/z 223.1 (M+H).

Step 2

A mixture of 3-nitro-2-(piperidin-1-yl)pyridin-4-amine (CIV) (3.87 g, 5.42 mmol, 1.0 eq) and Pd/C (0.80 g) in MeOH (20 mL) was stirred at room temperature under 50 psi H₂ overnight. After the starting material was consumed completely, the mixture was filtered through a Celite pad and the filtrate was concentrated in vacuo to give the 2-(piperidin-1-yl)pyridine-3,4-diamine (CV) (2.63 g, 13.7 mmol, 78.5% yield) as a black solid. ESIMS found C₁₀H₁₆N₄ m/z 193.0 (M+H).

The following intermediates were prepared in accordance with the procedure described in the above Scheme 20.

2-(4,4-Difluoropiperidin-1-yl)pyridine-3,4-diamine (CVI): Black Solid (1.9 g, 8.32 mol, 97.7% yield). ESIMS found for C₁₀H₁₄F₂N₄ m/z 229.1 (M+H).

2-Morpholinopyridine-3,4-diamine (CVII): Black Solid (1.4 g, 7.21 mol, 89.8% yield). ESIMS found for C₉H₁₄N₄O m/z 195.1 (M+H).

Preparation of intermediate 2-(4-methyl-1H-imidazol-1-yl)pyridine-3,4-diamine (CXI) is depicted below in Scheme 21.

Step 1

A solution of 2-methyl-3-nitropyridin-4-amine (CVIII) (1.00 g, 5.76 mmol, 1.0 eq), 4-methyl-1H-imidazole (CIX) (0.94 g, 11.5 mmol, 2.0 eq) in DMF (10 mL) was stirred at 80° C. for 3 h under microwave irradiation. The reaction was then quenched by water (15 mL). The mixture was extracted with EtOAc (20 mL×3), the organic layer were combined, washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo, the resultant residue was purified by chromatography on silica gel (PE:EtOAc=5:1→3:1) to afford 2-(4-methyl-1H-imidazol-1-yl)-3-nitropyridin-4-amine (CX) (700 mg, 3.19 mmol, 56.1% yield) as a yellow solid. ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.13 (s, 3H), 6.88 (d, J=6 Hz, 1H), 7.03 (s, 1H), 7.54 (brs, 2H), 7.82 (s, 1H), 8.01 (d, J=5.6 Hz, 1H); ESIMS found for C₉H₉N₅O₂ m/z 220.1 (M+H).

Step 2

To a solution of 2-(4-methyl-1H-imidazol-1-yl)-3-nitropyridin-4-amine (CX) (700 mg, 3.19 mmol, 1.0 eq) in MeOH (20 mL) was added Pd/C (0.3 g) under a nitrogen atmosphere. The mixture was stirred under 50 psi of H₂ for 12 h at room temperature. The mixture was the filtered and concentrated in vacuo to afford 2-(4-methyl-1H-imidazol-1-yl)pyridine-3,4-diamine (CXI) (500 mg, 2.64 mmol, 82.7% yield) as a white solid. ¹H NMR (DMSO-d₆, 400 MHz) 2.17 (s, 3H), 4.36 (brs, 2H), 5.86 (brs, 2H), 6.51 (d, J=5.2 Hz, 1H), 7.14 (s, 1H), 7.43 (d, J=5.2 Hz, 1H), 7.77 (s, 1H); ESIMS found C₉H₁₁N₅ m/z 190.1 (M+H).

Preparation of intermediate 2-(4-methylpiperazin-1-yl)pyridine-3,4-diamine (CXIV) is depicted below in Scheme 22.

Step 1

A mixture of 1-methylpiperazine (CXII) (20 mL) and 2-chloro-3-nitropyridin-4-amine (LXXXI) (4.0 g, 23.1 mmol, 1.0 eq) was stirred at 50° C. for 1 h under microwave irradiation. The reaction mixture was diluted with water (100 mL) and filtered, the cake was washed with water (30 mL×3), dried in vacuo to give 2-(4-methylpiperazin-1-yl)-3-nitropyridin-4-amine (CXIII) (4.0 g, 16.9 mmol, 73.2% yield) as a yellow solid. ESIMS found for C₁₀H₁₅N₅O₂ m/z 238.1 (M+H).

Step 2

A mixture of 2-(4-methylpiperazin-1-yl)-3-nitropyridin-4-amine (CXIII) (4.0 g, 16.9 mmol, 1.0 eq) and Pd/C (0.5 g) in MeOH (200 mL) was stirred under 50 psi of H₂ at room temperature overnight. The reaction was monitored by TLC. The mixture was filtered and the filtrate was concentrated in vacuo to give 2-(4-methylpiperazin-1-yl)pyridine-3,4-diamine (CXIV) (3.13 g, 89.6% yield) as a black solid. ¹H NMR (DMSO-d₆, 400 MHz) 2.74 (s, 4H), 3.12 (s, 3H), 3.44 (brs, 4H), 5.19 (brs, 4H), 6.60 (d, J=6.4 Hz, 2H); ESIMS found C₁₀H₁₇N₅ m/z 208.1 (M+H).

Preparation of intermediate N-(3-(3,4-diaminopyridin-2-yl)-5-fluorobenzyl)methanesulfonamide (CXX) is depicted below in Scheme 23.

Step 1

A solution of 3-bromo-5-fluorobenzonitrile (CXV) (44.0 g, 220.0 mmol, 1.0 eq) was dissolved in THF (30 mL). BH₃-Me₂S (33.43 g, 440.0 mmol, 2.0 eq) was added to the solution at 20° C. Then it was stirred at 80° C. for 2 h, HCl (6 N, 100 mL) was added to the mixture slowly at 20° C. The mixture was stirred at 80° C. for 1 h, then it was washed with EtOAc (300 ml). The water phase was basified with 50% aqueous NaOH and it was extracted with EtOAc (300 mL×3). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated in vacuo to produce (3-bromo-5-fluoro-phenyl)methanamine (CXVI) (24.0 g, 117.62 mmol, 53.5% yield). ¹H NMR (CDCl₃, 300 MHz) 3.86 (s, 2H), 7.01 (d, J=8 Hz, 1H), 7.12 (d, J=8 Hz, 1H), 7.28 (s, 1H); ESIMS found C₇H₇BrFN m/z 203.9 (Br⁷⁹M+H).

Step 2

A solution of (3-bromo-5-fluoro-phenyl)methanamine (CXVI) (23.0 g, 112.7 mmol, 1.0 eq) was dissolved in DCM (15 mL), TEA (34.22 g, 338.2 mmol, 3.0 eq) was added to the mixture. Then MsCl (13.44 g, 117.3 mmol, 1.04 eq) was added slowly to the solution at 0° C. It was stirred at 0-30° C. for 2 h. The reaction was washed with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated to give N-(3-bromo-5-fluorobenzyl)methanesulfonamide (CXVII) (34.0 g, 102.44 mmol, 90.9% yield, 85% purity) as an oil. ¹H NMR (CDCl₃, 300 MHz) 2.88 (s, 3H), 4.24 (d, J=4.5 Hz, 2H), 6.99 (d, J=9 Hz, 1H), 7.13 (dt, J=8.1 Hz, J=2 Hz, 1H), 7.25 (s, 1H); ESIMS found C₈H₉BrFNO₂S m/z 282.0 (Br⁷⁹M+H).

Step 3

A solution of N-(3-bromo-5-fluorobenzyl)methanesulfonamide (CXVII) (34.0 g, 102.4 mmol, 1.0 eq) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (52.02 g, 204.9 mmol, 2.0 eq), KOAc (20.11 g, 204.9 mmol, 2.0 eq) was dissolved in dioxane (20 mL). Then Pd(dppf)Cl₂ (7.60 g, 10.2 mmol, 0.1 eq) was added to the mixture. It was stirred at 90° C. for 2 h. Then the solvent was removed to get the residue which was purified by silica gel column (PE:EtOAc=10:1→100% EtOAc) to get N-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)methanesulfonamide (CXVIII) (30.0 g, crude). ¹H NMR (CDCl₃, 400 MHz) 1.37 (s, 12H), 2.92 (s, 3H), 4.34 (d, J=6.3 Hz, 2H), 7.19 (dt, J=9.3 Hz, J=2.1 Hz, 1H), 7.44 (dd, J=8.7 Hz, J=2.4 Hz, 1H), 7.54 (s, 1H); ESIMS found C₁₄H₂₁BFNO₄S m/z 330.1 (M+H).

Step 4

A solution of N-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzyl)methanesulfonamide (CXVIII) (5.00 g, 15.19 mmol, 1.0 eq) and 2-chloro-3-nitropyridin-4-amine (LXXXI) (2.64 g, 15.19 mmol, 1.0 eq), Cs₂CO₃ (9.90 g, 30.4 mmol, 2.0 eq) was dissolved in dioxane (40 mL) and water (8 mL). Then Pd(dppf)Cl₂ (1.13 g, 1.52 mmol, 0.1 eq) was added to the mixture. The mixture was stirred at 100° C. for 10 h under N₂. The solvent was removed to get the residue which was purified by silica column to get N-(3-(4-amino-3-nitropyridin-2-yl)-5-fluorobenzyl)methanesulfonamide (CXIX) (3.00 g, 8.81 mmol, 58.0% yield) as an oil. ESIMS found C₁₃H₁₃FN₄O₄S m/z 341.1 (M+H).

Step 5

A solution of N-[[3-(4-amino-3-nitro-2-pyridyl)-5-fluoro-phenyl]methyl]methanesulfonamide (CXIX) (3.00 g, 8.8 mmol, 1.0 eq), Fe (2.46 g, 44.1 mmol, 5.0 eq) and NH₄Cl (2.36 g, 44.1 mmol, 5.0 eq) was dissolved in MeOH (35 mL). The mixture was stirred at 80° C. for 2 h. After filtration, the filtrate was concentrated to get N-(3-(3,4-diaminopyridin-2-yl)-5-fluorobenzyl)methanesulfonamide (CXX) (2.20 g, 7.09 mmol, 80.5% yield) as black solid. ¹H NMR (CDCl₃, 400 MHz) 2.96 (s, 3H), 4.28 (d, J=6 Hz, 2H), 5.33 (brs, 2H), 6.81 (d, J=6.5 Hz, 1H), 7.38-7.40 (m, 2H), 7.75 (d, J=6.5 Hz, 1H); ESIMS found Cl₃H₁₅FN₄O₂S m/z 311.1 (M+H).

Preparation of intermediate 5-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)pyridine-3,4-diamine (CXXVI) is depicted below in Scheme 24.

Step 1

A solution of 3-bromo-5-fluorobenzaldehyde (CXXI) (20.0 g, 98.2 mmol, 1.0 eq) in MeOH (1.8 L) was added N¹,N¹-dimethylethane-1,2-diamine (21.5 mL, 196.4 mmol, 2.0 eq). The pH was adjusted to 6 using HOAc and stirred for 1 h. NaCNBH₃ (8.6 g, 137.5 mmol, 1.4 eq) was added and stirred at room temperature overnight. The MeOH was removed under vacuum and the residue was partitioned between CHCl₃ and saturated aqueous NaHCO₃. The organic layer was dried over MgSO₄ and evaporated under vacuum. The crude product was purified on a silica gel column (100% CHCl₃→3:97 MeOH[7N NH₃]:CHCl₃) to produce N¹-(3-bromo-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine (CXXII) as a yellow oil (13.0 g, 49.9 mmol, 51% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.28 (s, 6H), 2.39 (t, J=4 Hz, 2H), 3.07 (q, J=6 Hz, 2H), 6.10 (t, J=5 Hz, 1H), 6.38 (td, J=12 Hz, J=2 Hz, 1H), 6.51 (td, J=8.6 Hz, J=2 Hz, 1H), 6.61 (t, J=2 Hz, 1H); ESIMS found C₁₀H₁₄BrFN₂ m/z 261.0 (M+H).

Step 2

A solution of N¹-(3-bromo-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine (CXXII) (13.0 g, 49.9 mmol, 1.0 eq), bis(pinacolato)diboron (12.6 g, 59.9 mmol, 1.2 eq), KOAc (12.1 g, 124.3 mmol, 2.5 eq) and dioxane (600 mL) was purged with argon. Pd(dppf)Cl₂ (2.0 g, 2.47 mmol, 0.05 eq) was added to the reaction and purged again with argon. The solution was heated at 90° C. for 2 h. Once TLC showed the disappearance of (CXXII), the solution was cooled to room temperature and then concentrated under reduced pressure to produce crude N¹-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-N²,N²-dimethylethane-1,2-diamine (CXXIII) (7.4 g, 24.0 mmol, 48.2% yield).

Step 3

To a solution of N¹-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-N²,N²-dimethylethane-1,2-diamine (CXXIII) (2.00 g, 6.49 mmol, 1.2 eq), 2-bromo-3-nitropyridin-4-amine (CXXIV) (1.18 g, 5.41 mmol, 1.0 eq), Na₂CO₃ (1.15 g, 10.82 mmol, 2.0 eq) and Pd(dppf)Cl₂ (395.73 mg, 540.83 μmol, 0.1 eq) in dioxane (40 mL) and H₂O (8 mL) was de-gassed and then heated to 80° C. overnight under N₂. TLC (PE:EtOAc=1:1) showed the starting material was consumed completely. The reaction mixture was poured into H₂O (300 mL). The mixture was extracted with EtOAc (3×250 mL). The organic phase was washed with saturated brine (300 mL), dried over anhydrous MgSO₄, concentrated in vacuum to give a residue, which was purified by silica gel column chromatography (PE/EtOAc=5/1) to afford N¹-(3-(4-amino-3-nitropyridin-2-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine (CXXV) (1.50 g, 4.70 mmol, 86.9% yield) as a solid. ESIMS found for C₁₅H₁₈FN₅O₂ m/z 320.1 (M+H).

Step 4

To a solution of N¹-(3-(4-amino-3-nitropyridin-2-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine (CXXV) (1.50 g, 4.70 mmol, 1.0 eq) in MeOH (30 mL) was added Zn (1.54 g, 23.50 mmol, 5.0 eq) and NH₄Cl (754.21 mg, 14.10 mmol, 3.0 eq) in one portion at room temperature. The mixture was stirred at room temperature for 10 min. TLC showed the reaction was completed. The mixture was filtered and concentrated in vacuum to afford 5-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)pyridine-3,4-diamine (CXXVI) (1.2 g, 4.15 mmol, 4.15 mmol, 88.2% yield) as a yellow oil. ¹H NMR (CD₃OD, 300 MHz) 2.44 (s, 6H), 2.78 (t, J=5.25 Hz, 2H), 3.24-3.34 (m, 2H), 6.40-6.51 (m, 2H), 6.53 (d, J=1.5 Hz, 1H), 6.71 (d, J=6.3 Hz, 1H), 7.58 (d, J=6.6 Hz, 1H); ESIMS found for C₁₅H₂₀FN₅ m/z 290.1 (M+H).

Example 1

Preparation of N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide (34) is depicted below in Scheme 25.

Step 1

To a solution of N-(5-bromopyridin-3-yl)pivalamide (XXXVI) (800 mg, 3.11 mmol, 1.0 eq) and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2-trimethylsilylethoxymethyl)indazole-3-carbaldehyde (XIV) (1.56 g, 3.73 mmol, 1.2 eq), Pd(dppf)Cl₂ (228 mg, 0.31 mmol, 0.10 eq) and Na₂CO₃ (659 mg, 6.22 mmol, 2.0 eq) in dioxane (34 mL) and H₂O (5.5 mL) was de-gassed and then heated to 100° C. for 3 h under N₂. TLC (100% EtOAc) showed the starting material was consumed completely. The reaction mixture was concentrated in vacuum to give a residue, which was pre-purified by silica gel column chromatography (PE:EtOAc=10:1→1:1) to afford pure N-(5-(3-formyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide (CXXVII) as a red brown solid (1.25 mg, 2.76 mmol, 88.8% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm −0.03 (s, 9H), 0.94 (t, J=8 Hz, 2H), 1.40 (s, 9H), 3.63 (t, J=8 Hz, 2H), 5.88 (s, 2H), 7.58 (s, 1H), 7.86-7.91 (m, 2H), 8.47 (d, J=2.4 Hz, 1H), 8.53 (s, 1H), 8.67 (dd, J=5.6 Hz, J=2.4 Hz, 2H), 10.31 (s, 1H); ESIMS found for C₂₄H₃₂N₄O₃Si m/z 453.1 (M+H).

Step 2-3

A solution of N-(5-(3-formyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide (CXXVII) (100.0 mg, 0.22 mmol, 1.0 eq), 2-(4-fluorophenyl)pyridine-3,4-diamine (LXXXV) (45 mg, 0.22 mmol, 1.0 eq) and Na₂S₂O₅ (49 mg, 0.26 mmol, 1.20 eq) in DMF (2 mL) was stirred at 120° C. for 20 h. LC/MS showed the starting material was consumed. Water (5 mL) was then added dropwise to the mixture and stirred at room temperature for 10 min, the mixture was filtered, then the filtrate was washed by H₂O (2 mL×3), dried over anhydrous MgSO₄, and evaporated under vacuum to give crude N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide (CXXVIII). CXXVIII was dissolved in dry DCM (5 mL) before adding triethylsilane (84 μL, 0.52 mmol) and TFA (2.5 mL). The reaction was stirred at room temperature for 2 h under N₂. The solvent was evaporated under reduced pressure; the residue was taken up water (10 mL), and basified with 5N NH₄OH. The precipitates were filtered, washed by cold water and dried under vacuum at room temperature. The crude product was suspended in DCM (10 mL), sonicated briefly and then heated to boiling for 5 min. The solution was cooled to room temperature and the solids were filtered, washed with DCM and dried under vacuum at room temperature to produce N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamie (34) as a yellow solid (41.0 mg, 0.08 mmol, 36.4% yield). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.31 (s, 9H), 7.38 (t, J=8.23 Hz, 2H), 7.51 (d, J=5.27 Hz, 1H), 7.82-7.92 (m, 2H), 8.16 (s, 1H), 8.43 (d, J=5.52 Hz, 1H), 8.65-8.74 (m, 2H), 8.88 (s, 1H), 8.90 (d, J=2.26 Hz, 1H), 9.06 (dd, J=8.80 Hz, J=6.04 Hz, 2H), 9.65 (s, 1H), 13.68 (brs, 1H), 13.99 (brs, 1H); ESIMS found for C₂₉H₂₄FN₇O m/z 506.3 (M+1).

The following compounds were prepared in accordance with the procedure described in the above Example 1.

N-(5-(3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide 1.

White solid (18.9 mg, 0.04 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.14 (t, J=7.53 Hz, 3H), 2.46 (q, J=7.52 Hz, 4H), 7.34-7.46 (m, 1H), 7.63-7.79 (m, 2H), 7.82-7.92 (m, 2H), 8.52 (d, J=6.02 Hz, 1H), 8.60 (d, J=0.76 Hz, 1H), 8.67-8.75 (m, 2H), 8.76-8.77 (m, 1H), 8.79 (s, 1H), 8.86 (s, 1H), 10.40 (brs, 1H), 14.21 (brs, 1H), 14.27 (brs, 1H); ESIMS found for C₂₇H₂₀FN₇O m/z 478.1 (M+1).

N-(5-(3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide 2.

Beige solid (34.0 mg, 0.07 mmol). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 0.98 (d, J=7 Hz, 6H), 2.13 (non, J=7 Hz, 1H), 2.29 (d, J=7 Hz, 2H), 7.27 (td, J=2 Hz, J=8 Hz, 1H), 7.55 (d, J=5.5 Hz, 1H), 7.61 (q, J=8 Hz, 1H), 7.84 (dd, J=1.5 Hz, J=8.5 Hz, 1H), 7.87 (d, J=9 Hz, 1H), 8.46 (d, J=5.5 Hz, 1H), 8.54 (t, J=2 Hz, 1H), 8.71 (d, J=1.5 Hz, 1H), 8.78 (d, J=2 Hz, 1H), 8.83 (d, J=4.5 Hz, 1H), 8.85 (s, 1H), 8.91 (s, 1H), 10.24 (s, 1H), 13.72 (brs, 1H), 13.99 (brs, 1H); ESIMS found for C₂₉H₂₄FN₇O m/z 506.0 (M+1).

5-(3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N,N-dimethylpyridin-3-amine 7.

White solid (8.1 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 3.04 (s, 6H), 7.32 (dd, J=8.28 Hz, J=2.0 Hz, 1H), 7.36 (t, J=2.01 Hz, 1H), 7.53-7.61 (m, 2H), 7.80-7.91 (m, 3H), 8.18 (d, J=2.76 Hz, 1H), 8.20 (s, 1H), 8.33 (d, J=1.76 Hz, 1H), 8.46 (d, J=5.27 Hz, 1H), 8.77-8.86 (m, 2H), 8.88 (s, 1H), 13.72 (brs, 1H), 13.98 (brs, 1H); ESIMS found for C₂₆H₂₀FN₇ m/z 450.1 (M+1).

1-(5-(3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine 13.

White solid (31.7 mg, 0.07 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.21-2.40 (m, 6H), 3.69 (s, 2H), 7.34 (td, J=8.16, 3.01 Hz, 1H), 7.55 (d, J=5.27 Hz, 1H), 7.59-7.69 (m, 1H), 7.81-7.97 (m, 2H), 8.08-8.20 (m, 2H), 8.46 (d, J=5.27 Hz, 1H), 8.57 (d, J=1.76 Hz, 1H), 8.76-8.90 (m, 2H), 8.93 (s, 1H), 8.98 (d, J=2.01 Hz, 1H), 13.73 (brs, 1H), 14.00 (s, 1H); ESIMS found for C₂₇H₂₂FN₇ m/z 464.3 (M+1).

N-(5-(3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide 19.

White solid (20.7 mg, 0.04 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 0.80-0.95 (m, 4H), 1.81-1.93 (m, 1H), 7.29 (dt, J=8.28 Hz, J=2.00 Hz, 1H), 7.51-7.67 (m, 2H), 7.86 (s, 2H), 8.26 (s, 1H), 8.46 (d, J=5.52 Hz, 1H), 8.56 (d, J=1.76 Hz, 1H), 8.71 (d, J=3.69 Hz, 1H), 8.74 (d, J=5.81 Hz, 1H), 8.77-8.88 (m, 2H), 8.91 (s, 1H), 10.60 (s, 1H), 13.75 (brs, 1H), 14.04 (brs, 1H); ESIMS found for C₂₈H₂₀FN₇O m/z 490.2 (M+1).

N-(5-(3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide 21.

White solid (27.6 mg, 0.05 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.54-1.64 (m, 2H), 1.64-1.73 (m, 2H), 1.74-1.86 (m, 2H), 1.88-2.02 (m, 2H), 2.97 (quin, J=7.80 Hz, 1H), 7.49 (td, J=8.34, 2.13 Hz, 1H), 7.76-7.84 (m, 1H), 7.85-7.92 (m, 2H), 7.95 (d, J=6.27 Hz, 1H), 8.55 (d, J=6.28 Hz, 1H), 8.52-8.63 (m, 2H), 8.73 (s, 1H), 8.87 (s, 1H), 8.89 (s, 1H), 9.10 (d, J=1.76 Hz, 1H), 11.06 (s, 1H), 14.47 (brs, 1H), 14.86 (brs, 1H); ESIMS found for C₃₀H₂₄FN₇O m/z 518.2 (M+1).

2-(5-(5-((3,3-Difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridine 25.

White solid (91.7 mg, 0.17 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.18-2.31 (m, 2H), 2.77 (t, J=6.90 Hz, 2H), 2.96 (t, J=13.28 Hz, 2H), 3.81 (s, 2H), 7.34 (td, J=8.41, 2.26 Hz, 1H), 7.56 (d, J=5.27 Hz, 1H), 7.57-7.67 (m, 1H), 7.86 (d, J=8.80 Hz, 1H), 7.92 (dd, J=8.76 Hz, J=1.76 Hz, 1H), 8.10 (t, J=2.01 Hz, 1H), 8.17-8.21 (m, 1H), 8.46 (d, J=5.27 Hz, 1H), 8.58 (d, J=2.01 Hz, 1H), 8.75-8.83 (m, 1H), 8.89 (d, J=11.80 Hz, 1H), 8.93 (s, 1H), 8.97 (d, J=2.26 Hz, 1H), 13.74 (brs, 1H), 14.01 (brs, 1H); ESIMS found for C₂₉H₂₂F₃N₇ m/z 526.3 (M+1).

N-(5-(3-(4-(4-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide 28.

White solid (37.8 mg, 0.07 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 0.98 (d, J=6.53 Hz, 6H), 2.17 (non, J=13.43, 6.84 Hz, 1H), 2.32 (d, J=7.03 Hz, 3H), 7.39 (t, J=8.29 Hz, 2H), 7.51 (d, J=5.27 Hz, 1H), 7.86 (s, 2H), 8.25 (s, 1H), 8.43 (d, J=5.27 Hz, 1H), 8.66 (s, 1H), 8.72 (dd, J=8.16, 2.13 Hz, 2H), 8.87 (s, 1H), 9.04 (dd, J=7.91, 6.40 Hz, 2H), 10.35 (s, 1H), 13.69 (brs, 1H), 14.02 (brs, 1H); ESIMS found for C₂₉H₂₄FN₇O m/z 506.3 (M+1).

5-(3-(4-(4-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N-isopropylpyridin-3-amine 38.

White solid (40.6 mg, 0.09 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.23 (d, J=6.27 Hz, 6H), 3.79-3.90 (m, 1H), 6.89 (brs, 1H), 7.48 (t, J=8.78 Hz, 2H), 7.68 (d, J=5.77 Hz, 1H), 7.80 (brs, 1H), 7.89 (s, 2H), 8.10 (d, J=2.26 Hz, 1H), 8.37 (d, J=0.75 Hz, 1H), 8.48 (d, J=5.77 Hz, 1H), 8.84 (s, 1H), 8.88-8.97 (m, 2H), 14.14 (brs, 1H), 14.27 (s, 1H); ESIMS found for C₂₇H₂₂FN₇ m/z 464.3 (M+1).

4-(4-Fluorophenyl)-2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine 40.

White solid (16.1 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.67-1.77 (m, 4H), 2.53-2.58 (m, 4H), 3.79 (s, 2H), 7.40 (t, J=8.22 Hz, 2H), 7.51 (d, J=5.27 Hz, 1H), 7.84 (d, J=8.78 Hz, 1H), 7.94 (dd, J=8.76 Hz, J=1.52 Hz, 1H), 8.12-8.15 (m, 1H), 8.20 (s, 2H), 8.43 (d, J=5.27 Hz, 1H), 8.57 (d, J=1.76 Hz, 1H), 8.94 (s, 1H), 8.96 (d, J=2.01 Hz, 1H), 8.98-9.06 (m, 2H), 13.70 (brs, 1H), 14.00 (brs, 1H); ESIMS found for C₂₉H₂₄FN₇ m/z 490.3 (M+1).

N-(5-(3-(4-(4-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide 46.

White solid (14.1 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.79-1.90 (m, 2H), 1.92-2.06 (m, 2H), 2.13-2.23 (m, 3H), 2.25-2.38 (m, 3H), 4.57 (s, 1H), 7.41 (t, J=8.91 Hz, 2H), 7.51 (d, J=5.52 Hz, 1H), 7.86 (s, 2H), 8.43 (d, J=5.27 Hz, 1H), 8.69 (s, 1H), 8.72 (s, 2H), 8.88 (s, 1H), 9.05 (dd, J=9.28 Hz, J=6.00 Hz, 2H), 10.24 (s, 1H), 13.70 (brs, 1H), 14.03 (brs, 1H); ESIMS found for C₂₉H₂₂FN₇O m/z 504.2 (M+1).

4-(4-Fluorophenyl)-2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine 52.

White solid (17.1 mg, 0.04 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 7.40 (t, J=8.66 Hz, 2H), 7.54-7.66 (m, 1H), 7.88 (d, J=9.03 Hz, 1H), 7.99 (d, J=9.03 Hz, 1H), 8.45 (d, J=5.52 Hz, 1H), 8.97 (brs, 3H), 9.29 (d, J=11.04 Hz, 3H), 13.88 (brs, 1H) 14.06 (s, 1H); ESIMS found for C₂₃H₁₄FN₇ m/z 408.1 (M+1).

5-(3-(4-(2-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine 55.

White solid (20.3 mg, 0.05 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 7.63-7.74 (m, 2H), 7.78-7.89 (m, 2H), 7.91-8.02 (m, 2H), 8.09 (d, J=2.26 Hz, 1H), 8.11-8.16 (m, 1H), 8.18-8.29 (m, 1H), 8.35 (s, 1H), 8.63-8.76 (m, 2H), 14.57 (brs, 1H), 15.04 (brs 1H); ESIMS found for C₂₄H₁₆FN₇ m/z 422.1 (M+1).

5-(3-(4-(2-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N,N-dimethylpyridin-3-amine 59.

White solid (14.3 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 3.12 (s, 6H), 7.46-7.59 (m, 2H), 7.67-7.78 (m, 2H), 7.84-7.89 (m, 1H), 7.92 (d, J=5.27 Hz, 1H), 7.96 (dd, J=8.78, 1.25 Hz, 1H), 8.03-8.15 (m, 1H), 8.20 (d, J=2.51 Hz, 1H), 8.35 (s, 1H), 8.58 (d, J=6.02 Hz, 1H), 8.72 (s, 1H), 14.38 (s, 1H); ESIMS found for C₂₆H₂₀FN₇ m/z 450.1 (M+1).

N-(5-(3-(4-(2-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide 61.

White solid (11.8 mg, 0.02 mmol). ¹H NMR (CD₃OD, 400 MHz) δ ppm 1.27 (d, J=6.78 Hz, 6H), 2.73 (spt, J=6.87 Hz, 1H), 7.34-7.46 (m, 2H), 7.54-7.64 (m, 1H), 7.72-7.77 (m, 1H), 7.77-7.84 (m, 2H), 7.91-8.00 (m, 1H), 8.27-8.34 (m, 1H), 8.44 (d, J=5.77 Hz, 1H), 8.49 (t, J=2.13 Hz, 1H), 8.64 (d, J=1.51 Hz, 1H), 8.77 (d, J=2.26 Hz, 1H), 8.79 (s, 1H); ESIMS found for C₂₈H₂₂FN₇O m/z 492.2 (M+1).

N-(5-(3-(4-(2-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide 68.

White solid (43.9 mg, 0.08 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.05-1.11 (m, 9H), 2.29 (s, 2H), 7.31-7.42 (m, 2H), 7.47-7.60 (m, 2H), 7.74-7.86 (m, 2H), 8.02 (t, J=7.28 Hz, 1H), 8.18 (s, 1H), 8.45 (d, J=5.52 Hz, 2H), 8.59 (s, 1H), 8.73 (s, 2H), 10.20 (s, 1H), 13.61 (brs, 1H), 13.94 (brs, 1H); ESIMS found for C₃₀H₂₆FN₇O m/z 520.3 (M+1).

N-(5-(3-(4-(2-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide 69.

White solid (15.8 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 0.97 (t, J=7.28 Hz, 3H), 1.68 (sxt, J=7.18 Hz, 2H), 2.42 (t, J=7.15 Hz, 2H), 7.48 (t, J=7.53 Hz, 2H), 7.61-7.70 (m, 1H), 7.77-7.83 (m, 1H), 7.84-7.91 (m, 2H), 8.13 (brs, 1H), 8.51 (brs, 1H), 8.56 (d, J=5.77 Hz, 1H), 8.60 (brs, 1H), 8.68 (s, 1H), 8.79 (brs, 1H), 10.51 (brs, 1H), 14.30 (brs, 2H); ESIMS found for C₂₈H₂₂FN₇O m/z 492.1 (M+1).

N-(5-(3-(4-(2-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide 73.

White solid (43.8 mg, 0.09 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.52-1.85 (m, 6H), 1.87-2.03 (m, 2H), 2.82-2.95 (m, 1H), 7.33-7.43 (m, 2H), 7.47-7.63 (m, 2H), 7.74-7.91 (m, 2H), 7.98-8.08 (m, 1H), 8.17 (s, 1H), 8.39-8.53 (m, 2H), 8.56-8.66 (m, 1H), 8.70-8.82 (m, 2H), 10.23-10.31 (m, 1H), 13.61 (brs, 1H), 13.94 (brs, 1H); ESIMS found for C₃₀H₂₄FN₇O m/z 518.3 (M+1).

4-(Pyridin-3-yl)-2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine 82.

White solid (16.8 mg, 0.04 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 7.54-7.65 (m, 3H), 7.82-7.95 (m, 2H), 8.22 (d, J=8.28 Hz, 1H), 8.49 (d, J=5.27 Hz, 1H), 8.65 (d, J=4.52 Hz, 1H), 8.70 (d, J=4.02 Hz, 1H), 8.92 (s, 1H), 9.05 (s, 1H), 9.23 (d, J=8.28 Hz, 1H), 10.03 (brs, 1H), 13.78 (brs, 1H), 14.00 (s, 1H); ESIMS found for C₂₃H₁₅N₇ m/z 390.0 (M+1).

N-(5-(3-(4-(Pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide 86.

White solid (16.4 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.27-1.38 (m, 9H), 7.90 (d, J=5.52 Hz, 1H), 7.95 (s, 2H), 8.11 (td, J=6.34, 1.38 Hz, 1H), 8.61 (d, J=5.77 Hz, 1H), 8.86 (s, 1H), 8.94 (d, J=4.77 Hz, 1H), 9.07 (s, 1H), 9.18 (brs, 1H), 9.34 (s, 1H), 9.50 (brs, 1H), 9.99 (brs, 1H), 10.48 (s, 1H), 14.47 (brs, 1H); ESIMS found for C₂₈H₂₄N₈O m/z 489.2 (M+1).

N-(5-(3-(4-(Pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide 87.

White solid (24.7 mg, 0.05 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.19 (d, J=6.78 Hz, 6H), 2.78 (spt, J=6.76 Hz, 1H), 7.88-7.96 (m, 3H), 8.08 (dd, J=7.78, 5.52 Hz, 1H), 8.62 (d, J=6.02 Hz, 1H), 8.83 (s, 1H), 8.88 (s, 1H), 8.94 (dd, J=5.14, 1.38 Hz, 1H), 8.97 (d, J=1.76 Hz, 1H), 9.11 (d, J=2.01 Hz, 1H), 9.38-9.54 (m, 1H), 9.88-9.98 (m, 1H), 10.97 (s, 1H), 14.41 (s, 1H), 14.54 (brs, 1H); ESIMS found for C₂₇H₂₂N₈O m/z 475.3 (M+1).

N-Isopropyl-5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine 90.

White solid (36.5 mg, 0.08 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.22 (d, J=6.27 Hz, 6H), 3.81-391 (m, 1H), 7.65 (d, J=5.27 Hz, 1H), 7.68-7.82 (m, 2H), 7.88 (s, 2H), 8.10 (d, J=1.72 1H), 8.36 (s, 1H), 8.51 (d, J=5.52 Hz, 1H), 8.72 (d, J=4.52 Hz, 1H), 8.87 (s, 1H), 9.23 (d, J=6.78 Hz, 1H), 10.01 (brs, 1H), 14.00 (brs, 1H), 14.30 (s, 1H); ESIMS found for C₂₆H₂₂N₈ m/z 447.3 (M+1).

2-(5-(5-(Piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridine 93.

White solid (11.1 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.33-1.44 (m, 2H), 1.44-1.57 (m, 4H), 2.37-2.46 (m, 4H), 3.65 (s, 2H), 7.55-7.65 (m, 2H), 7.85 (d, J=8.78 Hz, 1H), 7.93 (dd, J=8.76 Hz, J=1.52 Hz, 1H), 8.06-8.12 (m, 1H), 8.27 (s, 1H), 8.46-8.52 (m, 1H), 8.54 (d, J=1.76 Hz, 1H), 8.68 (dd, J=4.77, 1.51 Hz, 1H), 8.89-8.99 (m, 2H), 9.13-9.23 (m, 1H), 10.07 (d, J=1.25 Hz, 1H); ESIMS found for C₂₉H₂₆N₈ m/z 487.1 (M+1).

N-Benzyl-1-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine 101.

White solid (29.1 mg, 0.06 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 4.31 (s, 2H), 4.50 (s, 2H), 7.38-7.49 (m, 2H), 7.61 (dd, J=7.65, 1.88 Hz, 2H), 7.85-7.99 (m, 2H), 8.04 (dd, J=8.78, 1.76 Hz, 2H), 8.63 (d, J=6.02 Hz, 1H), 8.79-9.06 (m, 3H), 9.24 (d, J=1.51 Hz, 1H), 9.33-9.47 (brs, 1H), 10.04 (brs Hz, 2H), 14.43 (brs, 1H); ESIMS found for C₃₁H₂₄N₈ m/z 509.3 (M+1).

2-(5-(4-Methylpyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-4-yl)-1H-imidazo [4,5-c]pyridine 109.

White solid (11.7 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.44 (s, 3H), 7.43 (d, J=5.02 Hz, 1H), 7.58 (dd, J=8.28, 1.00 Hz, 1H), 7.63 (d, J=5.27 Hz, 1H), 7.82 (d, J=8.53 Hz, 1H), 8.50 (dd, J=5.02, 3.51 Hz, 2H), 8.57 (s, 1H), 8.64 (s, 1H), 8.66 (s, 1H), 8.67 (s, 1H), 8.76 (d, J=5.27 Hz, 2H); ESIMS found for C₂₄H₁₇N₇ m/z 404.0 (M+1).

2-Phenyl-N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide 114.

White solid (27.7 mg, 0.05 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 3.76-3.84 (m, 2H), 7.09-7.18 (m, 1H), 7.22-7.29 (m, 1H), 7.33 (t, J=7.53 Hz, 2H), 7.37-7.44 (m, 2H), 7.63 (d, J=5.52 Hz, 1H), 7.86 (s, 2H), 8.52 (d, J=5.27 Hz, 1H), 8.62 (s, 1H), 8.75 (d, J=1.00 Hz, 1H), 8.81 (brs, 2H), 8.87 (d, J=6.02 Hz, 2H), 8.92 (s, 1H), 10.81 (s, 1H), 13.84 (brs, 1H), 14.12 (s, 1H); ESIMS found for C₃₁H₂₂N₈O m/z 523.2 (M+1).

N-(5-(3-(4-(Pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide 121.

White solid (14.8 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ 0.97 (t, J=7.28 Hz, 3H), 1.629 (sxt, J=7.04 Hz, 2H), 2.43 (t, J=7.28 Hz, 2H), 7.65 (d, J=5.52 Hz, 1H), 7.88 (s, 2H), 8.53 (d, J=5.28 Hz, 2H), 8.70 (d, J=1.76 Hz, 1H), 8.73 (s, 1H), 8.81 (d, J=5.77 Hz, 1H), 8.91 (brs, 3H), 10.41 (brs, 1H), 13.88 (brs, 1H), 14.10 (brs, 1H); ESIMS found for C₂₇H₂₂N₈O m/z 475.2 (M+1).

N-(5-(3-(4-(Pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide 126.

White solid (15.8 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.17-1.39 (m, 3H), 1.40-1.58 (m, 2H), 1.63-1.72 (m, 1H), 1.72-1.84 (m, 2H), 1.86-2.01 (m, 2H), 7.63 (d, J=5.52 Hz, 1H), 7.87 (s, 2H), 8.51 (d, J=5.52 Hz, 1H), 8.62-8.76 (m, 3H), 8.76-8.81 (m, 2H), 8.83-8.90 (m, 2H), 8.91 (s, 1H), 10.36 (s, 1H); ESIMS found for C₃₀H₂₆N₈O m/z 515.3 (M+1).

N-((5-(3-(4-(Pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)ethanamine 136.

White solid (13.2 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.31 (t, J=7.15 Hz, 3H), 2.97-3.15 (m, 2H), 4.32 (brs, 2H), 7.67-7.83 (m, 1H), 7.89 (d, J=8.52 Hz, 1H), 7.93-8.12 (m, 2H), 8.26 (t, J=4.52 Hz, 1H), 8.55 (d, J=6.27 Hz, 1H), 8.66 (brs, 1H), 8.81 (d, J=5.02 Hz, 2H), 8.97 (d, J=4.02 Hz, 1H), 9.07 (brs, 1H), 9.44-9.66 (m, 1H), 9.71-9.98 (m, 2H), 14.57 (brs, 1H), 15.04 (brs, 1H); ESIMS found for C₂₆H₂₂N₈ m/z 447.2 (M+1).

N-(5-(3-(4-(Pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide 141.

White solid (12.9 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 7.53-7.67 (m, 3H), 7.71 (t, J=7.52 Hz, 1H), 7.92-8.02 (m, 2H), 8.04 (d, J=6.27 Hz, 1H), 8.14 (d, J=7.28 Hz, 2H), 8.34 (dt, J=7.78 Hz, J=1.48 Hz, 1H), 8.57 (d, J=6.27 Hz, 1H), 8.89 (s, 1H), 8.95 (d, J=4.77 Hz, 1H), 9.01 (s, 1H), 9.17 (d, J=10.79 Hz, 2H), 9.61 (d, J=8.03 Hz, 1H), 11.18 (s, 1H), 14.57 (s, 1H), 15.05 (brs, 1H); ESIMS found for C₃₀H₂₀N₈O m/z 509.1 (M+1).

N-(5-(3-(4-(Pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide 148.

White solid (15.7 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 300 MHz) δ 0.96 (t, J=7.53 Hz, 3H), 1.36-1.49 (m, 2H), 1.60-1.76 (m, 2H), 2.34-2.46 (m, 2H), 7.48-7.60 (m, 1H), 7.75-7.93 (m, 2H), 8.01-8.12 (m, 1H), 8.36-8.45 (m, 1H), 8.52 (d, J=4.90 Hz, 1H), 8.64 (brs, 1H), 8.71-8.82 (m, 1H), 8.81-8.89 (m, 1H), 8.90-8.98 (m, 1H), 10.01-10.13 (m, 1H); ESIMS found for C₂₈H₂₄N₈O m/z 489.1 (M+1).

N-(5-(3-(4-(Pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl) pyridin-3-yl)cyclobutanecarboxamide 150.

White solid (17.8 mg, 0.04 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.80-1.92 (m, 1H), 1.95-2.08 (m, 1H), 2.16-2.36 (m, 4H), 3.36-3.46 (m, 1H), 7.69-7.77 (m, 1H), 7.90 (s, 2H), 8.02 (d, J=6.27 Hz, 1H), 8.36 (t, J=7.53 Hz, 1H), 8.55 (d, J=6.27 Hz, 1H), 8.75 (s, 1H), 8.77 (s, 1H), 8.83 (s, 1H), 8.87 (brs, 1H), 8.96 (d, J=4.27 Hz, 1H), 9.56 (brs, 1H), 10.65 (brs, 1H), 14.53 (s, 1H), 15.00 (brs, 1H); ESIMS found for C₂₈H₂₂N₈O m/z 487.2 (M+1).

1-Cyclopentyl-N-((5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)methanamine 154.

White solid (21.5 mg, 0.04 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.19-1.37 (m, 2H), 1.41-1.68 (m, 4H), 1.73-1.92 (m, 2H), 2.23-2.37 (m, 1H), 2.92-3.05 (m, 2H), 4.29-4.49 (m, 2H), 7.84 (dd, J=7.28 Hz, J=4.76 Hz, 1H), 7.96-8.03 (m, 1H), 8.03-8.13 (m, 2H), 8.40 (t, J=8.02 Hz, 1H), 8.62 (d, J=6.52 Hz, 1H), 8.84-8.99 (m, 2H), 9.03 (d, J=4.02 Hz, 1H), 9.25 (s, 1H), 9.57 (brs, 2H), 9.67 (d, J=7.52 Hz, 1H), 14.59 (brs, 1H), 15.09 (brs, 1H); ESIMS found for C₃₀H₂₈N₈ m/z 501.2 (M+1).

N-(5-(3-(4-(Piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide 157.

White solid (28.8 mg, 0.06 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.14 (t, J=7.53 Hz, 3H), 1.56-1.75 (m, 6H), 2.41 (q, J=7.53 Hz, 2H), 4.19 (brs, 4H), 6.80 (d, J=5.52 Hz, 1H), 7.76-7.86 (m, 2H), 8.17 (s, 1H), 8.55-8.60 (m, 1H), 8.63 (dd, J=4.14, 2.13 Hz, 2H), 8.75 (s, 1H), 10.25 (s, 1H), 13.20 (brs, 1H) 13.75 (brs, 1H); ESIMS found for C₂₆H₂₆N₈O m/z 467.2 (M+1).

4-(Piperidin-1-yl)-2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine 160.

Orange-yellow solid (72.9 mg, 0.184 mmol, 77.0% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.70 (br s, 6H), 4.20 (br d, J=5.21 Hz, 4H), 6.81 (d, J=5.49 Hz, 1H), 7.55 (dd, J=7.82, 4.80 Hz, 1H), 7.76-7.83 (m, 2H), 7.84-7.90 (m, 1H), 8.10-8.16 (m, 1H), 8.60 (dd, J=4.67, 1.37 Hz, 1H), 8.79 (s, 1H), 8.96 (d, J=2.20 Hz, 1H), 13.19 (s, 1H), 13.71 (s, 1H); ESIMS found for C₂₃H₂₁N₇ m/z 396.2 (M+1).

N,N-Dimethyl-5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine 163.

White solid (17.1 mg, 0.04 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.69 (s, 6H), 3.03 (s, 6H), 3.49-3.71 (m, 4H), 4.15-4.33 (m, 4H), 6.80-6.90 (m, 1H), 7.32 (t, J=2.26 Hz, 1H), 7.78 (t, J=5.76 Hz, 2H), 7.84 (dd, J=8.56 Hz, J=1.28 Hz, 1H), 8.13 (d, J=2.76 Hz, 1H), 8.23 (d, J=1.25 Hz, 1H), 8.70 (s, 1H), 13.36 (brs, 1H), 13.79 (brs, 1H); ESIMS found for C₂₅H₂₆N₈ m/z 439.1 (M+1).

N-Isopropyl-5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine 168.

White solid (13.6 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.22 (d, J=6.27 Hz, 6H), 1.69-1.90 (m, 6H), 3.77-3.91 (m, 1H), 4.35 (brs, 4H), 6.92 (brs, 1H), 7.13 (d, J=6.78 Hz, 1H), 7.73 (d, J=6.78 Hz, 1H), 7.76 (brs, 1H), 7.87 (s, 2H), 8.07 (brs, 1H), 8.27 (s, 1H), 8.62 (s, 1H), 14.20 (s, 1H), 14.36 (s, 1H); ESIMS found for C₂₆H₂₈N₈ m/z 453.2 (M+1).

N,N-Dimethyl-1-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine 169.

White solid (25.8 mg, 0.06 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.71 (brs, 6H), 2.25 (s, 6H), 3.57 (s, 2H), 4.20 (brs, 4H), 6.81 (d, J=5.52 Hz, 1H), 7.76-7.83 (m, 2H), 7.89 (dd, J=8.8 Hz, J=1.52 Hz, 1H), 8.05 (s, 1H), 8.14 (s, 2H), 8.50 (d, J=1.51 Hz, 1H), 8.78 (s, 1H), 8.89 (d, J=2.26 Hz, 1H), 13.21 (brs, 1H), 13.74 (brs, 1H); ESIMS found for C₂₆H₂₈N₈ m/z 453.3 (M+1).

N-(5-(3-(4-(Piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide 175.

White solid (30.4 mg, 0.06 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 0.88 (d, J=6.02 Hz, 4H), 1.67 (brs, 6H), 1.85 (q, J=6.28 Hz, 1H), 4.18 (brs, 4H), 6.80 (d, J=5.52 Hz, 1H), 7.76-7.84 (m, 2H), 8.17 (s, 1H), 8.58-8.66 (m, 3H), 8.75 (s, 1H), 10.58 (s, 1H), 13.74 (brs, 1H); ESIMS found for C₂₇H₂₆N₈O m/z 479.3 (M+1).

2-(5-(5-((3,3-Difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridine 181.

White solid (46.6 mg, 0.09 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.70 (brs, 6H), 2.21-2.37 (m, 3H), 2.76 (t, J=6.78 Hz, 2H), 2.94 (t, J=13.30 Hz, 2H), 3.76 (s, 2H), 4.20 (brs, 4H), 6.81 (d, J=5.52 Hz, 1H), 7.75-7.83 (m, 2H), 7.88 (dd, J=8.78, 1.76 Hz, 1H), 8.05 (t, J=2.01 Hz, 1H), 8.18 (s, 1H), 8.53 (d, J=1.76 Hz, 1H), 8.78 (s, 1H), 8.89 (d, J=2.26 Hz, 1H), 13.21 (brs, 1H), 13.75 (brs, 1H); ESIMS found for C₂₈H₂₈F₂N₈ m/z 515.3 (M+1).

3-Methyl-N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide 184.

White solid (10.2 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 0.97 (d, J=6.53 Hz, 6H), 2.07-2.19 (m, 1H), 2.33 (d, J=7.04 Hz, 2H), 2.44 (s, 3H), 7.73 (d, J=5.52 Hz, 1H), 7.82-7.97 (m, 2H), 8.35 (d, J=5.28 Hz, 1H), 8.68 (d, J=6.78 Hz, 2H), 8.83 (s, 1H), 8.87 (brs, 1H), 8.96 (brs, 1H), 10.19 (s, 1H), 10.78 (brs, 1H), 14.27 (brs, 1H), 14.32 (brs, 1H); ESIMS found for C₂₇H₂₅N₉O m/z 492.1 (M+1).

N-(5-(3-(4-(4-Methyl-1H-imidazol-1-yl)-1H-imidazo-[4,5-c]pyrimidin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide 190.

White solid (11.2 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.31 (s, 9H), 2.44 (s, 3H), 7.74 (d, J=5.27 Hz, 1H), 7.86-7.96 (m, 2H), 8.35 (d, J=5.27 Hz, 1H), 8.71 (s, 1H), 8.88 (s, 1H), 8.94-9.03 (m, 2H), 9.19 (s, 1H), 10.19-10.32 (m, 2H), 14.30 (brs, 1H), 14.38 (s, 1H); ESIMS found for C₂₇H₂₅N₉O m/z 492.2 (M+1).

N-(5-(3-(4-(4-Methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1 H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide 202.

White solid (10.2 mg, 0.02 mmol) ¹H NMR (DMSO-d₆ 400 MHz) δ ppm 1.73-1.91 (m, 1H), 1.92-2.08 (m, 1H), 2.09-2.36 (m, 5H), 2.44 (s, 3H) 7.74 (d, J=5.02 Hz, 1H), 7.82-8.01 (m, 2H) 8.36 (d, J=5.76 Hz, 1H), 8.73 (brs, 2H), 8.86 (s, 1H), 8.92 (d, J=1.0 Hz, 1H), 8.99 (s, 1H), 10.23 (s, 1H), 10.60 (brs, 1H), 14.29 (brs, 1H), ESIMS found for C₂₇H₂₃N₉O m/z 490.3 (M+1).

5-(3-(4-(4-Methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine 211.

White solid (7.7 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.84 (s, 3H), 3.49-3.68 (m, 4H), 5.25-5.55 (m, 2H), 5.86-6.21 (m, 2H), 7.04 (d, J=6.33 Hz, 1H), 7.56 (brs, 1H), 7.72-7.86 (m, 2H), 7.90 (d, J=5.77 Hz, 1H), 8.01 (d, J=2.51 Hz, 1H), 8.26 (s, 1H), 8.66 (s, 1H), 13.58 (brs, 1H) 13.96 (s, 1H); ESIMS found for C₂₃H₂₃N₉ m/z 426.1 (M+1).

4-(4-Methylpiperazin-1-yl)-2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine 212.

White solid (35.5 mg, 0.086 mmol, 87.8% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.26 (s, 3H), 2.51-2.55 (m, 4H), 4.19 (br s, 4H), 6.86 (d, J=5.49 Hz, 1H), 7.56 (dd, J=7.96, 4.67 Hz, 1H), 7.79 (d, J=8.51 Hz, 1H), 7.82 (d, J=5.49 Hz, 1H), 7.87 (dd, J=8.64, 1.78 Hz, 1H), 8.14 (dt, J=7.96, 1.92 Hz, 1H), 8.61 (dd, J=4.80, 1.51 Hz, 1H), 8.76 (d, J=0.10 Hz, 1H), 8.97 (d, J=1.92 Hz, 1H), 13.26 (s, 1H), 13.70 (s, 1H); ESIMS found for C₂₃H₂₂N₈ m/z 411.2 (M+1).

N-(5-(3-(4-(4-Methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide 217.

White solid (18.8 mg, 0.04 mmol). ¹H NMR (CD₃OD, 400 MHz) δ ppm 1.27 (d, J=6.78 Hz, 6H), 2.73 (spt, J=6.81 Hz, 1H), 2.84 (s, 3H), 3.32-3.37 (m, 4H), 4.30-4.59 (m, 4H), 7.07 (d, J=5.77 Hz, 1H), 7.70-7.79 (m, 2H), 7.86 (d, J=5.77 Hz, 1H), 8.33-8.51 (m, 1H), 8.55-8.64 (m, 2H), 8.66 (d, J=2.01 Hz, 1H), 8.68 (s, 1H); ESIMS found for C₂₇H₂₉N₉O m/z 496.2 (M+1).

4-(4-Methylpiperazin-1-yl)-2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine 223.

White solid (11.2 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.31-1.49 (m, 1H), 1.66-1.76 (m, 1H), 1.76-1.91 (m, 3H), 2.85 (s, 3H), 2.91-3.06 (m, 2H), 3.64-3.73 (m, 2H), 3.90-4.09 (m, 2H), 4.47 (brs, 2H), 5.34-5.54 (m, 2H), 5.51-5.54 (m, 1H), 7.26 (d, J=6.27 Hz, 1H), 7.81-7.93 (m, 2H), 7.99 (dd, J=8.78, 1.51 Hz, 1H), 8.63-8.76 (m, 2H), 8.77-8.86 (m, 1H), 9.12 (s, 1H), 11.20 (brs, 1H), 11.60 (brs, 1H), 14.25 (brs, 1H), 14.41 (brs, 1H); ESIMS found for C₂₉H₃₃N₉ m/z 508.2 (M+1).

3,3-Dimethyl-N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide 224.

White solid (30.4 mg, 0.06 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.07 (s, 9H), 2.41 (s, 2H), 2.89 (brs, 3H), 3.42-3.53 (m, 2H), 3.70-3.80 (m, 2H), 3.91-4.03 (m, 2H), 5.33-5.46 (m, 2H), 7.26 (d, J=6.53 Hz, 1H), 7.80-7.94 (m, 3H), 8.61 (s, 1H), 8.92 (brs, 1H), 8.96 (s, 1H), 9.14 (brs, 1H), 11.29 (brs, 1H), 11.49 (brs, 1H), 14.31 (s, 1H), 14.49 (s, 1H); ESIMS found for C₂₉H₃₃N₉O m/z 524.2 (M+1).

N-(5-(3-(4-(4-Methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide 229.

White solid (19.4 mg, 0.04 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.52-1.65 (m, 2H), 1.65-1.84 (m, 4H), 1.85-1.97 (m, 2H), 2.23 (s, 3H), 2.42-2.49 (m, 4H), 2.86 (quin, J=7.91 Hz, 2H), 4.20 (brs, 4H), 6.86 (d, J=5.77 Hz, 1H), 7.79-7.82 (m, 2H), 7.83 (s, 1H), 8.17 (s, 1H), 8.59 (t, J=2.01 Hz, 1H), 8.62 (d, J=1.76 Hz, 1H), 8.68 (d, J=2.01 Hz, 1H), 8.70 (s, 1H), 10.27 (s, 1H), 13.27 (brs, 1H), 13.79 (brs, 1H); ESIMS found for C₂₉H₃₁N₉O m/z 522.3 (M+1).

4-(4-Methylpiperazin-1-yl)-2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine 234.

White solid (23.5 mg, 0.06 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.85 (s, 3H), 3.61-3.70 (m, 4H), 3.88-4.03 (m, 2H), 5.30-5.45 (m, 2H), 7.28 (d, J=6.78 Hz, 1H), 7.83-7.87 (m, 1H), 7.89 (s, 1H), 7.92-7.98 (m, 1H), 8.63 (s, 1H), 9.22-9.28 (m, 3H), 14.24 (brs, 1H), 14.48 (brs, 1H); ESIMS found for C₂₂H₂₂N₉ m/z 412.1 (M+1).

2-(5-(4-Methylpyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine 239.

White solid (39.4 mg, 0.10 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.43 (s, 3H), 7.41-7.48 (m, 2H), 7.60 (d, J=8.78 Hz, 1H), 7.64 (dd, J=4.89, 3.14 Hz, 1H), 7.82 (d, J=8.78 Hz, 1H), 8.30 (d, J=4.77 Hz, 1H), 8.35 (d, J=5.52 Hz, 1H), 8.50 (d, J=5.02 Hz, 1H), 8.56 (s, 1H), 8.60 (s, 1H), 8.87 (d, J=1.76 Hz, 1H), 14.01 (brs, 1H); ESIMS found for C₂₃H₁₆N₆S m/z 409.0 (M+1).

N-(5-(3-(4-(Thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl) pyridin-3-yl)pivalamide 242.

White solid (22.8 mg, 0.05 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.32 (s, 9H), 7.91 (d, J=6.02 Hz, 1H), 7.93-8.01 (m, 3H), 8.49 (d, J=6.53 Hz, 1H), 8.52 (d, J=4.77 Hz, 1H), 8.85 (s, 1H), 8.90 (s, 1H), 8.94 (d, J=1.51 Hz, 1H), 9.11 (s, 1H), 9.35 (brs, 1H), 10.04 (brs, 1H), 14.43 (s, 1H), 14.85 (brs, 1H); ESIMS found for C₂₇H₂₃N₇OS m/z 494.2 (M+1).

2-Phenyl-N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide 244.

White solid (11.9 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 3.85 (s, 2H), 7.25-7.32 (m, 1H), 7.36 (t, J=7.40 Hz, 2H), 7.40-7.46 (m, 2H), 7.79 (dd, J=5.14, 2.89 Hz, 1H), 7.86 (d, J=6.27 Hz, 1H), 7.90 (s, 2H), 8.44 (d, J=6.53 Hz, 1H), 8.54 (d, J=5.02 Hz, 1H), 8.74 (s, 1H), 8.83 (s, 1H), 8.87 (brs, 2H), 9.28 (d, J=1.25 Hz, 1H), 11.15 (brs, 1H), 14.40 (s, 1H), 14.78 (brs, 1H); ESIMS found for C₃₀H₂₁N₇OS m/z 528.1 (M+1).

N-(5-(3-(4-(Thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide 245.

White solid (40.2 mg, 0.08 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 7.43-7.49 (m, 1H), 7.57-7.69 (m, 4H), 7.83-7.90 (m, 1H), 7.90-7.96 (m, 1H), 8.05-8.11 (m, 2H), 8.17 (s, 1H), 8.28-8.34 (m, 1H), 8.35-8.40 (m, 1H), 8.77-8.84 (m, 2H), 8.93-9.04 (m, 3H), 10.67 (d, J=3.01 Hz, 1H), 13.64 (brs, 1H), 14.00 (brs, 1H); ESIMS found for C₂₉H₁₉N₇OS m/z 514.2 (M+1).

N-(5-(3-(4-(Thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide 251.

White solid (14.9 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 0.97 (t, J=7.40 Hz, 3H), 1.69 (sxt, J=7.24 Hz, 2H), 2.42 (t, J=7.28 Hz, 3H), 7.45 (d, J=5.52 Hz, 1H), 7.68 (dd, J=4.89, 2.89 Hz, 1H), 7.86 (s, 2H), 8.26 (s, 1H), 8.32 (d, J=5.02 Hz, 1H), 8.37 (d, J=5.27 Hz, 1H), 8.66 (brs, 1H), 8.70 (d, J=1.76 Hz, 1H), 8.72 (d, J=2.01 Hz, 1H), 8.88 (s, 1H), 8.96 (d, J=2.76 Hz, 1H), 10.33 (s, 1H); ESIMS found for C₂₆H₂₁N₇OS m/z 480.2 (M+1).

N-(5-(3-(4-(Thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide 253.

White solid (9.0 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 0.92 (d, J=5.77 Hz, 4H), 1.87-1.99 (m, 1H), 7.84-8.01 (m, 4H), 8.44-8.53 (m, 2H), 8.77-8.88 (m, 4H), 9.26-9.36 (m, 1H), 11.03 (brs, 1H), 14.40 (s, 1H), 14.84 (brs, 1H); ESIMS found for C₂₆H₁₉N₇OS m/z 478.1 (M+1).

N-(5-(3-(4-(Thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide 255.

White solid (14.5 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.53-1.75 (m, 4H), 1.76-1.88 (m, 2H), 1.90-2.02 (m, 2H), 2.99 (quin, J=8.00 Hz, 1H), 7.91 (d, J=6.53 Hz, 1H), 7.95 (s, 2H), 7.99 (dd, J=4.64, 3.14 Hz, 1H), 8.47 (d, J=6.53 Hz, 1H), 8.59 (d, J=5.27 Hz, 1H), 8.84 (s, 1H), 9.01 (s, 1H), 9.04 (s, 1H), 9.12 (s, 1H), 9.39 (brs, 1H), 11.21 (s, 1H), 14.53 (brs, 1H), 14.89 (brs, 1H); ESIMS found for C₂₈H₂₃N₇OS m/z 506.1 (M+1).

N-Benzyl-1-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine 257.

White solid (33.5 mg, 0.07 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ 4.28 (s, 2H), 4.37 (s, 2H), 7.36-7.51 (m, 4H), 7.54-7.62 (m, 2H), 7.67 (dd, J=4.89, 2.89 Hz, 1H), 7.89 (d, J=8.8 Hz, 1H), 7.96 (dd, J=9.04 Hz, J=1.52 Hz, 1H), 8.33 (d, J=6.02 Hz, 1H), 8.37 (d, J=5.27 Hz, 1H), 8.51 (br. s., 1H), 8.75 (d, J=1.25 Hz, 1H), 8.96 (s, 1H), 9.04 (d, J=3.0 Hz, 1H), 9.09 (d, J=1.51 Hz, 1H), 13.69 (s, 1H), 14.10 (s, 1H); ESIMS found for C₃₀H₂₃N₇S m/z 514.2 (M+1).

N-((5-(3-(4-(Furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)ethanamine 266.

White solid (40.7 mg, 0.09 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1H NMR (400 MHz, DMSO) δ 1.30 (t, J=7.28 Hz, 3H), 3.05 (q, J=7.03 Hz, 2H), 4.31 (s, 2H), 7.42 (s, 1H), 7.45 (d, J=5.52 Hz, 1H), 7.83-7.92 (m, 2H), 7.96 (dd, J=8.76 Hz, J=1.48 Hz, 1H), 8.35 (d, J=5.52 Hz, 1H), 8.57 (s, 1H), 8.79 (d, J=1.26 Hz, 1H), 8.92 (s, 1H), 8.99 (s, 1H), 9.08 (d, J=2.01 Hz, 1H), 9.64 (brs, 2H), 13.65 (brs, 1H), 14.18 (s, 1H); ESIMS found for C₂₅H₂₁N₇O m/z 436.2 (M+1).

5-(3-(4-(Furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N-isopropylpyridin-3-amine 272.

White solid (23.2 mg, 0.05 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.22 (d, J=6.27 Hz, 5H), 3.74 (spt, J=7.03 Hz, 1H), 5.92 (d, J=7.78 Hz, 1H), 7.22 (t, J=2.26 Hz, 1H), 7.40 (d, J=1.51 Hz, 1H), 7.42 (d, J=5.27 Hz, 1H), 7.81 (d, J=1.00 Hz, 2H), 7.85 (t, J=1.63 Hz, 1H), 8.01 (d, J=2.51 Hz, 1H), 8.14 (d, J=1.76 Hz, 1H), 8.34 (d, J=5.52 Hz, 1H), 8.78 (s, 1H), 8.92 (d, J=1.00 Hz, 1H), 13.58 (s, 1H), 13.98 (s, 1H); ESIMS found for C₂₅H₂₂N₇O m/z 436.3 (M+1).

N-(5-(3-(4-(Furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide 278.

White solid (36.6 mg, 0.08 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 0.92 (t, J=7.40 Hz, 3H), 1.37 (sxt, J=7.52 Hz, 2H), 1.63 (quin, J=7.28, 2H), 2.42 (t, J=7.40 Hz, 2H), 7.53 (br. s., 2H), 7.82-7.93 (m, 3H), 8.37 (d, J=5.77 Hz, 1H), 8.62 (s, 1H), 8.70 (d, J=1.76 Hz, 1H), 8.73 (d, J=2.01 Hz, 1H), 8.82 (s, 1H), 8.97 (brs, 1H), 10.34 (s, 1H), 13.88 (brs, 1H), 14.10 (brs, 1H); ESIMS found for C₂₇H₂₃N₇O₂ m/z 478.2 (M+1).

N-(5-(3-(4-(Furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide 280.

White solid (11.8 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.80-1.91 (m, 1H), 1.94-2.09 (m, 1H), 2.13-2.24 (m, 2H), 2.25-2.37 (m, 2H), 3.40 (quin, J=8.56 Hz, 1H), 7.83 (d, J=6.27 Hz, 1H), 7.89 (s, 3H), 8.06 (s, 1H), 8.41 (d, J=6.52 Hz, 1H), 8.74 (s, 1H), 8.98 (s, 2H), 9.05 (brs, 1H), 9.28 (s, 1H), 10.93 (s, 1H), 14.46 (brs, 1H), 14.78 (brs, 1H); ESIMS found for C₂₇H₂₁N₇O₂ m/z 476.2 (M+1).

1-Cyclopentyl-N-((5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)methanamine 284.

White solid (14.9 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.17-1.38 (m, 2H), 1.43-1.70 (m, 4H), 1.72-1.89 (m, 2H), 2.30 (dd, J=15.43, 8.16 Hz, 1H), 2.92-3.07 (m, 2H), 4.39 (t, J=5.52 Hz, 2H), 7.82-7.94 (m, 2H), 7.94-8.08 (m, 2H), 8.12 (s, 1H), 8.47 (d, J=6.53 Hz, 1H), 8.85 (brs, 1H), 8.89 (brs, 2H), 9.24 (s, 1H), 9.43 (s, 1H), 9.46-9.60 (m, 2H), 14.49 (brs, 1H), 14.86 (brs, 1H); ESIMS found for C₂₉H₂₇N₇O m/z 490.2 (M+1).

N-(5-(3-(4-(Thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide 287.

White solid (6.0 mg, 0.01 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.15 (t, J=7.53 Hz, 3H), 2.46 (q, J=7.52 Hz, 2H), 7.29 (dd, J=5.02, 3.76 Hz, 1H), 7.44 (d, J=5.27 Hz, 1H), 7.69 (dd, J=5.04 Hz, J=1.00 Hz, 1H), 7.87 (s, 2H), 8.30 (d, J=5.52 Hz, 1H), 8.66-8.71 (m, 2H), 8.71-8.74 (m, 1H), 8.75 (d, J=2.76 Hz, 1H), 8.92 (s, 1H), 10.41 (s, 1H), 13.68 (brs, 1H), 14.07 (brs, 1H); ESIMS found for C₂₅H₁₉N₇OS m/z 466.2 (M+1).

N,N-Dimethyl-5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine 293.

White solid (11.4 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 3.11 (s, 6H), 7.22-7.27 (m, 1H), 7.45 (d, J=5.52 Hz, 1H), 7.54 (brs, 1H), 7.73 (d, J=5.02 Hz, 1H), 7.84 (d, J=8.56 Hz, 1H), 7.93 (dd, J=8.53 Hz, J=1.48 Hz, 1H), 8.13 (s, 1H), 8.21 (d, J=2.26 Hz, 1H), 8.31 (d, J=5.52 Hz, 1H), 8.38 (s, 1H), 8.73 (d, J=3.26 Hz, 1H), 8.95 (s, 1H), 13.68 (brs, 1H), 13.98 (s, 1H); ESIMS found for C₂₄H₁₉N₇S m/z 438.1 (M+1).

N-(5-(3-(4-(Thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide 295.

White solid (32.4 mg, 0.07 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.18 (d, J=6.78 Hz, 6H), 2.75 (spt, J=6.76 Hz, 1H), 7.39 (t, J=4.39 Hz, 1H), 7.65 (d, J=5.77 Hz, 1H), 7.89 (s, 2H), 7.95 (brs, 1H), 8.37 (d, J=6.02 Hz, 1H), 8.72-8.77 (m, 2H), 8.78-8.84 (m, 2H), 8.93 (s, 1H), 10.55 (s, 1H), 14.27 (brs, 2H); ESIMS found for C₂₆H₂₁N₇OS m/z 480.1 (M+1).

N,N-Dimethyl-1-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine 299.

White solid (32.9 mg, 0.07 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.35 (s, 6H), 3.75 (brs, 2H), 7.27 (dd, J=5.00 Hz, J=3.52 Hz, 1H), 7.44 (d, J=5.52 Hz, 1H), 7.73 (dd, J=5.02, 1.00 Hz, 1H), 7.83-7.90 (m, 1H), 7.93 (dd, J=8.52 Hz, J=1.28 Hz, 1H), 8.14 (s, 1H), 8.17 (s, 1H), 8.31 (d, J=5.52 Hz, 1H), 8.58 (d, J=1.51 Hz, 1H), 8.75 (dd, J=3.51, 1.00 Hz, 1H), 8.96 (s, 1H), 8.99 (d, J=2.01 Hz, 1H), 13.67 (s, 1H), 13.99 (s, 1H); ESIMS found for C₂₅H₂₁N₇S m/z 452.2 (M+1).

N-(5-(3-(4-(Thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide 305.

White solid (13.7 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 0.87-0.97 (m, 4H), 1.90-1.99 (m, 1H), 7.43-7.49 (m, 1H), 7.74-7.80 (m, 1H), 7.93 (d, J=1.00 Hz, 2H), 8.05-8.10 (m, 1H), 8.43 (d, J=6.27 Hz, 1H), 8.73 (d, J=4.02 Hz, 1H), 8.83 (s, 2H), 8.86 (brs, 1H), 8.96 (s, 1H), 11.06 (brs, 1H), 14.34 (s, 1H), 14.66 (brs, 1H); ESIMS found for C₂₆H₁₉N₇OS m/z 478.2 (M+1).

N-(5-(3-(4-(Thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide 307.

White solid (14.2 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.55-1.65 (m, 2H), 1.66-1.74 (m, 2H), 1.75-1.86 (m, 2H), 1.91-2.02 (m, 2H), 2.99 (spt, J=7.76 Hz, 1H), 7.44 (t, J=4.39 Hz, 1H), 7.77 (d, J=6.27 Hz, 1H), 7.90 (s, 2H), 8.19 (d, J=5.27 Hz, 1H), 8.40 (d, J=6.53 Hz, 1H), 8.78 (d, J=3.26 Hz, 1H), 8.87 (s, 1H), 8.90 (s, 1H), 8.98 (s, 1H), 9.05 (s, 1H), 11.11 (brs, 1H), 14.42 (s, 1H), 14.74 (brs, 1H); ESIMS found for C₂₈H₂₃N₇OS m/z 506.1 (M+1).

2-(5-(5-((3,3-Difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine 311.

White solid (60.5 mg, 0.12 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.20-2.31 (m, 2H), 2.79 (t, J=7.03 Hz, 2H), 2.98 (t, J=13.30 Hz, 2H), 3.82 (s, 2H), 7.28 (dd, J=5.02, 3.76 Hz, 1H), 7.44 (d, J=5.52 Hz, 1H), 7.73 (dd, J=5.02, 1.25 Hz, 1H), 7.86 (d, J=8.53 Hz, 1H), 7.92 (dd, J=8.76 Hz, J=1.48 Hz, 1H), 8.13 (t, J=2.01 Hz, 1H), 8.17 (s, 1H), 8.31 (d, J=5.52 Hz, 1H), 8.58 (d, J=1.76 Hz, 1H), 8.76 (d, J=2.76 Hz, 1H), 8.97 (d, J=1.76 Hz, 2H), 13.67 (brs, 1H), 13.98 (brs, 1H); ESIMS found for C₂₇H₂₁F₂N₇S m/z 514.2 (M+1).

N-(5-(3-(4-(5-Fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide 314.

White solid (2.7 mg, 0.005 mmol). ¹H NMR (CD₃OD, 400 MHz) δ ppm 1.06 (d, J=6.65 Hz, 6H), 2.24 (non, J=6.92 Hz, 1H), 2.43 (d, J=7.15 Hz, 2H), 6.96 (d, J=3.76 Hz, 1H), 7.80 (d, J=6.65 Hz, 1H), 7.84-7.94 (m, 2H), 8.16 (t, J=4.02 Hz, 1H), 8.32 (d, J=6.53 Hz, 1H), 8.90 (s, 1H), 8.95 (s, 1H), 9.09 (s, 1H), 9.26 (s, 1H); ESIMS found for C₂₇H₂₂FN₇OS m/z 512.1 (M+1).

N-(5-(3-(4-(5-Fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide 320.

White solid (17.1 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.26-1.30 (m, 9H), 7.12 (d, J=4.27 Hz, 1H), 7.84 (d, J=6.53 Hz, 1H), 7.92-8.00 (m, 2H), 8.38 (d, J=6.52 Hz, 1H), 8.66 (t, J=3.52 Hz, 1H), 8.88 (s, 1H), 9.05 (s, 1H), 9.41 (d, J=1.51 Hz, 1H), 9.45 (s, 1H), 10.76 (s, 1H), 14.69 (brs, 1H), 14.96 (brs, 1H); ESIMS found for C₂₇H₂₂FN₇OS m/z 512.1 (M+1).

4-(5-Fluorothiophen-2-yl)-2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine 326.

White solid (13.0 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.86-1.98 (m, 2H), 2.01-2.11 (m, 2H), 3.10-3.22 (m, 4H), 4.54 (d, J=5.02 Hz, 2H), 7.06 (d, J=2.64 Hz, 1H), 7.66 (d, J=5.77 Hz, 1H), 7.89-7.94 (m, 1H), 8.00 (dd, J=8.66, 1.63 Hz, 1H), 8.36 (d, J=6.15 Hz, 1H), 8.49-8.54 (m, 1H), 8.66 (br. s., 1H), 8.86 (d, J=1.38 Hz, 1H), 8.92 (s, 1H), 9.13 (d, J=2.13 Hz, 1H), 11.30 (brs, 1H), 14.30 (brs, 1H), 14.37 (brs, 1H); ESIMS found for C₂₇H₂₂FN₇S m/z 496.1 (M+1).

N-(5-(3-(4-(5-Fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide 332.

White solid (5.1 mg, 0.01 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.79-1.92 (m, 1H), 1.94-2.07 (m, 1H), 2.13-2.24 (m, 2H), 2.24-2.36 (m, 2H), 3.21-3.30 (m, 1H), 6.88-6.94 (m, 1H), 7.43 (d, J=5.52 Hz, 1H), 7.83-7.94 (m, 2H), 8.27 (d, J=5.40 Hz, 1H), 8.42 (t, J=4.02 Hz, 1H), 8.69 (s, 2H), 8.72 (brs, 1H), 8.87 (s, 1H), 10.18 (s, 1H), 13.70 (brs, 1H), 14.01 (brs, 1H); ESIMS found for C₂₇H₂₀FN₇OS m/z 510.1 (M+1).

5-(3-(4-(5-Methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine 341.

White solid (9.0 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.63 (s, 3H), 7.14 (d, J=2.51 Hz, 1H), 7.69 (d, J=6.27 Hz, 1H), 7.81-7.86 (m, 1H), 7.87-7.93 (m, 1H), 7.99 (brs, 1H), 8.10 (d, J=1.00 Hz, 1H), 8.32 (d, J=6.27 Hz, 1H), 8.41 (s, 1H), 8.59 (d, J=3.76 Hz, 1H), 8.85 (s, 1H), 14.41 (brs, 1H), 14.69 (brs, 1H); ESIMS found for C₂₃H₁₇N₇S m/z 424.1 (M+1).

N-(5-(3-(4-(5-Methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide 347.

White solid (27.0 mg, 0.05 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.18 (d, J=6.78 Hz, 6H), 2.53 (s, 3H), 2.64-2.81 (m, 2H), 6.98 (d, J=2.76 Hz, 1H), 7.39 (d, J=5.52 Hz, 1H), 7.85 (s, 2H), 8.26 (d, J=5.52 Hz, 1H), 8.52 (d, J=3.26 Hz, 1H), 8.64 (s, 1H), 8.71 (d, J=1.76 Hz, 1H), 8.79 (d, J=2.26 Hz, 1H), 8.95 (s, 1H), 10.38 (s, 1H); ESIMS found for C₂₇H₂₃N₇OS m/z 494.2 (M+1).

4-(5-Methylthiophen-2-yl)-2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine 353.

White solid (39.6 mg, 0.08 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.32-1.91 (m, 6H), 2.58 (s, 3H), 4.26-4.51 (m, 4H), 6.97 (d, J=2.63 Hz, 1H), 7.41 (d, J=5.52 Hz, 1H), 7.88-7.95 (m, 2H), 8.14 (s, 1H), 8.28 (d, J=5.52 Hz, 1H), 8.36 (brs, 1H), 8.50 (d, J=3.26 Hz, 1H), 8.73 (s, 1H), 9.03 (s, 1H), 9.15 (s, 1H), 13.65 (s, 1H), 14.03 (s, 1H); ESIMS found for C₂₉H₂₇N₇S m/z 506.3 (M+1).

3,3-Dimethyl-N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide 354.

White solid (44.0 mg, 0.08 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.05 (s, 9H), 2.32 (s, 2H), 2.60 (s, 3H), 7.16 (d, J=3.76 Hz, 1H), 7.75 (d, J=6.27 Hz, 1H), 7.87 (dd, J=8.76 Hz, J=1.52 Hz, 1H), 7.93 (d, J=8.68 Hz, 1H), 8.37 (d, J=6.40 Hz, 1H), 8.55 (d, J=1.13 Hz, 1H), 8.71 (brs, 1H), 8.87 (s, 1H), 8.98 (s, 1H), 9.00 (brs, 1H), 10.71 (brs, 1H), 14.36 (s, 1H), 14.76 (brs, 1H); ESIMS found for C₂₉H₂₇N₇OS m/z 522.2 (M+1).

N-(5-(3-(4-(5-Methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide 358.

White solid (14.9 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.78-1.89 (m, 1H), 1.95-2.05 (m, 1H), 2.12-2.22 (m, 2H), 2.22-2.30 (m, 2H), 2.59 (s, 3H), 3.35 (spt, J=8.28 Hz, 1H), 7.17 (d, J=3.26 Hz, 1H), 7.75 (d, J=6.53 Hz, 1H), 7.89 (dd, J=9.00 Hz, J=1.52 Hz, 1H), 7.93 (d, J=8.52 Hz, 1H), 8.38 (d, J=6.27 Hz, 1H), 8.57 (d, J=4.02 Hz, 1H), 8.73 (s, 1H), 8.85 (s, 1H), 9.00 (brs, 2H), 10.57 (brs, 1H), 14.35 (s, 1H), 14.75 (brs, 1H); ESIMS found for C₂₈H₂₃N₇OS m/z 506.1 (M+1).

N-(5-(3-(4-(5-Methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide 359.

White solid (9.0 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.53-1.66 (m, 2H), 1.66-1.76 (m, 2H), 1.76-1.86 (m, 2H), 1.88-1.99 (m, 2H), 2.53 (s, 3H), 2.83-2.94 (m, 1H), 6.95-7.00 (m, 1H), 7.39 (d, J=5.52 Hz, 1H), 7.83-7.89 (m, 2H), 8.23-8.31 (m, 2H), 8.50-8.55 (m, 1H), 8.62-8.68 (m, 1H), 8.69-8.73 (m, 1H), 8.74-8.78 (m, 1H), 8.93-8.99 (m, 1H), 10.29-10.35 (m, 1H), 13.64 (brs, 1H), 14.01 (brs, 1H); ESIMS found for C₂₉H₂₅N₇OS m/z 520.3 (M+1).

1-(5-(2-(5-(Pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one 368.

White solid (41.1 mg, 0.09 mmol). ¹H NMR (DMSO-d₆, 300 MHz) δ ppm 2.63 (s, 3H), 7.57 (d, J=5.65 Hz, 1H), 7.79-7.93 (m, 2H), 7.99 (dd, J=8.67 Hz, J=1.11 Hz, 1H), 8.06 (d, J=3.77 Hz, 1H), 8.40 (d, J=5.27 Hz, 1H), 8.52 (d, J=7.91 Hz, 1H), 8.64 (d, J=3.77 Hz, 1H), 8.70-8.87 (m, 1H), 8.99 (s, 1H), 9.17 (brs, 1H), 13.92 (brs, 1H), 14.11 (s, 1H); ESIMS found for C₂₄H₁₆N₆OS m/z 437.2 (M+1).

N-(5-(3-(4-(5-Acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide 374.

White solid (11.1 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.52 (s, 3H), 3.79 (s, 2H), 7.18-7.46 (m, 5H), 7.63 (d, J=5.52 Hz, 1H), 7.85-7.95 (m, 2H), 8.08 (d, J=4.02 Hz, 1H), 8.37-8.46 (m, 1H), 8.73 (d, J=2.01 Hz, 1H), 8.75 (d, J=4.02 Hz, 1H), 8.86 (d, J=2.01 Hz, 1H), 8.92 (s, 1H), 8.94 (d, J=2.01 Hz, 1H), 10.85-10.95 (m, 1H), 14.06 (brs, 1H), 14.19 (brs, 1H); ESIMS found for C₃₂H₂₃N₇O₂S m/z 570.1 (M+1).

N-(5-(3-(4-(5-Acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide 380.

White solid (16.6 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.05 (s, 9H), 2.32 (s, 2H), 2.58 (s, 3H), 7.55 (d, J=5.27 Hz, 1H), 7.87 (s, 2H), 8.03 (d, J=3.51 Hz, 1H), 8.37 (d, J=5.27 Hz, 1H), 8.64 (brs, 1H), 8.70 (brs, 1H), 8.74-8.82 (m, 2H), 8.84 (s, 1H), 10.35 (s, 1H), 13.82 (brs, 1H), 14.15 (brs, 1H); ESIMS found for C₃₀H₂₇N₇O₂S m/z 550.2 (M+1).

N-(5-(3-(4-(5-Acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide 386.

White solid (27.4 mg, 0.05 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.15-1.38 (m, 3H), 1.40-1.56 (m, 2H), 1.67 (dd, J=11.67, 2.64 Hz, 1H), 1.72-1.83 (m, 2H), 1.90 (d, J=12.30 Hz, 2H), 2.43 (tt, J=11.89, 3.92 Hz, 1H), 2.57 (s, 3H), 7.54 (d, J=5.52 Hz, 1H), 7.87 (d, J=1.00 Hz, 2H), 8.02 (d, J=4.02 Hz, 1H), 8.38 (d, J=5.28 Hz, 1H), 8.65 (d, J=2.01 Hz, 1H), 8.68 (d, J=2.01 Hz, 1H), 8.73 (d, J=2.26 Hz, 1H), 8.79 (d, J=3.76 Hz, 1H), 8.84 (s, 1H), 10.23 (s, 1H), 13.78 (brs, 1H), 14.06 (brs, 1H); ESIMS found for C₃₁H₂₇N₇O₂S m/z 562.2 (M+1).

N-(3-Fluoro-5-(2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide 395.

White solid (12.6 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ 2.39 (s, 3H), 2.91 (s, 3H), 4.22 (d, J=6.27 Hz, 2H), 7.24 (d, J=9.54 Hz, 1H), 7.42 (d, J=5.02 Hz, 1H), 7.55 (d, J=5.52 Hz, 1H), 7.57-7.63 (m, 1H), 7.72 (t, J=6.40 Hz, 1H), 7.78-7.87 (m, 1H), 8.18 (s, 1H), 8.45 (d, J=5.52 Hz, 1H), 8.49 (d, J=5.02 Hz, 1H), 8.53-8.59 (m, 2H), 8.61 (s, 1H), 8.85 (d, J=9.29 Hz, 1H), 13.74 (brs, 1H), 14.02 (brs, 1H); ESIMS found for C₂₇H₂₂FN₇O₂S m/z 528.2 (M+1).

N-(5-(3-(4-(3-Fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide 400.

White solid (13.7 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.90 (s, 3H), 3.80 (brs, 2H), 4.32 (d, J=6.02 Hz, 2H), 7.25-7.31 (m, 1H), 7.32-7.42 (m, 4H), 7.45-7.52 (m, 1H), 7.80 (t, J=6.27 Hz, 1H), 7.85-7.90 (m, 1H), 7.95 (d, J=8.53 Hz, 2H), 8.48 (d, J=2.51 Hz, 1H), 8.51-8.57 (m, 1H), 8.60 (d, J=6.52 Hz, 1H), 8.63-8.71 (m, 1H), 8.81 (s, 1H), 8.84-8.89 (m, 1H), 8.95-9.02 (m, 1H), 11.04 (brs, 1H), 14.41 (s, 1H), 14.78 (brs, 1H); ESIMS found for C₃₄H₂₇FN₈O₃S m/z 647.2 (M+1).

N-(5-(3-(4-(3-Fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide 401.

White solid (10.0 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.90 (s, 3H), 4.28 (d, J=6.02 Hz, 2H), 7.06-7.15 (m, 1H), 7.56-7.69 (m, 3H), 7.74 (t, J=6.53 Hz, 1H), 7.91 (s, 2H), 8.03 (d, J=7.28 Hz, 2H), 8.28 (d, J=1.00 Hz, 1H), 8.48 (d, J=5.27 Hz, 1H), 8.63 (d, J=13.05 Hz, 2H), 8.81 (d, J=1.25 Hz, 1H), 8.89-9.04 (m, 2H), 9.07 (d, J=2.01 Hz, 1H), 10.61 (s, 1H), 13.78 (brs, 1H), 14.08 (brs, 1H); ESIMS found for C₃₃H₂₅FN₅O₃S m/z 633.2 (M+1).

N-(5-(3-(4-(3-Fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide 407.

White solid (10.9 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 0.95 (t, J=7.28 Hz, 3H), 1.65 (dq, J=14.62, 7.17 Hz, 2H), 2.37 (t, J=7.40 Hz, 2H), 2.88 (s, 3H), 4.29 (d, J=6.00 Hz, 2H), 7.26 (d, J=9.79 Hz, 1H), 7.57 (d, J=5.52 Hz, 1H), 7.75 (t, J=6.28 Hz, 1H), 7.82 (dd, J=8.28 Hz, J=1.52 Hz, 1H), 7.88 (d, J=9.04 Hz, 1H), 8.32 (brs, 1H), 8.44-8.50 (m, 2H), 8.63 (brs, 1H), 8.71 (d, J=2.01 Hz, 1H), 8.79 (d, J=2.26 Hz, 1H), 8.87-8.91 (m, 1H), 8.92-9.01 (m, 1H), 10.25 (s, 1H), 13.77 (brs, 1H), 14.08 (brs, 1H); ESIMS found for C₃₀H₂₇FN₈O₃S m/z 599.3 (M+1).

N-(3-(2-(5-(5-((Benzylamino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide 413.

White solid (38.1 mg, 0.06 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.91 (s, 3H), 3.77-4.08 (m, 4H), 4.23-4.38 (m, 2H), 7.18-7.38 (m, 4H), 7.38-7.50 (m, 2H), 7.57 (d, J=5.27 Hz, 1H), 7.74-7.84 (m, 1H), 7.84-8.01 (m, 2H), 8.16-8.32 (m, 1H), 8.47 (d, J=5.52 Hz, 1H), 8.57-8.70 (m, 2H), 8.91 (s, 1H), 8.94-9.09 (m, 2H), 13.78 (brs, 1H), 14.13 (brs, 1H); ESIMS found for C₃₄H₂₉FN₈O₂S m/z 633.3 (M+1).

N-(3-Fluoro-5-(2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide 416.

White solid (6.6 mg, 0.01 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.98 (s, 2H), 4.37 (d, J=5.52 Hz, 2H), 7.56 (d, J=8.53 Hz, 1H), 7.86 (d, J=8.53 Hz, 2H), 7.90-8.00 (m, 2H), 8.44 (s, 1H), 8.50 (d, J=9.54 Hz, 1H), 8.55 (d, J=6.27 Hz, 1H), 8.73 (s, 1H), 9.2 s (d, J=4.04 Hz, 2H), 14.46 (brs, 1H), 14.93 (brs, 1H); ESIMS found for C₂₅H₁₉FN₅O₂S m/z 515.2 (M+1).

N¹-(3-(2-(5-(5-((Ethylamino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine 422.

White solid (21.0 mg, 0.04 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.29 (t, J=7.15 Hz, 3H), 2.76-2.95 (m, 6H), 2.96-3.12 (m, 2H), 3.29-3.44 (m, 2H), 3.55-3.76 (m, 2H), 3.91-4.08 (m, 2H), 6.83 (d, J=11.8 Hz, 1H), 7.74 (s, 1H), 7.83-8.11 (m, 4H), 8.55 (d, J=6.52 Hz, 1H), 8.71-8.93 (m, 2H), 8.98 (s, 2H), 9.13-9.34 (m, 2H), 9.85-10.10 (m, 2H), 10.67 (brs, 1H), 14.60 (brs, 1H), 14.99 (brs, 1H); ESIMS found for C₃₁H₃₂FN₉ m/z 550.2 (M+1).

N¹-(3-Fluoro-5-(2-(5-(5-(isopropylamino)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N²,N²-dimethylethane-1,2-diamine 428.

White solid (36.8 mg, 0.07 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.19 (d, J=6.28 Hz, 6H), 2.81 (s, 6H), 3.21-3.32 (m, 2H), 3.50-3.60 (m, 2H), 3.72-3.86 (m, 1H), 6.41-6.58 (m, 2H), 6.64 (dd, J=10.54, 2.51 Hz, 1H), 7.51 (d, J=2.26 Hz, 1H), 7.65 (d, J=3.76 Hz, 1H), 7.75-7.96 (m, 3H), 8.06 (d, J=2.26 Hz, 1H), 8.09-8.22 (m, 1H), 8.30 (s, 1H), 8.46 (d, J=5.52 Hz, 1H), 8.80 (s, 1H), 10.48 (brs, 1H), 14.01 (brs, 1H) 14.23 (brs, 1H); ESIMS found for C₃₁H₃₂FN₉ m/z 550.3 (M+1).

N-(5-(3-(4-(3-((2-(Dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide 434.

White solid (13.0 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 0.92 (t, J=6.80 Hz, 3H), 1.30-1.43 (m, 2H), 1.56-1.69 (m, 2H), 2.12 (s, 6H), 2.27-2.43 (m, 4H), 3.06-3.18 (m, 2H), 5.77-5.87 (m, 1H), 6.44-6.54 (m, 1H), 7.48-7.55 (m, 1H), 7.76-7.91 (m, 2H), 7.94-8.02 (m, 1H), 8.05-8.13 (m, 1H), 8.17-8.24 (m, 1H), 8.37-8.47 (m, 2H), 8.64-8.71 (m, 1H), 8.79-8.89 (m, 2H), 10.20-10.28 (m, 1H); ESIMS found for C₃₃H₃₄FN₉O m/z 592.3 (M+1).

N¹-(3-(2-(5-(5-(((Cyclopentylmethyl)amino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine 440.

White solid (14.5 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 1.17-1.36 (m, 2H), 1.41-1.65 (m, 4H), 1.71-1.91 (m, 2H), 2.18-2.37 (m, 2H), 2.79-3.01 (m, 6H), 3.32-3.45 (m, 3H), 3.59-3.77 (m, 2H), 4.24-4.40 (m, 2H), 6.70-6.97 (m, 2H), 7.77 (d, J=1.76 Hz, 1H), 7.88-8.07 (m, 3H), 8.51-8.72 (m, 2H), 8.76-8.93 (m, 2H), 9.14 (s, 1H), 9.53 (brs, 2H), 10.56 (brs, 1H), 14.47 (brs, 1H), 14.89 (brs, 1H); ESIMS found for C₃₅H₃₈FN₉ m/z 604.3 (M+1).

4-(3-Fluorophenyl)-2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine 1769.

Brown solid (7.0 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.68 (qd, J=12.35, 4.12 Hz, 2H), 1.94 (br d, J=12.35 Hz, 2H), 2.66-2.75 (m, 2H), 2.81 (br t, J=12.08 Hz, 1H), 3.13 (br d, J=12.35 Hz, 2H), 7.33 (td, J=8.23, 2.20 Hz, 1H), 7.42 (dd, J=8.51, 1.37 Hz, 1H), 7.52 (d, J=5.21 Hz, 1H), 7.59-7.66 (m, 2H), 8.42 (d, J=5.21 Hz, 1H), 8.53 (s, 1H), 8.81 (d, J=7.96 Hz, 1H), 8.96 (br d, J=11.25 Hz, 1H), 13.68 (s, 1H); ESIMS found for C₂₄H₂₁FN₆ m/z 413.2 (M+1).

4-(3-Fluorophenyl)-2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine 1770.

White solid (11.0 mg, 0.03 mmol). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.60 (br s, 2H), 3.05 (t, J=5.63 Hz, 2H), 3.47 (br d, J=2.74 Hz, 2H), 6.40 (br s, 1H), 7.34 (td, J=8.37, 2.20 Hz, 1H), 7.53 (d, J=5.21 Hz, 1H), 7.60 (td, J=7.96, 6.31 Hz, 1H), 7.63-7.67 (m, 1H), 7.72 (dd, J=9.06, 1.65 Hz, 1H), 8.44 (d, J=5.49 Hz, 1H), 8.71 (s, 1H), 8.75 (d, J=7.68 Hz, 1H), 8.99 (br d, J=10.43 Hz, 1H); ESIMS found for C₂₄H₁₉FN₆ m/z 411.2 (M+1).

2-(5-(1H-Pyrazol-4-yl)-1H-indazol-3-yl)-4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridine 1771.

Pink solid (7.7 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 7.37 (br t, J=7.41 Hz, 1H), 7.54 (br d, J=4.94 Hz, 1H), 7.61-7.68 (m, 1H), 7.70 (br d, J=8.23 Hz, 1H), 7.81 (br d, J=9.06 Hz, 1H), 8.02 (br s, 1H), 8.22 (br s, 1H), 8.45 (d, J=5.21 Hz, 1H), 8.74 (br d, J=7.96 Hz, 1H), 8.79 (s, 1H), 9.08 (br d, J=11.53 Hz, 1H), 13.06 (br s, 1H), 13.62 (br s, 1H), 13.80 (br s, 1H); ESIMS found for C₂₂H₁₄FN₇ m/z 396.2 (M+1).

4-(3-Fluorophenyl)-2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine 1772.

Yellow solid (7.3 mg, 0.02 mmol). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 3.94 (s, 3H), 7.38 (td, J=8.37, 2.47 Hz, 1H), 7.54 (d, J=5.21 Hz, 1H), 7.62-7.68 (m, 1H), 7.68-7.73 (m, 1H), 7.73-7.78 (m, 1H), 7.94 (s, 1H), 8.17 (s, 1H), 8.45 (d, J=5.21 Hz, 1H), 8.72 (br d, J=7.96 Hz, 1H), 8.78 (s, 1H), 9.08 (br d, J=11.53 Hz, 1H), 13.66 (br s, 1H), 13.79 (br s, 1H); ESIMS found for C₂₃H₁₆FN₇ m/z 410.2 (M+1).

2-(5-(1,2-Dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridine 1773.

Yellow solid (4.5 mg, 0.01 mmol). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.43 (s, 3H), 3.68 (s, 3H), 7.01 (s, 1H), 7.33 (td, J=8.23, 2.20 Hz, 1H), 7.54 (d, J=5.21 Hz, 1H), 7.57-7.64 (m, 2H), 7.79 (d, J=8.78 Hz, 1H), 8.45 (d, J=5.21 Hz, 1H), 8.63 (s, 1H), 8.72 (d, J=7.68 Hz, 1H), 8.84 (br d, J=10.43 Hz, 1H), 13.67 (br s, 1H), 13.94 (s, 1H); ESIMS found for C₂₄H₁₈FN₇ m/z 424 (M+1).

1-(6-(3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyrazin-2-yl)azetidin-3-amine 1774.

Yellow solid (3.7 mg, 0.008 mmol). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 3.44-3.52 (m, 1H), 3.44-3.52 (m, 1H), 3.58 (dt, J=13.65, 5.52 Hz, 1H), 4.01-4.11 (m, 2H), 4.31-4.39 (m, 1H), 7.31-7.39 (m, 2H), 7.56 (d, J=5.21 Hz, 1H), 7.62 (td, J=7.96, 6.31 Hz, 1H), 7.78 (s, 1H), 7.81 (d, J=8.78 Hz, 1H), 7.98 (s, 1H), 8.28 (dd, J=8.78, 1.65 Hz, 1H), 8.42-8.49 (m, 2H), 8.81 (d, J=7.96 Hz, 1H), 8.88-8.94 (m, 1H), 9.22 (s, 1H), 13.70 (br s, 1H), 13.96 (s, 1H); ESIMS found for C₂₆H₂₀FN₉ m/z 520.2 (M+MeCN).

2-(5-(5-(Cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridine 1775.

Yellow solid (20 mg, 0.038 mmol, 31.7% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.25-1.35 (m, 1H), 1.35-1.46 (m, 2H), 1.47-1.59 (m, 3H), 168-1.78 (m, 2H), 1.95-2.05 (m, 2H), 4.57-4.66 (m, 1H), 7.30 (td, J=8.30, 2.06 Hz, 1H), 7.55 (d, J=5.21 Hz, 1H), 7.61 (td, J=8.10, 6.31 Hz, 1H), 7.73 (t, J=2.33 Hz, 1H), 7.83 (d, J=8.78 Hz, 1H), 7.91 (dd, J=8.64, 1.78 Hz, 1H), 8.34 (d, J=2.74 Hz, 1H), 8.44 (d, J=5.49 Hz, 1H), 8.62 (d, J=1.92 Hz, 1H), 8.81-8.89 (m, 2H), 8.95 (d, J=0.82 Hz, 1H); ESIMS found for C₃₀H₂₅FN₆O m/z 505.2 (M+1).

4-(3-Fluorophenyl)-2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine 1776.

Yellow solid (12 mg, 0.021 mmol, 60.4% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.86-1.99 (m, 2H), 2.13-2.23 (m, 2H), 3.06-3.17 (m, 2H), 3.27-3.33 (m, 2H), 4.93 (dt, J=7.34, 3.88 Hz, 1H), 7.36 (td, J=8.23, 2.47 Hz, 1H), 7.57 (d, J=5.21 Hz, 1H), 7.59-7.66 (m, 1H), 7.82-7.88 (m, 2H), 7.93 (dd, J=8.78, 1.65 Hz, 1H), 8.44 (d, J=2.47 Hz, 1H), 8.47 (d, J=5.49 Hz, 1H), 8.52 (br s, 2H), 8.69 (d, J=1.37 Hz, 1H), 8.83 (br d, J=7.96 Hz, 1H), 8.87 (br d, J=10.98 Hz, 1H), 8.95 (s, 1H), 13.77 (br s, 1H), 14.02 (s, 1H); ESIMS found for C₂₉H₂₄FN₇O m/z 507.2 (M+1).

N-(5-(3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide 1777.

Yellow solid (5.5 mg, 0.01 mmol). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.00-1.11 (m, 1H) 1.13-1.22 (m, 1H) 1.68-1.80 (m, 2H) 2.01-2.10 (m, 1H) 2.35 (dd, J=7.00, 2.33 Hz, 2H) 2.52-2.58 (m, 1H) 2.97-3.06 (m, 1H) 3.78 (br d, J=14.27 Hz, 1H) 4.35 (br d, J=12.90 Hz, 1H) 7.08-7.15 (m, 1H) 7.39 (d, J=5.21 Hz, 1H) 7.46-7.53 (m, 1H) 7.64 (br d, J=8.51 Hz, 1H) 7.68-7.74 (m, 1H) 8.06 (br d, J=4.67 Hz, 1H) 8.42 (br d, J=2.20 Hz, 1H) 8.69 (d, J=1.92 Hz, 1H) 8.80 (d, J=2.20 Hz, 1H) 8.98 (br d, J=7.68 Hz, 1H) 9.06 (br d, J=11.25 Hz, 1H) 9.10 (br s, 1H) 10.29 (s, 1H); ESIMS found for C₃₁H₂₇FN₈O m/z 547.2 (M+1).

4-(3-Fluorophenyl)-2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine 1778.

Brown solid (18 mg, 0.033 mmol, 52.2% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.68 (dt, J=6.72, 3.22 Hz, 4H), 2.55 (br s, 4H), 2.87 (t, J=5.76 Hz, 2H), 4.28 (t, J=5.76 Hz, 2H), 7.31 (td, J=8.23, 2.47 Hz, 1H), 7.55 (d, J=5.49 Hz, 1H), 7.60 (td, J=7.96, 6.31 Hz, 1H), 7.76 (t, J=2.33 Hz, 1H), 7.84 (d, J=8.51 Hz, 1H), 7.94 (dd, J=8.78, 1.65 Hz, 1H), 8.36 (d, J=2.74 Hz, 1H), 8.46 (d, J=5.49 Hz, 1H), 8.65 (d, J=1.65 Hz, 1H), 8.79-8.88 (m, 2H), 8.95 (s, 1H), 13.71 (br s, 1H), 13.97 (br s, 1H); ESIMS found for C₃₀H₂₆FN₇O m/z 520.2 (M+1).

2-((5-(3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine 1779.

Yellow solid (4.3 mg, 0.009 mmol). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.21-2.27 (m, 1H) 2.25 (s, 5H) 2.70 (t, J=5.76 Hz, 2H) 4.26 (t, J=5.76 Hz, 2H) 7.28-7.35 (m, 1H) 7.55 (d, J=5.49 Hz, 1H) 7.58-7.65 (m, 1H) 7.73-7.77 (m, 1H) 7.83 (d, J=8.78 Hz, 1H) 7.93 (dd, J=8.78, 1.65 Hz, 1H) 8.36 (d, J=2.47 Hz, 1H) 8.45 (d, J=5.21 Hz, 1H) 8.64 (d, J=1.92 Hz, 1H) 8.80-8.88 (m, 2H) 8.95 (s, 1H) 13.83 (br s, 1H); ESIMS found for C₂₈H₂₄FN₇O m/z 494.3 (M+1).

4-(3-Fluorophenyl)-2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine 1780.

Brown solid (25.6 mg, 0.06 mmol). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 3.96 (s, 3H) 7.38 (td, J=8.23, 2.20 Hz, 1H) 7.59-7.66 (m, 2H) 7.73-7.77 (m, 1H) 7.85 (d, J=8.78 Hz, 1H) 7.93 (dd, J=8.78, 1.65 Hz, 1H) 8.37 (d, J=2.74 Hz, 1H) 8.48 (d, J=5.49 Hz, 1H) 8.65 (d, J=1.65 Hz, 1H) 8.74 (br d, J=7.68 Hz, 1H) 8.81 (br d, J=10.98 Hz, 1H) 8.92 (s, 1H) 13.89 (br s, 1H) 14.03 (s, 1H); ESIMS found for C₂₅H₁₇FN₆O m/z 437.1 (M+1).

5-(3-(4-(3-Fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol 1781.

Yellow solid (1.3 mg, 0.003 mmol). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 7.31 (br d, J=5.76 Hz, 1H) 7.50-7.56 (m, 2H) 7.61 (br d, J=6.59 Hz, 1H) 7.82 (br s, 2H) 8.20 (br s, 1H) 8.43 (br s, 1H) 8.51 (s, 1H) 8.78-8.90 (m, 2H) 8.93 (br s, 1H) 13.74 (brs, 1H); ESIMS found for C₂₄H₁₅FN₆O m/z 423.1 (M+1).

2-(5-(5-(Benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridine 1782.

White solid (42 mg, 0.078 mmol, 39.7% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 5.32 (s, 2H), 7.19 (td, J=7.82, 1.92 Hz, 1H), 7.35-7.40 (m, 1H), 7.42-7.48 (m, 2H), 7.52-7.56 (m, 3H), 7.56-7.63 (m, 1H), 7.82-7.88 (m, 2H), 7.94 (dd, J=8.78, 1.65 Hz, 1H), 8.44 (d, J=2.74 Hz, 1H), 8.46 (d, J=5.21 Hz, 1H), 8.68 (d, J=1.65 Hz, 1H), 8.83 (br s, 1H), 8.84 (br s, 1H), 8.97 (s, 1H), 13.74 (br s, 1H), 13.96 (br s, 1H); ESIMS found for C₃₁H₂₁FN₆O m/z 513.2 (M+1).

2-Cyclohexyl-N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide 1783.

White solid (21 mg, 0.037 mmol, 46.1% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 0.95-1.06 (m, 2H), 1.09-1.30 (m, 3H), 1.62 (br d, J=11.80 Hz, 1H), 1.64-1.71 (m, 2H), 1.74 (br d, J=13.17 Hz, 2H), 1.81 (dtd, J=14.51, 7.22, 7.22, 3.70 Hz, 1H), 2.29 (d, J=7.14 Hz, 2H), 7.23-7.31 (m, 1H), 7.55 (d, J=5.21 Hz, 1H), 7.57-7.65 (m, 1H), 7.81-7.90 (m, 2H), 8.46 (d, J=5.21 Hz, 1H), 8.54 (s, 1H), 8.70 (d, J=1.92 Hz, 1H), 8.76 (d, J=2.20 Hz, 1H), 8.83 (br s, 1H), 8.85 (br s, 1H), 8.90 (s, 1H), 10.24 (s, 1H), 13.73 (br s, 1H), 13.99 (br s, 1H); ESIMS found for C₃₂H₂₈FN₇O m/z 546.3 (M+1).

4-(3-Fluorophenyl)-2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine 1784.

White solid (60.0 mg, 0.14 mmol). ¹H NMR (DMSO-d₆, 500 MHz) δ 7.37 (td, J=8.30, 2.61 Hz, 1H) 7.56 (d, J=5.49 Hz, 1H) 7.61-7.68 (m, 1H) 7.84-7.90 (m, 3H) 8.00 (dd, J=8.78, 1.65 Hz, 1H) 8.47 (d, J=5.49 Hz, 1H) 8.70-8.76 (m, 3H) 9.01 (br d, J=11.25 Hz, 1H) 9.11 (s, 1H) 13.75 (s, 1H) 14.01 (s, 1H); ESIMS found for C₂₄H₁₅FN₆ m/z 407.1 (M+1).

4-(3-Fluorophenyl)-2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine 1785.

Light yellow solid (22 mg, 0.051 mmol, 71.0% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 7.37 (td, J=8.37, 2.47 Hz, 1H), 7.41 (dd, J=7.41, 4.94 Hz, 1H), 7.56 (d, J=5.21 Hz, 1H), 7.65 (td, J=7.96, 6.31 Hz, 1H), 7.81 (d, J=8.78 Hz, 1H), 7.96 (td, J=7.68, 1.65 Hz, 1H), 8.11 (d, J=7.96 Hz, 1H), 8.32 (dd, J=8.78, 1.65 Hz, 1H), 8.47 (d, J=5.21 Hz, 1H), 8.76 (d, J=4.67 Hz, 1H), 8.81 (br d, J=7.68 Hz, 1H), 9.01 (br d, J=10.98 Hz, 1H), 9.43 (s, 1H), 13.74 (brs, 1H), 13.95 (brs, 1H); ESIMS found for C₂₄H₁₅FN₆ m/z 407.1 (M+1).

4-(3-Fluorophenyl)-2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine 1786.

Pink solid (45 mg, 0.105 mmol, 48.7% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 7.33-7.40 (m, 1H), 7.56 (d, J=5.21 Hz, 1H), 7.64 (td, J=8.03, 6.17 Hz, 1H), 7.86 (d, J=8.78 Hz, 1H), 8.33 (dd, J=8.78, 1.65 Hz, 1H), 8.47 (d, J=5.49 Hz, 1H), 8.66 (d, J=2.47 Hz, 1H), 8.80 (dd, J=2.33, 1.51 Hz, 1H), 8.83 (d, J=7.96 Hz, 1H), 8.95 (br d, J=10.70 Hz, 1H), 9.38 (d, J=1.65 Hz, 1H), 9.49 (s, 1H), 13.75 (brs, 1H), 14.01 (brs, 1H); ESIMS found for C₂₃H₁₄FN₇ m/z 408.1 (M+1).

2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(piperidin-1-yl)-1H-imidazo [4,5-c]pyridine 1879.

Light yellow solid (63.9 mg, 0.166 mmol, 43.2% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.73 (br s, 6H), 4.22 (br s, 4H), 6.80 (d, J=5.49 Hz, 1H), 7.64 (d, J=8.51 Hz, 1H), 7.74 (dd, J=8.64, 1.51 Hz, 1H), 7.80 (d, J=5.49 Hz, 1H), 7.88 (br s, 1H), 8.15 (br s, 1H), 8.60 (s, 1H), 12.99 (br s, 2H), 13.54 (br s, 1H); ESIMS found for C₂₁H₂₀N₈ m/z 385.2 (M+1).

2-(5-(1-Methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridine 1880.

Orange-yellow solid (44.6 mg, 0.112 mmol, 37.1% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.73 (br s, 6H), 4.21 (br s, 4H), 6.80 (d, J=5.49 Hz, 1H), 7.62-7.66 (m, 1H), 7.66-7.71 (m, 1H), 7.79 (s, 1H), 7.80 (d, J=5.49 Hz, 1H), 8.10 (s, 1H), 8.57 (s, 1H), 13.11 (br s, 1H), 13.56 (br s, 1H); ESIMS found for C₂₂H₂₂N₈ m/z 399.2 (M+1).

2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridine 1915.

Off-white solid (45.5 mg, 0.114 mmol, 39.2% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.29 (s, 3H), 2.57 (br s, 4H), 4.22 (br s, 4H), 6.86 (d, J=5.49 Hz, 1H), 7.64 (d, J=8.78 Hz, 1H), 7.74 (dd, J=8.78, 1.65 Hz, 1H), 7.82 (d, J=5.49 Hz, 1H), 7.88 (br s, 1H), 8.16 (br s, 1H), 8.56 (s, 1H), 13.00 (br s, 1H), 13.16 (s, 1H), 13.57 (s, 1H); ESIMS found for C₂₁H₂₁N₉ m/z 400 (M+1).

2-(5-(1-Methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridine 1916.

Beige solid (47.7 mg, 0.115 mmol, 60.6% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.28 (s, 3H), 2.56 (t, J=4.94 Hz, 4H), 3.91 (s, 3H), 4.21 (br s, 4H), 6.86 (d, J=5.49 Hz, 1H), 7.62-7.71 (m, 2H), 7.80 (s, 1H), 7.82 (d, J=5.49 Hz, 1H), 8.10 (s, 1H), 8.54 (s, 1H), 13.16 (br s, 1H), 13.57 (br s, 1H); ESIMS found for C₂₂H₂₃N₉ m/z 414.1 (M+1).

N-(5-(3-(4-(3-(2-(Dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide 2076.

Yellow solid (17.7 mg, 0.030 mmol, 44.9% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 0.97 (d, J=6.86 Hz, 6H), 2.06-2.17 (m, 1H), 2.28 (d, J=6.86 Hz, 2H), 2.85 (br s, 6H), 3.54 (br s, 2H), 4.48 (br s, 2H), 7.08 (br s, 1H), 7.67 (br s, 1H), 7.79-7.84 (m, 1H), 7.87-7.93 (m, 1H), 8.37 (br s, 1H), 8.45 (s, 1H), 8.49 (br d, J=5.49 Hz, 1H), 8.56 (br s, 1H), 8.75 (s, 1H), 8.86 (br s, 2H), 9.79 (br s, 1H), 10.29 (s, 1H), 14.12 (br s, 1H); ESIMS found for C₃₃H₃₃FN₈O₂ m/z 593.3 (M+1).

N-(5-(3-(4-(3-Fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide 2120.

Yellow solid (8.3 mg, 0.013 mmol, 20.95% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 0.96 (d, J=6.59 Hz, 6H), 1.61 (br s, 4H), 2.10 (dquin, J=13.60, 6.69, 6.69, 6.69, 6.69 Hz, 1H), 2.26 (d, J=7.14 Hz, 2H), 2.44 (br s, 3H), 2.56-2.67 (m, 2H), 4.06-4.16 (m, 2H), 6.89 (br d, J=10.43 Hz, 1H), 7.55 (d, J=5.21 Hz, 1H), 7.80 (dd, J=8.78, 1.65 Hz, 1H), 7.85-7.91 (m, 1H), 8.39 (br d, J=11.25 Hz, 1H), 8.43 (t, J=2.06 Hz, 1H), 8.45 (d, J=5.21 Hz, 1H), 8.49 (s, 1H), 8.67 (d, J=2.20 Hz, 1H), 8.82 (d, J=2.20 Hz, 1H), 8.83 (s, 1H), 10.22 (s, 1H), 13.71 (br s, 1H), 14.01 (br s, 1H); ESIMS found for C₃₅H₃₅FN₈O₂ m/z 619.3 (M+1).

N-(5-(3-(4-(3-Fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide 2164.

Yellow solid (12.6 mg, 0.024 mmol, 17.23% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 0.97 (d, J=6.59 Hz, 6H), 2.12 (dquin, J=13.64, 6.81, 6.81, 6.81, 6.81 Hz, 1H), 2.27 (d, J=7.14 Hz, 2H), 6.60-6.68 (m, 1H), 7.53 (d, J=5.21 Hz, 1H), 7.79-7.89 (m, 2H), 8.16 (s, 1H), 8.40-8.45 (m, 2H), 8.45-8.51 (m, 1H), 8.72 (d, J=1.92 Hz, 1H), 8.81 (d, J=2.20 Hz, 1H), 8.89 (s, 1H), 9.97 (br s, 1H), 10.17 (s, 1H), 13.67 (br s, 1H), 13.98 (br s, 1H); ESIMS found for C₂₉H₂₄FN₇O₂ m/z 522.2 (M+1).

N-(5-(3-(4-(3-Fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide 2208.

Yellow solid 33.6 mg, 0.063 mmol, 51.8% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 0.96 (d, J=6.59 Hz, 6H), 2.11 (dquin, J=13.64, 6.81, 6.81, 6.81, 6.81 Hz, 1H), 2.27 (d, J=7.14 Hz, 2H), 3.81 (s, 3H), 6.89 (dt, J=10.50, 2.30 Hz, 1H), 7.56 (d, J=5.49 Hz, 1H), 7.80 (dd, J=8.78, 1.65 Hz, 1H), 7.85-7.90 (m, 1H), 8.36 (br d, J=10.15 Hz, 1H), 8.42-8.48 (m, 2H), 8.58 (s, 1H), 8.69 (d, J=1.92 Hz, 1H), 8.82 (d, J=2.20 Hz, 1H), 8.86 (s, 1H), 10.22 (s, 1H), 13.73 (s, 1H), 14.01 (s, 1H); ESIMS found for C₃₀H₂₆FN₇O₂ m/z 536.2 (M+1).

2-(Dimethylamino)-N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide 2251.

Yellow solid (3.6 mg, 0.007 mmol). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.33 (s, 6H) 3.17 (s, 2H) 7.28 (td, J=8.44, 2.33 Hz, 1H) 7.55 (d, J=5.21 Hz, 1H) 7.57-7.64 (m, 1H) 7.82-7.89 (m, 2H) 8.45 (d, J=5.49 Hz, 1H) 8.58 (t, J=2.06 Hz, 1H) 8.73 (d, J=1.92 Hz, 1H) 8.81-8.89 (m, 2H) 8.89-8.95 (m, 2H) 10.10 (s, 1H) 13.90 (br s, 2H); ESIMS found for C₂₈H₂₃FN₈O m/z 507.2 (M+1).

4-(2-(5-(Pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)morpholine 2272.

White solid (46 mg, 0.116 mmol, 76.3% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 3.78-3.88 (m, 4H), 4.12-4.21 (m, 4H), 6.91 (d, J=5.49 Hz, 1H), 7.56 (dd, J=7.96, 4.94 Hz, 1H), 7.79 (d, J=8.78 Hz, 1H), 7.85 (d, J=5.49 Hz, 1H), 7.87 (dd, J=8.64, 1.78 Hz, 1H), 8.14 (dt, J=8.10, 1.85 Hz, 1H), 8.60 (dd, J=4.67, 1.37 Hz, 1H), 8.74 (s, 1H), 8.96 (d, J=1.92 Hz, 1H), 13.29 (s, 1H), 13.75 (s, 1H); ESIMS found for C₂₂H₁₉N₇O m/z 398.2 (M+1).

4-(4,4-Difluoropiperidin-1-yl)-2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo [4,5-c]pyridine 2273.

White solid (31 mg, 0.072 mmol, 70.2% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.06-2.18 (m, 4H), 4.35 (br t, J=5.63 Hz, 4H), 6.92 (d, J=5.49 Hz, 1H), 7.55 (dd, J=8.10, 4.53 Hz, 1H), 7.77-7.82 (m, 1H), 7.86 (s, 1H), 7.86-7.89 (m, 1H), 8.12-8.19 (m, 1H), 8.61 (dd, J=4.80, 1.51 Hz, 1H), 8.73 (s, 1H), 8.97 (d, J=1.92 Hz, 1H), 13.32 (s, 1H), 13.77 (s, 1H); ESIMS found for C₂₃H₁₉F₂N₇ m/z 432.1 (M+1).

4-(2-(5-(5-Fluoropyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)morpholine 2275.

White solid (65 mg, 0.156 mmol, 99.1% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 3.78-3.88 (m, 4H), 4.17 (br s, 4H), 6.91 (d, J=5.49 Hz, 1H), 7.80 (d, J=8.78 Hz, 1H), 7.85 (d, J=5.49 Hz, 1H), 7.92 (dd, J=8.64, 1.78 Hz, 1H), 8.11 (dt, J=10.22, 2.30 Hz, 1H), 8.61 (d, J=2.74 Hz, 1H), 8.79 (s, 1H), 8.86 (s, 1H), 13.32 (br s, 1H), 13.76 (br s, 1H); ESIMS found for C₂₂H₁₈FN₇O m/z 416.1 (M+1).

2-(5-(5-Fluoropyridin-3-yl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridine 2276.

White solid (21 mg, 0.049 mmol, 32.9% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.31 (br s, 3H), 2.55-2.70 (m, 4H), 4.21 (br s, 4H), 6.88 (d, J=5.49 Hz, 1H), 7.80 (d, J=8.51 Hz, 1H), 7.83 (d, J=5.49 Hz, 1H), 7.93 (dd, J=8.78, 1.65 Hz, 1H), 8.10 (dt, J=10.29, 2.26 Hz, 1H), 8.62 (d, J=2.74 Hz, 1H), 8.81 (s, 1H), 8.85-8.90 (m, 1H), 13.28 (s, 1H), 13.78 (s, 1H); ESIMS found for C₂₃H₂₁FN₈ m/z 429.2 (M+1).

4-(4,4-Difluoropiperidin-1-yl)-2-(5-(5-fluoropyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine 2277.

Off-white solid (25 mg, 0.056 mmol, 63.1% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.07-2.19 (m, 4H), 4.35 (br s, 4H), 6.92 (d, J=5.49 Hz, 1H), 7.80 (d, J=8.78 Hz, 1H), 7.85 (d, J=5.76 Hz, 1H), 7.90 (dd, J=8.64, 1.78 Hz, 1H), 8.12 (dt, J=10.22, 2.30 Hz, 1H), 8.61 (d, J=2.47 Hz, 1H), 8.79 (d, J=0.82 Hz, 1H), 8.87 (t, J=1.65 Hz, 1H); ESIMS found for C₂₃H₁₈F₃N₇ m/z 450.1 (M+1).

2-(5-(5-Fluoropyridin-3-yl)-1H-indazol-3-yl)-4-(piperidin-1-yl)-1H-imidazo [4,5-c]pyridine 2279.

Tan solid (44.6 mg, 0.108 mmol, 36.4% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.70 (br s, 6H), 4.19 (br s, 4H), 6.81 (d, J=5.76 Hz, 1H), 7.77-7.83 (m, 2H), 7.91 (dd, J=8.78, 1.92 Hz, 1H), 8.09 (dt, J=10.36, 2.23 Hz, 1H), 8.60 (d, J=2.47 Hz, 1H), 8.83 (s, 1H), 8.86 (t, J=1.65 Hz, 1H), 13.21 (s, 1H), 13.75 (s, 1H); ESIMS found for C₂₃H₂₀FN₇ m/z 414.1 (M+1).

4-(2-(5-(1-Methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)morpholine 2280.

White solid (25 mg, 0.062 mmol, 48.9% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 3.84-3.90 (m, 4H), 3.91 (s, 3H), 4.16-4.22 (m, 4H), 6.91 (d, J=5.49 Hz, 1H), 7.63-7.71 (m, 2H), 7.81 (s, 1H), 7.84 (d, J=5.49 Hz, 1H), 8.10 (s, 1H), 8.50 (s, 1H), 13.25 (br s, 1H), 13.61 (s, 1H); ESIMS found for C₂₁H₂₀N₈O m/z 401.2 (M+1).

4-(4,4-Difluoropiperidin-1-yl)-2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine 2281.

White solid (41 mg, 0.094 mmol, 65.2% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.09-2.21 (m, 4H), 4.37 (br s, 4H), 6.92 (d, J=5.76 Hz, 1H), 7.62-7.71 (m, 2H), 7.83 (s, 1H), 7.86 (d, J=5.49 Hz, 1H), 8.13 (s, 1H), 8.52 (s, 1H), 13.24 (br s, 1H), 13.61 (br s, 1H); ESIMS found for C₂₂H₂₀F₂N₈ m/z 435.2 (M+1).

2-(5-(1-Cyclopropyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridine 2284.

White solid (42.4 mg, 0.096 mmol, 56.5% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 0.97-1.04 (m, 2H), 1.10-1.15 (m, 2H), 2.30 (s, 3H), 2.58 (br t, J=4.67 Hz, 4H), 3.78 (tt, J=7.34, 3.77 Hz, 1H), 4.20 (br s, 4H), 6.86 (d, J=5.49 Hz, 1H), 7.61-7.66 (m, 1H), 7.72 (dd, J=8.64, 1.51 Hz, 1H), 7.81 (d, J=0.55 Hz, 1H), 7.82 (d, J=5.49 Hz, 1H), 8.17 (s, 1H), 8.55 (s, 1H), 13.16 (br s, 1H), 13.58 (br s, 1H); ESIMS found for C₂₄H₂₅N₉ m/z 440.2 (M+1).

2-(5-(1-Cyclopropyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridine 2287.

Off-white solid (71.1 mg, 0.167 mmol, 68.0% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 0.97-1.04 (m, 2H), 1.08-1.14 (m, 2H), 1.74 (br s, 6H), 3.78 (tt, J=7.34, 3.77 Hz, 1H), 4.21 (br s, 4H), 6.81 (d, J=5.49 Hz, 1H), 7.61-7.66 (m, 1H), 7.69-7.74 (m, 1H), 7.77-7.83 (m, 2H), 8.19 (s, 1H), 8.58 (s, 1H), 13.13 (br s, 1H), 13.53 (br s, 1H); ESIMS found for C₂₄H₂₄N₈ m/z 425.2 (M+1).

Example 2

Preparation of intermediate 5-(5-((dimethylamino)methyl)pyridin-3-yl)-6-fluoro-1H-indazole-3-carbaldehyde (CXXXII) is depicted below in Scheme 26.

Step 1

A solution of 6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (XXII) (19.5 g, 56.3 mmol, 1.0 eq) in DME (215 mL) was added 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine (LIV) (11.5 g, 53.5 mmol, 1.0 eq), Pd(PPh₃)₄ (1.95 g, 1.69 mmol, 0.03 eq), aq. Na₂CO₃ (2 M, 56 mL, 2.00 eq). The mixture was stirred at 100° C. for 12 h under N₂. TLC (DCM:MeOH=10:1, Rf=0.9) showed (XXII) was consumed completely. The solvent was concentrated under reduce pressure. The residue was dissolved in water (500 ml) and the aqueous phase was extracted with EtOAc (200 ml). The organic layer was washed with brine (100 mL), dried over anhydrous Na₂SO₄ and filtered. The filtrate was concentrated to give crude product which was purified by silica gel column (DCM:MeOH=30:1) to give 1-(5-(6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine (CXXVIII) as a brown oil (18 g, 50.8 mmol, 94.9% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.85-1.74 (m, 3H), 2.32-2.15 (m, 2H), 2.32 (s, 6H), 2.60-2.51 (m, 1H), 3.55 (s, 2H), 3.81-3.76 (m, 1H), 4.06 (d, J=11.8 Hz, 1H), 5.71 (d, J=8.8 Hz, 1H), 7.42 (d, J=11.8 Hz, 1H), 7.80 (s, 1H), 7.89 (s, 1H), 8.07 (s, 1H), 8.54 (s, 1H), 8.71 (s, 1H); ESIMS found C₂₀H₂₃FN₄O m/z 355.1 (M+1).

Step 2

To a solution of 1-(5-(6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine (CXXVIII) (18 g, 50.8 mmol, 1.0 eq) in DCM (50 mL) was added Et₃SiH (13.2 g, 113 mmol, 2.5 eq) and TFA (51 g, 454 mmol, 10 eq). The mixture was stirred at 25° C. for 12 h. LC/MS showed (CXXVIII) was consumed. The reaction mixture was concentrated in vacuo. The residue was diluted with TBME (200 mL). The mixture was stirred for 0.5 h at −65° C., 1 h at 25° C. The precipitate was filtered and the solid was concentrated in vacuo. The residue was dissolve in MeOH (200 mL), weakly basic resin was added. The mixture was stirred for 0.5 h, pH=7. The solid was filtered and dried in vacuo to give 1-(5-(6-fluoro-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine (CXXIX) as white solid (12.0 g, 44.4 mmol, 88.3% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 2.96 (s, 6H), 4.52 (s, 2H), 7.42 (d, J=11.2 Hz, 1H), 8.02 (d, J=7.2 Hz, 1H), 8.16 (s, 1H), 8.27 (s, 1H), 8.73 (s, 1H), 8.89 (s, 1H); ESIMS found Cl₅H₁₅FN₄ m/z 271.1 (M+1).

Step 3

To a solution of 1-(5-(6-fluoro-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine (CXXIX) (12.0 g, 44.4 mmol, 1.0 eq) in DMF (70 mL) was added KOH (7.4 g, 133.2 mmol, 3.0 eq) and I₂ (16.9 g, 66.6 mmol, 1.5 eq) at 25° C. The reaction mixture was stirred at 25° C. for 1 h. LC/MS showed (CXXIX) was consumed. The reaction mixture was quenched with 10% aqueous Na₂SO₃ (100 mL) and diluted with water (300 mL) and EtOAc (200 mL). The precipitated solid was filtered, dried to afford product. The solution was separated, and the organic layer was washed with water (100 mL) and sat NaCl (100 mL), then dried over anhydrous Na₂SO₄ and concentrated to afford 1-(5-(6-fluoro-3-iodo-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine (CXXX) as a yellow solid (10.0 g, 25.2 mmol, 56.8% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 2.31 (s, 6H), 4.02 (d, J=7.2 Hz, 2H), 7.59-7.55 (m, 2H), 7.92 (s, 1H), 8.53 (s, 1H), 8.69 (s, 1H), 13.71 (br, 1H); ESIMS found C₁₅H₁₄F₁N₄ m/z 397.1 (M+1).

Step 4

To a solution of 1-(5-(6-fluoro-3-iodo-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine (CXXX) (1.50 g, 3.79 mmol, 1.00 eq) in THF (20 mL) was added NaH (181 mg, 4.55 mmol, 1.20 eq) portion-wise at 0° C. The reaction mixture was stirred at 20° C. for 10 min then cooled to −10° C. and i-PrMgCl (2 M, 11.37 mL, 6.00 eq) was added. The reaction mixture was stirred at −10° C. for 1 h then morpholine-4-carbaldehyde (CXXXI) (3.49 g, 30.32 mmol, 8.00 eq) was slowly added. The mixture was stirred at −10° C. for 20 min then at 20° C. for 3 h. TLC (DCM:MeOH=5/1, R_f=0.55) show the reaction is complete. The reaction mixture was quenched with water (3 mL). The mixture was acidified with HCl (1N, 20 mL) to pH=7 and then concentrated to give crude product, which was further purified by silica gel on column chromatography (DCM/MeOH=50:1→3:1) to give 5-(5-((dimethylamino)methyl)pyridin-3-yl)-6-fluoro-1H-indazole-3-carbaldehyde (CXXXII) (2.9 g, 50% TLC purity) as yellow solid. The crude product was used for step 5 without further purification. ESIMS found C₁₆H₁₅FN₄O m/z 299.1 (M+1).

Step 5

Preparation of the following compounds were performed following the procedure listed in Scheme 25, Step 2.

The following compounds were prepared in accordance with the procedure described in the above Example 2.

1-(5-(7-Fluoro-3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine 456.

White solid (39.8 mg, 0.08 mmol). ESIMS found for C₂₇H₂₁F₂N₇ m/z 482.1 (M+1).

1-(5-(7-Fluoro-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine 688.

White solid (30.8 mg, 0.07 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.82 (br d, J=3.76 Hz, 6H), 4.52 (br d, J=3.28 Hz, 2H), 7.83 (br d, J=10.54 Hz, 1H), 7.93 (br d, J=6.02 Hz, 2H), 8.47 (br d, J=6.52 Hz, 1H), 8.58-8.66 (m, 2H), 8.71 (br d, J=7.28 Hz, 1H), 8.96 (s, 1H), 9.07 (br s, 1H), 9.47 (br s, 1H), 11.46 (br s, 1H), 14.59 (br s, 1H), 14.92 (br s, 1H); ESIMS found for C₂₅H₂₀FN₇S m/z 470.1 (M+1).

N-(3-(2-(5-(5-((Dimethylamino)methyl)pyridin-3-yl)-7-fluoro-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide 844.

White solid (36.5 mg, 0.06 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.82 (br s, 6H), 2.94 (s, 3H), 4.31 (br s, 2H), 4.64 (br s, 2H), 7.52 (br d, J=9.03 Hz, 1H), 7.66 (d, J=10.54 Hz, 1H), 7.88 (br d, J=6.27 Hz, 2H), 8.40 (br d, J=9.79 Hz, 1H), 8.43-8.51 (m, 3H), 8.90 (br s, 1H), 9.15 (br s, 1H), 9.20 (br s, 1H), 11.67 (br s, 1H), 14.63 (br s, 1H); ESIMS found for C₂₉H₂₆F₂N₅O₂S m/z 589.1 (M+1).

1-(5-(6-Fluoro-3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine 898.

White solid (27.2 mg, 0.06 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.84 (br s, 6H), 4.60 (br s, 2H), 7.47 (br t, J=7.40 Hz, 1H), 7.65-7.73 (m, 1H), 7.75-7.82 (m, 2H), 8.27 (s, 1H), 8.41 (br d, J=6.27 Hz, 1H), 8.44-8.52 (m, 2H), 8.88 (br s, 1H), 8.96 (s, 1H), 9.03 (s, 1H), 11.71 (br s, 1H), 14.78 (br s, 1H); ESIMS found for C₂₇H₂₁F₂N₇ m/z 482.3 (M+1).

1-(5-(6-Fluoro-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine 1132.

White solid (5.3 mg, 0.01 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.82 (br d, J=2.76 Hz, 6H), 4.53 (br s, 2H), 7.87 (d, J=6.52 Hz, 1H), 7.92-8.00 (m, 2H), 8.43 (d, J=6.53 Hz, 1H), 8.60 (d, J=5.02 Hz, 1H), 8.63 (s, 1H), 8.89 (br s, 1H), 8.92 (br s, 1H), 9.22 (d, J=1.76 Hz, 1H), 9.45 (d, J=1.76 Hz, 1H), 11.60 (br s, 1H), 14.90 (br s, 1H), 14.96 (br s, 1H); ESIMS found for C₂₅H₂₀FN₇S m/z 470.1 (M+1).

N-(3-(2-(5-(5-((Dimethylamino)methyl)pyridin-3-yl)-6-fluoro-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide 1288.

White solid (35.0 mg, 0.06 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.84 (br s, 6H), 2.98 (s, 3H), 4.34 (br s, 2H), 4.61 (br s, 2H), 7.50 (br d, J=8.78 Hz, 1H), 7.76-7.84 (m, 2H), 7.90 (br s, 1H), 8.28 (s, 1H), 8.37-8.46 (m, 3H), 8.93 (br s, 1H), 9.01 (s, 1H), 9.15 (s, 1H), 11.68 (br s, 1H), 14.82 (br s, 1H); ESIMS found for C₂₉H₂₆F₂N₈O₂S m/z 589.3 (M+1).

1-(5-(4-Fluoro-3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine 1339.

White solid (53.8 mg, 0.11 mmol). ESIMS found for C₂₇H₂₁F₂N₇ m/z 482.1 (M+1).

1-(5-(4-Fluoro-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine 1573.

White solid (3.9 mg, 0.008 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.80 (br d, J=3.76 Hz, 6H), 4.51 (br d, J=3.80 Hz, 2H), 7.74 (d, J=8.53 Hz, 1H), 7.80-7.87 (m, 1H), 7.89 (d, J=6.78 Hz, 1H), 7.91-7.95 (m, 1H), 8.44 (d, J=6.53 Hz, 1H), 8.62 (br s, 1H), 8.71 (br d, J=5.02 Hz, 1H), 8.90 (s, 1H), 9.07 (s, 1H), 9.48 (br s, 1H), 11.49 (br s, 1H), 14.75 (br s, 1H), 14.84 (br s, 1H); ESIMS found for C₂₅H₂₀FN₇S m/z 470.1 (M+1).

N-(3-(2-(5-(5-((Dimethylamino)methyl)pyridin-3-yl)-4-fluoro-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide 1729.

White solid (6.9 mg, 0.01 mmol). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 2.78 (br s, 6H), 2.94 (br d, J=3.26 Hz, 3H), 4.32 (br s, 2H), 4.52 (br s, 2H), 7.53 (br d, J=8.53 Hz, 1H), 7.73 (br dd, J=8.78, 3.76 Hz, 1H), 7.84 (br s, 2H), 7.98 (br s, 1H), 8.55 (br s, 1H), 8.60-8.71 (m, 3H), 8.93 (br s, 1H), 9.11 (br s, 1H), 11.58 (br s, 1H), 14.90 (br s, 1H); ESIMS found for C₂₉H₂₆F₂N₈O₂S m/z 589.2 (M+1).

Example 3

The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) with a lentiviral construct that includes a Wnt-responsive promoter driving expression of the firefly luciferase gene.

SW480 colon carcinoma cells were transduced with a lentiviral vector expressing luciferase with a human Sp5 promoter consisting of a sequence of eight TCF/LEF binding sites. SW480 cells stably expressing the Sp5-Luc reporter gene and a hygromycin resistance gene were selected by treatment with 150 μg/ml of hygromycin for 7 days. These stably transduced SW480 cells were expanded in cell culture and used for all further screening activities. For Sp5-Luc reporter gene assays, the cells were plated at 10,000 cells/well in 96-well plates with growth medium containing 10% fetal calf serum and incubated overnight at 37° C. and 5% CO₂. Each compound was dissolved in DMSO as a 10 mM stock in standard j-vials and used to prepare compound source plates in dose-response format with 3-fold serial dilutions and a 10 mM top concentration. Compound transfer from serially diluted source plates to assay plates containing the cells was accomplished using a pintool (Multimek 96, Beckman equipped with V&P Scientific FP1S50H pins) based liquid handling protocol. This protocol used a slotted pin to transfer 50 nl of compound from a source plate well to an assay plate well containing 50 μl of cells in growth medium. The 1000-fold dilution resulted in a final DMSO concentration of 0.1% on the cells in each well. Control wells received 50 nl of DMSO treatment for normalization and calculating IC₅₀ values. The treated cells were incubated at 37° C. and 5% CO₂ for an additional forty-two hours. Following incubation, the growth medium was removed and 50 μl of BrightGlo luminescence reagent (Promega) was added to each well of the 96-well assay plates. The plates were placed on an orbital shaker for 5 min and then luminescence was quantified on the Victor3 (Perkin Elmer) plate reader. Readings were normalized to DMSO only treated cells, and normalized activities were utilized for IC₅₀ calculations using the dose-response log (inhibitor) vs. response-variable slope (four parameters) nonlinear regression feature available in GraphPad Prism 5.0 or 6.0. Table 2 shows the measured activity for selected compounds of Formula I as described herein.

	TABLE 2
	Com-	IC50	Com-	IC50	Com-	IC50
	pound	(μM)	pound	(μM)	pound	(μM)
	1	0.001	223	0.172	428	0.006
	2	0.005	224	0.6729	434	0.016
	7	0.004	229	0.711	440	0.5392
	13	0.001	234	0.021	456	0.090
	19	0.001	239	0.003	688	0.415
	21	0.0128	242	0.0274	844	0.096
	25	0.010	244	0.0691	898	1.453
	28	0.009	245	0.040	1132	3.680
	34	0.013	251	0.001	1288	0.637
	38	0.0429	253	0.1265	1339	1.180
	40	0.075	255	0.0594	1573	3.055
	46	0.010	257	0.007	1729	1.095
	52	0.025	266	0.036	1769	2.336
	55	0.0041	272	<0.001	1770	0.658
	59	0.0094	278	0.015	1771	0.004
	61	0.005	280	0.0279	1772	0.011
	68	0.020	284	>10	1773	0.023
	69	0.005	287	0.010	1774	0.171
	73	0.008	293	0.009	1775	0.252
	82	0.008	295	0.0308	1776	0.778
	86	0.0179	299	0.332	1777	0.243
	87	0.003	305	0.004	1778	0.280
	90	0.004	307	0.0348	1779	0.192
	93	0.318	311	0.320	1780	0.025
	101	0.047	314	0.0447	1781	0.006
	109	0.0405	320	0.0052	1782	0.575
	114	0.036	326	0.2837	1783	0.505
	121	0.102	332	0.0326	1784	>10
	126	1.187	341	0.0013	1785	0.633
	136	3.058	347	0.007	1786	0.035
	141	>10	353	0.844	1915	0.070
	148	0.2484	354	0.0127	1916	0.065
	150	0.0514	358	0.009	2076	0.370
	154	0.061	359	0.005	2120	0.305
	157	0.183	368	<0.001	2164	0.035
	163	0.003	374	0.009	2208	0.020
	168	0.0881	380	0.187	2251	0.124
	169	4.018	386	0.4755	2272	0.020
	175	0.278	395	0.085	2273	0.050
	181	0.067	400	>10	2275	0.080
	184	0.002	401	0.032	2276	0.439
	190	0.005	407	0.024	2277	0.315
	202	<0.001	413	0.187	2280	0.015
	211	0.0971	416	<0.001	2281	0.020
	212	0.065	422	0.108	2284	0.090
	217	0.245

Example 4

The above synthesized compounds were screened using primary human mesenchymal stem cells (hMSCs) to determine their ability to induce chondrogenesis (process by which cartilage is developed).

Human Mesenchymal Stem Cell Culture: Primary human mesenchymal stem cells (hMSCs) were purchased from Lonza (Walkersville, Md.) and expanded in Mesenchymal Stem Cell Growth Media (Lonza). Cells between passage 3 and 6 were used for the experiments.

Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:3, 6-point dose-response curves from 2700 nM to 10 nM) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, Calif.) into 96-well clear bottom assay plates (Greiner Bio-One) with appropriate DMSO backfill for a final DMSO concentration of 0.03%. hMSCs were plated at 20,000 cells/well in 250 μL/well Incomplete Chondrogenic Induction Medium (Lonza; DMEM, dexamethasone, ascorbate, insulin-transferrin-selenium [ITS supplement], gentamycin-amphotericin [GA-1000], sodium pyruvate, proline and L-glutamine). TGF-β3 (10 ng/mL) was used as a positive control for differentiation while negative control wells were treated with 75 nL DMSO for normalization and calculating EC₅₀ values. Cells were incubated at 37° C. and 5% CO₂ for 6 days. To image chondrogenic nodules, the cells were fixed using 4% formaldehyde (Electron Microscopy Sciences), and stained with 2 μg/mL Rhodamine B (Sigma-Aldrich) and 20 μM Nile Red (Sigma-Aldrich) [Johnson K., et. al, A Stem Cell-Based Approach to Cartilage Repair, Science, (2012), 336(6082), 717-721]. The nodules imaged (4 images per well at 4× magnification) by excitation at 531 nm and emission at 625 nm and quantified using the CellInsight CX5 (Thermo Scientific). Number of nodules in each well was normalized to the average of 3 DMSO treated wells on the same plate using Excel (Microsoft Inc.). The normalized averages (fold change over DMSO) of 3 replicate wells for each compound concentration were calculated. Due to solubility limitations of some of the compounds, curve fitting was incomplete leading to inaccurate EC₅₀ determinations.

Using TGF-β3 as a positive control, the concentration of test compounds required to induce equivalent levels of chondrogenesis is reported. In addition, the maximum activity of each compound and the respective dose that each compound reached maximum chondrogenesis activity is reported. Table 3 shows the activity of selected compounds as provided herein.

TABLE 3
	Conc	Max.	Conc		Conc	Max.	Conc
	(nM)	Activity	(nM) of		(nM)	Activity	(nM) of
	of	as 70%	100%		of	as 70%	100%
Com-	Max.	TGF-β3	TGF-β3	Com-	Max.	TGF-β3	TGF-β3
pound	activity	activity	activity	pound	activity	activity	activity
1	300	N/A	60.96	234	30	30	87.3
13	900	900	129.9	239	300	10	155.7
19	300	10	112.5	272	300	30	90.2
55	100	100	61.9	320	2700	2700	96.4
87	900	N/A	68.3	341	10	2700	163.1
114	900	N/A	48.2	368	10	10	105.8
163	10	N/A	62.8	416	30	30	73.1
184	30	30	73.7	428	30	30	85.1
202	30	30	76.2	2251	300	N/A	36.1

Example 5

The above synthesized compounds were screened using primary human fibroblasts (derived from IPF patients) treated with TGF-β1 to determine their ability to inhibit the fibrotic process.

Human Fibroblast Cell Culture:

Primary human fibroblasts derived from IPF patients (LL29 cells) [¹Xiaoqiu Liu, et. al., “Fibrotic Lung Fibroblasts Show Blunted Inhibition by cAMP Due to Deficient cAMP Response Element-Binding Protein Phosphorylation”, Journal of Pharmacology and Experimental Therapeutics (2005), 315(2), 678-687; ²Watts, K. L., et. al., “RhoA signaling modulates cyclin D1 expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis”, Respiratory Research (2006), 7(1), 88] were obtained from American Type Culture Collection (ATCC) and expanded in F12 medium supplemented with 15% Fetal Bovine Serum and Penicillin/Streptomycin.

Compound Screening:

Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point dose-response curves from 10 M to 1.87 nM) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, Calif.) into 384-well clear bottom assay plates (Greiner Bio-One) with appropriate DMSO backfill for a final DMSO concentration of 0.1%. LL29 cells were plated at 1,500 cells/well in 80 l/well F₁₂ medium supplemented with 1% Fetal Bovine Serum. One hour after addition of the cells, TGF-31 (Peprotech; 20 ng/mL) was added to the plates to induce fibrosis (ref. 1 and 2 above). Wells treated with TGF-β1 and containing DMSO were used as controls. Cells were incubated at 37° C. and 5% CO₂ for 4 days. Following incubation for 4 days, SYTOX green nucleic acid stain (Life Technologies [Thermo Fisher Scientific]) was added to the wells at a final concentration of 1 uM and incubated at room temperature for 30 min. Cells were then fixed using 4% formaldehyde (Electron Microscopy Sciences), washed 3 times with PBS followed by blocking and permeabilization using 3% Bovine Serum Albumin (BSA; Sigma) and 0.3% Triton X-100 (Sigma) in PBS. Cells were then stained with antibody specific to α-smooth muscle actin (αSMA; Abcam) (ref. 1 and 2 above) in 3% Bovine Serum Albumin (BSA; Sigma) and 0.3% Triton X-100 (Sigma) in PBS, and incubated overnight at 4° C. Cells were then washed 3 times with PBS, followed by incubation with Alexa Flor-647 conjugated secondary antibody (Life Technologies [Thermo Fisher Scientific]) and DAPI at room temperature for 1 hour. Cells were then washed 3 times with PBS and plates were sealed for imaging. αSMA staining was imaged by excitation at 630 nm and emission at 665 nm and quantified using the Compartmental Analysis program on the CellInsight CX5 (Thermo Scientific). Dead or apoptotic cells were excluded from analysis based on positive SYTOX green staining. % of total cells positive for αSMA were counted in each well and normalized to the average of 11 wells treated with TGF-β1 on the same plate using Dotmatics' Studies Software. The normalized averages (fold change over untreated) of 3 replicate wells for each compound concentration were used to create dose-responses curves and EC₅₀ values were calculated using non-linear regression curve fit in the Dotmatics' Studies Software. The EC₅₀ values are reported.

Table 4 shows the activity of selected compounds as provided herein.

TABLE 4
	Inhibition of		Inhibition of		Inhibition of
Com-	fibrosis	Com-	fibrosis	Com-	fibrosis
pound	EC50 (μM)	pound	EC50 (μM)	pound	EC50 (μM)
1	0.020	181	0.0805	347	0.038
2	0.009	184	0.049	353	0.009
7	0.009	190	0.050	354	0.086
13	0.009	202	0.013	358	0.021
19	0.009	217	4.452	359	0.041
21	0.317	223	1.113	368	0.014
25	0.056	224	1.094	374	0.009
28	0.009	229	9.990	386	0.536
34	0.009	234	0.280	395	0.026
38	0.126	239	0.060	400	0.009
40	0.024	242	1.179	401	9.990
46	0.009	244	0.203	407	0.019
52	0.539	245	0.017	413	0.009
55	0.017	251	0.018	416	0.027
59	0.018	253	0.544	422	0.108
61	0.079	255	1.221	428	0.009
68	0.009	257	0.009	434	0.459
69	0.074	266	0.009	440	0.009
73	0.009	272	0.009	1769	0.670
82	0.009	278	0.291	1770	9.990
86	0.993	280	1.244	1771	9.990
87	0.295	284	0.009	1772	9.990
90	0.009	287	0.062	1774	0.102
93	0.388	293	0.036	1775	0.009
101	2.432	295	0.186	1776	0.038
109	>10	299	0.608	1777	0.107
126	9.990	305	0.022	1779	0.041
136	0.009	307	0.422	1780	0.019
150	1.518	311	0.083	1781	0.079
154	0.061	314	0.665	1784	9.990
157	0.071	320	0.115	1785	0.009
163	1.548	326	0.940	1786	0.009
169	0.171	332	0.363	2251	0.075
175	0.115	341	0.009

Example 6

The above synthesized compounds were screened using ARPE-19 cells [a spontaneously arising retinal pigment epithelia (RPE) cell line] to determine their ability to transdifferentiate ARPE-19 into eye neuronal cells [photoreceptors].

ARPE-19 Cell Culture: ARPE-19 cells are cultured in standard culture medium containing Dulbecco's Modified Eagle's Medium and Ham's F₁₂ Nutrient Mixture (DMEM/F₁₂) mix (1:1)+GlutaMax with 1% penicillin-Streptomycin and 10% FBS (Fetal Bovine Serum). Cells are incubated at 37° C. with 5% CO₂. Cells are trypsinized and plated onto 384-well pre-spotted plate at a density of 3000 cells/well in 50 uL of media. Plating media: DMEM/F₁₂ (1:1)+3% charcoal filtered-FBS+GlutaMax+1% pen/Strep. Cells are incubated at 37° C. with 5% CO₂. At 40 hours, cells were fixed for 15 min with 10% Buffered Formalin. Cells were then washed 3 times with PBS for 5 min each, permeablize using 0.3% Triton X-100 in 1×PBS for 30 min, block for 1 h with 2% BSA in 1×PBS with 0.1% Triton X-100. The primary antibody (1:100 PAX6 Santa Cruz Biotech; sc-81649) was diluted and 10 μL/well was added to the cells. The cells were incubated overnight at 4° C. The plates were washed 3× with PBS before applying the secondary antibody (goat Anti-mouse 488), shake for 1 h in complete darkness, aspirate secondary, add 10 μL of DAPI (diamidino-2-phenylindole) (1 μg/mL), shake for 10 min. Wash 3× in PBS and scan on Thermo Fisher Scientific cell-Insight CX5. Readings were normalized to DMSO only treated cells, and normalized activities were utilized for EC₅₀ calculations using the dose-response log (activator) vs. response-variable slope (four parameters) nonlinear regression feature available in GraphPad Prism 5.0 or 6.0.

Table 5 shows the activity of selected compounds as provided herein.

TABLE 5
Compound PAX6 EC50 (μM)
1916     0.0037
2275     0.0434
2280     0.002
2284     0.006

Claims

1. A method of treating a bone or cartilage disease in a subject, wherein the bone or cartilage disease is selected from the group consisting of osteoarthritis, bone spur (osteophytes), craniosynostosis, fibrodysplasia ossificans progressive, fibrous dysplasia, giant cell tumor of bone, hip labral tear, meniscal tears, bone/osteoporotic fractures, articular cartilage (chondral) defects, degenerative disc disease, osteochondritis dissecans, osteochondroma, osteopetrosis, relapsing polychondritis, and Salter-Harris fractures, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof:

2. The method of claim 1, wherein R3 is -heteroaryl(R6)q.

3. The method of claim 2, wherein R3 is selected from the group consisting of -pyridinyl(R6)q, -pyrimidinyl(R6)q, -pyrazolyl(R6)q, and -imidazolyl(R6)q.

4. The method of claim 2, wherein q is 0, 1 or 2.

5. The method of claim 2, wherein R6 is selected from the group consisting of —(C1-3 alkyl), —CH2heterocyclyl(R11)h, —NHC(═O)R14, —NR15R16, —CH2NR17R18, and —OR24.

6. The method of claim 1, wherein R5 is -aryl(R10)k.

7. The method of claim 6, wherein R5 is -phenyl(R10)k.

8. The method of claim 6, wherein k is 1 or 2.

9. The method of claim 8, wherein each R10 is independently selected from the group consisting of halide and is —CH2NHSO2R19.

10. The method of claim 1, wherein R5 is -heteroaryl(R8)q.

11. The method of claim 10, wherein R5 is selected from the group consisting of -pyridinyl(R8)q, -imidazolyl(R8)q, -furanyl(R8)q, and -thiophenyl(R8)q.

12. The method of claim 10, wherein q is 0 or 1.

13. The method of claim 12, wherein q is 1 and R8 is selected from the group consisting of halide, —(C1-3 alkyl), and —C(═O)R19.

14. The method of claim 1, wherein R5 is -heterocyclyl(R9)h.

15. The method of claim 14, wherein R5 is selected from the group consisting of -piperidinyl(R9)h, -morpholinyl(R9)h, and -piperazinyl(R9)h.

16. The method of claim 14, wherein h is 0, 1, or 2.

17. The method of claim 16, wherein h is 1 or 2 and each R9 is independently selected from the group consisting of a halide and —(C1-3 alkyl).

18. The method of claim 1, wherein R1, R2, and R4 are H.

19. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of: N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [1];N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide [2];5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [3];4-(3-fluorophenyl)-2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [4];4-(3-fluorophenyl)-2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [5];N-((5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)ethanamine [6];5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N,N-dimethylpyridin-3-amine [7];N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [8];N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [9];N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide [10];N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [11];5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N-isopropylpyridin-3-amine [12];1-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [13];4-(3-fluorophenyl)-2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [14];4-(3-fluorophenyl)-2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [15];N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [16];N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [17];N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [18];N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [19];N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [20];N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [21];N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [22];N-benzyl-1-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [23];1-cyclopentyl-N-((5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)methanamine [24];2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridine [25];4-(3-fluorophenyl)-2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [26];N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [27];N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide [28];5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [29];4-(4-fluorophenyl)-2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [30];4-(4-fluorophenyl)-2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [31];N-((5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)ethanamine [32];5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N,N-dimethylpyridin-3-amine [33];N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [34];N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [35];N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide [36];N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [37];5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N-isopropylpyridin-3-amine [38];1-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [39];4-(4-fluorophenyl)-2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [40];4-(4-fluorophenyl)-2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [41];N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [42];N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [43];N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [44];N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [45];N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [46];N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [47];N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [48];N-benzyl-1-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [49];1-cyclopentyl-N-((5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)methanamine [50];2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridine [51];4-(4-fluorophenyl)-2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [52];N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [53];N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide [54];5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [55];4-(2-fluorophenyl)-2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [56];4-(2-fluorophenyl)-2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [57];N-((5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)ethanamine [58];5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N,N-dimethylpyridin-3-amine [59];N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [60];N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [61];N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide [62];N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [63];5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N-isopropylpyridin-3-amine [64];1-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [65];4-(2-fluorophenyl)-2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [66];4-(2-fluorophenyl)-2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [67];N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [68];N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [69];N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [70];N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [71];N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [72];N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [73];N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [74];N-benzyl-1-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [75];1-cyclopentyl-N-((5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)methanamine [76];2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridine [77];4-(2-fluorophenyl)-2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [78];N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [79];3-methyl-N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide [80];5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [81];4-(pyridin-3-yl)-2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [82];2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridine [83];N-((5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)ethanamine [84];N,N-dimethyl-5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [85];N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [86];N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [87];2-phenyl-N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [88];N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [89];N-isopropyl-5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [90];N,N-dimethyl-1-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [91];4-(pyridin-3-yl)-2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [92];2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridine [93];3,3-dimethyl-N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide [94];N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [95];N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [96];N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [97];N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [98];N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [99]; andN-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [100]; or a pharmaceutically acceptable salt thereof.

20. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of: N-benzyl-1-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [101];1-cyclopentyl-N-((5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)methanamine [102];2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridine [103];4-(pyridin-3-yl)-2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [104];N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [105];3-methyl-N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide [106];5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [107];2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridine [108];2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridine [109];N-((5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)ethanamine [110];N,N-dimethyl-5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [111];N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [112];N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [113];2-phenyl-N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [114];N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [115];N-isopropyl-5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [116];N,N-dimethyl-1-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [117];4-(pyridin-4-yl)-2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [118];2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridine [119];3,3-dimethyl-N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide [120];N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [121];N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [122];N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [123];N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [124];N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [125];N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [126];N-benzyl-1-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [127];1-cyclopentyl-N-((5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)methanamine [128];2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridine [129];4-(pyridin-4-yl)-2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [130];N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [131];3-methyl-N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide [132];5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [133];4-(pyridin-2-yl)-2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [134];2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridine [135];N-((5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)ethanamine [136];N,N-dimethyl-5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [137];N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [138];N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [139];2-phenyl-N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [140];N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [141];N-isopropyl-5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [142];N,N-dimethyl-1-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [143];4-(pyridin-2-yl)-2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [144];2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridine [145];3,3-dimethyl-N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide [146];N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [147];N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [148];N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [149];N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [150];N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [151];N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [152];N-benzyl-1-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [153];1-cyclopentyl-N-((5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)methanamine [154];2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridine [155];4-(pyridin-2-yl)-2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [156];N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [157];3-methyl-N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide [158];5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [159];4-(piperidin-1-yl)-2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [160];2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridine [161];N-((5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)ethanamine [162];N,N-dimethyl-5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [163];N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [164];N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [165];2-phenyl-N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [166];N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [167];N-isopropyl-5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [168];N,N-dimethyl-1-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [169];4-(piperidin-1-yl)-2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [170];4-(piperidin-1-yl)-2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [171];3,3-dimethyl-N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide [172];N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [173];N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [174];N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [175];N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [176];N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [177];N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [178];N-benzyl-1-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [179];1-cyclopentyl-N-((5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)methanamine [180];2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridine [181];4-(piperidin-1-yl)-2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [182];N-(5-(3-(4-(4-methyl-1H-imidazo-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [183];3-methyl-N-(5-(3-(4-(4-methyl-1H-imidazo-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide [184];5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [185];4-(4-methyl-1H-imidazol-1-yl)-2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [186];4-(4-methyl-1H-imidazol-1-yl)-2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [187];N-((5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)ethanamine [188];N,N-dimethyl-5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [189];N-(5-(3-(4-(4-methyl-1H-imidazo-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [190];N-(5-(3-(4-(4-methyl-1H-imidazo-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [191];N-(5-(3-(4-(4-methyl-1H-imidazo-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide [192];N-(5-(3-(4-(4-methyl-1H-imidazo-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [193];N-isopropyl-5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [194];N,N-dimethyl-1-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [195];4-(4-methyl-1H-imidazol-1-yl)-2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [196];4-(4-methyl-1H-imidazol-1-yl)-2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [197];3,3-dimethyl-N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide [198];N-(5-(3-(4-(4-methyl-1H-imidazo-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [199]; andN-(5-(3-(4-(4-methyl-1H-imidazo-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [200]; or a pharmaceutically acceptable salt thereof.

21. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of: N-(5-(3-(4-(4-methyl-1H-imidazo-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [201];N-(5-(3-(4-(4-methyl-1H-imidazo-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [202];N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [203];N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [204];N-benzyl-1-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [205];1-cyclopentyl-N-((5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)methanamine [206];2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridine [207];4-(4-methyl-1H-imidazol-1-yl)-2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [208];N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [209];3-methyl-N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide [210];5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [211];4-(4-methylpiperazin-1-yl)-2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [212];4-(4-methylpiperazin-1-yl)-2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [213];N-((5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)ethanamine [214];N,N-dimethyl-5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [215];N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [216];N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [217];N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide [218];N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [219];N-isopropyl-5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [220];N,N-dimethyl-1-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [221];4-(4-methylpiperazin-1-yl)-2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [222];4-(4-methylpiperazin-1-yl)-2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [223];3,3-dimethyl-N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide [224];N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [225];N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [226];N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [227];N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [228];N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [229];N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [230];N-benzyl-1-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [231];1-cyclopentyl-N-((5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)methanamine [232];2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridine [233];4-(4-methylpiperazin-1-yl)-2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [234];N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [235];3-methyl-N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide [236];5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [237];2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine [238];2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine [239];N-((5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)ethanamine [240];N,N-dimethyl-5-(3-(4-(thiophen-3-yl)-H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [241];N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [242];N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [243];2-phenyl-N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [244];N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [245];N-isopropyl-5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [246];N,N-dimethyl-1-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [247];2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine [248];2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine [249];3,3-dimethyl-N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide [250];N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [251];N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [252];N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [253];N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [254];N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [255];N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [256];N-benzyl-1-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [257];1-cyclopentyl-N-((5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)methanamine [258];2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine [259];2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine [260];N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [261];N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide [262]5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [263];4-(furan-3-yl)-2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [264];4-(furan-3-yl)-2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [265];N-((5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)ethanamine [266];5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N,N-dimethylpyridin-3-amine [267];N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [268];N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [269];N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide [270];N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [271];5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N-isopropylpyridin-3-amine [272];1-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [273];4-(furan-3-yl)-2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [274];4-(furan-3-yl)-2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [275];N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [276];N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [277];N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [278];N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [279];N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [280];N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [281];N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [282];N-benzyl-1-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [283];1-cyclopentyl-N-((5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)methanamine [284];2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(furan-3-yl)-1H-imidazo[4,5-c]pyridine [285];4-(furan-3-yl)-2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [286];N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [287];3-methyl-N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide [288];5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [289];2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine [290];2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine [291];N-((5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)ethanamine [292];N,N-dimethyl-5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [293];N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [294];N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [295];2-phenyl-N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [296];N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [297];N-isopropyl-5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [298];N,N-dimethyl-1-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [299]; and2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine [300]; or a pharmaceutically acceptable salt thereof.

22. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of: 2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine [301];3,3-dimethyl-N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide [302];N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [303];N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [304];N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [305];N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [306];N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [307];N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [308];N-benzyl-1-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [309];1-cyclopentyl-N-((5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)methanamine [310];2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine [311];2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine [312];N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [313];N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide [314];5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [315];4-(5-fluorothiophen-2-yl)-2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [316];4-(5-fluorothiophen-2-yl)-2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [317];N-((5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)ethanamine [318];5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N,N-dimethylpyridin-3-amine [319];N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [320];N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [321];N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide [322];N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [323];5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N-isopropylpyridin-3-amine [324];1-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [325];4-(5-fluorothiophen-2-yl)-2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [326];4-(5-fluorothiophen-2-yl)-2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [327];N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [328];N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [329];N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [330];N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [331];N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [332];N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [333];N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [334];N-benzyl-1-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [335];1-cyclopentyl-N-((5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)methanamine [336];2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridine [337];4-(5-fluorothiophen-2-yl)-2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [338];N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [339];3-methyl-N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide [340];5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [341];4-(5-methylthiophen-2-yl)-2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [342];2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridine [343];N-((5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)ethanamine [344];N,N-dimethyl-5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [345];N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [346];N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [347];N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide [348];N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [349];N-isopropyl-5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [350];N,N-dimethyl-1-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [351];4-(5-methylthiophen-2-yl)-2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [352];4-(5-methylthiophen-2-yl)-2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [353];3,3-dimethyl-N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide [354];N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [355];N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [356];N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [357];N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [358];N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [359];N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [360];N-benzyl-1-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [361];1-cyclopentyl-N-((5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)methanamine [362];2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridine [363];4-(5-methylthiophen-2-yl)-2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [364];N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [365];N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide [366];1-(5-(2-(5-(5-aminopyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [367];1-(5-(2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [368];1-(5-(2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [369];1-(5-(2-(5-(5-((ethylamino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [370];1-(5-(2-(5-(5-(dimethylamino)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [371];N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [372];N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [373];N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide [374];N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [375];1-(5-(2-(5-(5-(isopropylamino)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [376];1-(5-(2-(5-(5-((dimethylamino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [377];1-(5-(2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [378];1-(5-(2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [379];N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [380];N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [381];N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [382];N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [383];N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [384];N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [385];N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [386];1-(5-(2-(5-(5-((benzylamino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [387];1-(5-(2-(5-(5-(((cyclopentylmethyl)amino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [388];1-(5-(2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [389];1-(5-(2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [390];N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [391];N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide [392];N-(3-(2-(5-(5-aminopyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [393];N-(3-fluoro-5-(2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [394];N-(3-fluoro-5-(2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [395];N-(3-(2-(5-(5-((ethylamino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [396];N-(3-(2-(5-(5-(dimethylamino)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [397];N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [398];N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [399]; andN-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide [400]; or a pharmaceutically acceptable salt thereof.

23. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of: N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [401];N-(3-fluoro-5-(2-(5-(5-(isopropylamino)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [402];N-(3-(2-(5-(5-((dimethylamino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [403];N-(3-fluoro-5-(2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [404];N-(3-fluoro-5-(2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [405];N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [406];N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [407];N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [408];N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [409];N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [410];N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [411];N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [412];N-(3-(2-(5-(5-((benzylamino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [413];N-(3-(2-(5-(5-(((cyclopentylmethyl)amino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [414];N-(3-(2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [415];N-(3-fluoro-5-(2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [416];N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [417];N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide [418];N1-(3-(2-(5-(5-aminopyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [419];N1-(3-fluoro-5-(2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [420];N1-(3-fluoro-5-(2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [421];N1-(3-(2-(5-(5-((ethylamino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [422];N1-(3-(2-(5-(5-(dimethylamino)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [423];N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [424];N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [425];N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide [426];N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [427];N1-(3-fluoro-5-(2-(5-(5-(isopropylamino)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [428];N1-(3-(2-(5-(5-((dimethylamino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [429];N1-(3-fluoro-5-(2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [430];N1-(3-fluoro-5-(2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [431];N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [432];N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [433];N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [434];N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [435];N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [436];N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [437];N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [438];N1-(3-(2-(5-(5-((benzylamino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [439];N1-(3-(2-(5-(5-(((cyclopentylmethyl)amino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [440];N1-(3-(2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [441];N1-(3-fluoro-5-(2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [442];1-(5-(7-fluoro-3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [456];1-(5-(7-fluoro-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [688];N-(3-(2-(5-(5-((dimethylamino)methyl)pyridin-3-yl)-7-fluoro-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [844];1-(5-(6-fluoro-3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [898];1-(5-(6-fluoro-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [1132];N-(3-(2-(5-(5-((dimethylamino)methyl)pyridin-3-yl)-6-fluoro-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [1288];1-(5-(4-fluoro-3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [1339];1-(5-(4-fluoro-3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [1573];N-(3-(2-(5-(5-((dimethylamino)methyl)pyridin-3-yl)-4-fluoro-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [1729];4-(3-fluorophenyl)-2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1769];4-(3-fluorophenyl)-2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1770];2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridine [1771];4-(3-fluorophenyl)-2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1772];2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridine [1773];1-(6-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyrazin-2-yl)azetidin-3-amine [1774];2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridine [1775];4-(3-fluorophenyl)-2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1776];N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1777];4-(3-fluorophenyl)-2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1778];2-((5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [1779];4-(3-fluorophenyl)-2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1780];5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol [1781];2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridine [1782];2-cyclohexyl-N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [1783];4-(3-fluorophenyl)-2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1784];4-(3-fluorophenyl)-2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1785];4-(3-fluorophenyl)-2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1786];4-(4-fluorophenyl)-2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1787];4-(4-fluorophenyl)-2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1788];2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridine [1789];4-(4-fluorophenyl)-2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1790];2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridine [1791];1-(6-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyrazin-2-yl)azetidin-3-amine [1792];2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridine [1793];4-(4-fluorophenyl)-2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1794];N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1795];4-(4-fluorophenyl)-2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1796];2-((5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [1797];4-(4-fluorophenyl)-2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1798];5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol [1799]; and2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridine [1800]; or a pharmaceutically acceptable salt thereof.

24. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of: 2-cyclohexyl-N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [1801];4-(4-fluorophenyl)-2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1802];4-(4-fluorophenyl)-2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1803];4-(4-fluorophenyl)-2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1804];4-(2-fluorophenyl)-2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1805];4-(2-fluorophenyl)-2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1806];2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridine [1807];4-(2-fluorophenyl)-2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1808];2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridine [1809];1-(6-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyrazin-2-yl)azetidin-3-amine [1810];2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridine [1811];4-(2-fluorophenyl)-2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1812];N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1813];4-(2-fluorophenyl)-2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1814];2-((5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [1815];4-(2-fluorophenyl)-2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1816];5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol [1817];2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridine [1818];2-cyclohexyl-N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [1819];4-(2-fluorophenyl)-2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1820];4-(2-fluorophenyl)-2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1821];4-(2-fluorophenyl)-2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1822];2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridine [1823];4-(pyridin-3-yl)-2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1824];2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridine [1825];2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridine [1826];2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridine [1827];1-(6-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyrazin-2-yl)azetidin-3-amine [1828];2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridine [1829];2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridine [1830];2-(piperidin-4-yl)-N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [1831];4-(pyridin-3-yl)-2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1832];N,N-dimethyl-2-((5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)oxy)ethan-1-amine [1833];2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridine [1834];5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol [1835];2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridine [1836];2-cyclohexyl-N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [1837];4-(pyridin-3-yl)-2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1838];2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridine [1839];2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridine [1840];2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridine [1841];4-(pyridin-4-yl)-2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1842];2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridine [1843];2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridine [1844];2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridine [1845];1-(6-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyrazin-2-yl)azetidin-3-amine [1846];2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridine [1847];2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridine [1848];2-(piperidin-4-yl)-N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [1849];4-(pyridin-4-yl)-2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1850];N,N-dimethyl-2-((5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)oxy)ethan-1-amine [1851];2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridine [1852];5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol [1853];2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridine [1854];2-cyclohexyl-N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [1855];4-(pyridin-4-yl)-2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1856];2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridine [1857];2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridine [1858];2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridine [1859];4-(pyridin-2-yl)-2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1860];2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridine [1861];2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridine [1862];2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridine [1863];1-(6-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyrazin-2-yl)azetidin-3-amine [1864];2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridine [1865];2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridine [1866];2-(piperidin-4-yl)-N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [1867];4-(pyridin-2-yl)-2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1868];N,N-dimethyl-2-((5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)oxy)ethan-1-amine [1869];2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridine [1870];5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol [1871];2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridine [1872];2-cyclohexyl-N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [1873];4-(pyridin-2-yl)-2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1874];4-(pyridin-2-yl)-2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1875];2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridine [1876];4-(piperidin-1-yl)-2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1877];4-(piperidin-1-yl)-2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1878];2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridine [1879];2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridine [1880];2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridine [1881];1-(6-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyrazin-2-yl)azetidin-3-amine [1882];2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridine [1883];4-(piperidin-1-yl)-2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1884];N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1885];4-(piperidin-1-yl)-2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1886];N,N-dimethyl-2-((5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)oxy)ethan-1-amine [1887];2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridine [1888];5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol [1889];2-(5-(5-(benzyl oxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridine [1890];2-cyclohexyl-N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [1891];4-(piperidin-1-yl)-2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1892];4-(piperidin-1-yl)-2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1893];4-(piperidin-1-yl)-2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1894];4-(4-methyl-1H-imidazol-1-yl)-2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1895];4-(4-methyl-1H-imidazol-1-yl)-2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1896];2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(4-methyl-1H-imidazo-1-yl)-1H-imidazo[4,5-c]pyridine [1897];4-(4-methyl-1H-imidazol-1-yl)-2-(5-(l -methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1898];2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridine [1899]; and1-(6-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyrazin-2-yl)azetidin-3-amine [1900]; or a pharmaceutically acceptable salt thereof.

25. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of: 2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridine [1901];4-(4-methyl-1H-imidazol-1-yl)-2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1902];N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1903];4-(4-methyl-1H-imidazol-1-yl)-2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1904];N,N-dimethyl-2-((5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)oxy)ethan-1-amine [1905];2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridine [1906];5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol [1907];2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridine [1908];2-cyclohexyl-N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [1909];4-(4-methyl-1H-imidazol-1-yl)-2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1910];4-(4-methyl-1H-imidazol-1-yl)-2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1911];4-(4-methyl-1H-imidazol-1-yl)-2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1912];4-(4-methylpiperazin-1-yl)-2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1913];4-(4-methylpiperazin-1-yl)-2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1914];2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridine [1915];2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridine [1916];2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridine [1917];1-(6-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyrazin-2-yl)azetidin-3-amine [1918];2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridine [1919];4-(4-methylpiperazin-1-yl)-2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1920];N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1921];4-(4-methylpiperazin-1-yl)-2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1922];N,N-dimethyl-2-((5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)oxy)ethan-1-amine [1923];2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridine [1924];5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol [1925];2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridine [1926];2-cyclohexyl-N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [1927];4-(4-methylpiperazin-1-yl)-2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1928];4-(4-methylpiperazin-1-yl)-2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1929];4-(4-methylpiperazin-1-yl)-2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1930];2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine [1931];2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine [1932];2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine [1933];2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine [1934];2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine [1935];1-(6-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyrazin-2-yl)azetidin-3-amine [1936];2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine [1937];2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine [1938];2-(piperidin-4-yl)-N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [1939];2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine [1940];N,N-dimethyl-2-((5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)oxy)ethan-1-amine [1941];2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine [1942];5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol [1943];2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine [1944];2-cyclohexyl-N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [1945];2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine [1946];2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine [1947];2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine [1948];4-(furan-3-yl)-2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1949];4-(furan-3-yl)-2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1950];2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(furan-3-yl)-1H-imidazo[4,5-c]pyridine [1951];4-(furan-3-yl)-2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1952];2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-4-(furan-3-yl)-1H-imidazo[4,5-c]pyridine [1953];1-(6-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyrazin-2-yl)azetidin-3-amine [1954];2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(furan-3-yl)-1H-imidazo[4,5-c]pyridine [1955];4-(furan-3-yl)-2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1956];N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1957];4-(furan-3-yl)-2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1958];2-((5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [1959];4-(furan-3-yl)-2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1960];5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol [1961];2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(furan-3-yl)-1H-imidazo[4,5-c]pyridine [1962];2-cyclohexyl-N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [1963];4-(furan-3-yl)-2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1964];4-(furan-3-yl)-2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1965];4-(furan-3-yl)-2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1966];2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine [1967];2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine [1968];2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine [1969];2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine [1970];2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine [1971];1-(6-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyrazin-2-yl)azetidin-3-amine [1972];2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine [1973];2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine [1974];2-(piperidin-4-yl)-N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [1975];2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine [1976];N,N-dimethyl-2-((5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)oxy)ethan-1-amine [1977];2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine [1978];5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol [1979];2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine [1980];2-cyclohexyl-N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [1981];2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine[1982];2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine [1983];2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine [1984];4-(5-fluorothiophen-2-yl)-2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1985];4-(5-fluorothiophen-2-yl)-2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1986];2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridine [1987];4-(5-fluorothiophen-2-yl)-2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1988];2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridine [1989];1-(6-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyrazin-2-yl)azetidin-3-amine [1990];2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridine [1991];4-(5-fluorothiophen-2-yl)-2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1992];N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1993];4-(5-fluorothiophen-2-yl)-2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1994];2-((5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [1995];4-(5-fluorothiophen-2-yl)-2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1996];5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol [1997];2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridine [1998];2-cyclohexyl-N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [1999]; and4-(5-fluorothiophen-2-yl)-2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2000]; or a pharmaceutically acceptable salt thereof.

26. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of: 4-(5-fluorothiophen-2-yl)-2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2001];4-(5-fluorothiophen-2-yl)-2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2002];4-(5-methylthiophen-2-yl)-2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2003];4-(5-methylthiophen-2-yl)-2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2004];2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridine [2005];2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridine [2006];2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridine [2007];1-(6-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyrazin-2-yl)azetidin-3-amine [2008];2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridine [2009];4-(5-methylthiophen-2-yl)-2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2010];N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [2011];4-(5-methylthiophen-2-yl)-2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2012];N,N-dimethyl-2-((5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)oxy)ethan-1-amine [2013];2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridine [2014];5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol [2015];2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridine [2016];2-cyclohexyl-N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2017];4-(5-methylthiophen-2-yl)-2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2018];4-(5-methylthiophen-2-yl)-2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2019];4-(5-methylthiophen-2-yl)-2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2020];1-(5-(2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [2021];1-(5-(2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [2022];1-(5-(2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [2023];1-(5-(2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [2024];1-(5-(2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [2025];1-(5-(2-(5-(6-(3-aminoazetidin-1-yl)pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [2026];1-(5-(2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [2027];1-(5-(2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [2028];N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [2029];1-(5-(2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [2030];1-(5-(2-(5-(5-(2-(dimethylamino)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [2031];1-(5-(2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [2032];1-(5-(2-(5-(5-hydroxypyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [2033];1-(5-(2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [2034];N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-cyclohexylacetamide [2035];1-(5-(2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [2036];1-(5-(2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [2037];1-(5-(2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [2038];N-(3-fluoro-5-(2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [2039];N-(3-fluoro-5-(2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [2040];N-(3-(2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [2041];N-(3-fluoro-5-(2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [2042];N-(3-(2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [2043];N-(3-(2-(5-(6-(3-aminoazetidin-1-yl)pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [2045];N-(3-(2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [2045];N-(3-fluoro-5-(2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [2046];N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [2047];N-(3-fluoro-5-(2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [2048];N-(3-(2-(5-(5-(2-(dimethylamino)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [2049];N-(3-fluoro-5-(2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [2050];N-(3-fluoro-5-(2-(5-(5-hydroxypyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [2051];N-(3-(2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [2052];2-cyclohexyl-N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2053];N-(3-fluoro-5-(2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [2054];N-(3-fluoro-5-(2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [2055];N-(3-fluoro-5-(2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [2056];N1-(3-fluoro-5-(2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [2057];N1-(3-fluoro-5-(2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [2058];N1-(3-(2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [2059];N1-(3-fluoro-5-(2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [2060];N1-(3-(2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [2061];N1-(3-(2-(5-(6-(3-aminoazetidin-1-yl)pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [2062];N1-(3-(2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [2063];N1-(3-fluoro-5-(2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [2064];N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [2065];N1-(3-fluoro-5-(2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [2066];N1-(3-(2-(5-(5-(2-(dimethylamino)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [2067];N1-(3-fluoro-5-(2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [2068];5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol [2069];N1-(3-(2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [2070];2-cyclohexyl-N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2071];N1-(3-fluoro-5-(2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [2072];N1-(3-fluoro-5-(2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [2073];N1-(3-fluoro-5-(2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [2074];N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [2075];N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide [2076];5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [2077];2-(3-fluoro-5-(2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [2078];2-(3-fluoro-5-(2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [2079];2-(3-(2-(5-(5-((ethylamino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [2080];5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N,N-dimethylpyridin-3-amine [2081];N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [2082];N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [2083];N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide [2084];N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [2085];5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N-isopropylpyridin-3-amine [2086];2-(3-(2-(5-(5-((dimethylamino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [2087];2-(3-fluoro-5-(2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [2088];2-(3-fluoro-5-(2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [2089];N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [2090];N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [2091];N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [2092];N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [2093];N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [2094];N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [2095];N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [2096];2-(3-(2-(5-(5-((benzylamino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [2097];2-(3-(2-(5-(5-(((cyclopentylmethyl)amino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [2098];2-(3-(2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [2099]; and2-(3-fluoro-5-(2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [2100]; or a pharmaceutically acceptable salt thereof.

27. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of: 2-(3-fluoro-5-(2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [2101];2-(3-fluoro-5-(2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [2102];2-(3-fluoro-5-(2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [2103];2-(3-(2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [2104];2-(3-fluoro-5-(2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [2105];2-(3-(2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [2106];1-(6-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyrazin-2-yl)azetidin-3-amine [2107];2-(3-(2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [2108];2-(3-fluoro-5-(2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [2109];N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [2110];2-(3-fluoro-5-(2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [2111];2-((5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [2112];2-(3-fluoro-5-(2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [2113];5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol [2114];2-(3-(2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [2115];2-cyclohexyl-N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2116];2-(3-fluoro-5-(2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [2117];2-(3-fluoro-5-(2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenoxy)-N,N-dimethylethan-1-amine [2118];N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [2119];N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide [2120];5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [2121];4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2122];4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2123];N-((5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)ethanamine [2124];5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N,N-dimethylpyridin-3-amine [2125];N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [2126];N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [2127];N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide [2128];N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [2129];5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N-isopropylpyridin-3-amine [2130];1-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [2131];4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2132];4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2133];N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [2134];N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [2135];N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [2136];N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [2137];N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [2138];N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [2139];N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [2140];N-benzyl-1-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [2141];1-cyclopentyl-N-((5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)methanamine [2142];2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridine [2143];4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2144];4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2145];4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2146];4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2147];2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridine [2148];4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2149];2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-4-(3-fluoro-5-(2-(pyrroliddin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridine [2150];1-(6-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyrazin-2-yl)azetidin-3-amine [2151];2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridine [2152];4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2153];N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [2154];4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2155];2-((5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [2156];4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2157];5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol [2158];2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridine [2159];2-cyclohexyl-N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2160];4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2161];4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2162];N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [2163];N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide [2164];3-(2-(5-(5-aminopyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [2165];3-fluoro-5-(2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [2166];3-fluoro-5-(2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [2167];3-(2-(5-(5-((ethylamino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [2168];3-(2-(5-(5-(dimethylamino)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [2169];N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [2170];N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [2171];N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide [2172];N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [2173];3-fluoro-5-(2-(5-(5-(isopropylamino)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [2174];3-(2-(5-(5-((dimethylamino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [2175];3-fluoro-5-(2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [2176];3-fluoro-5-(2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [2177];N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [2178];N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [2179];N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [2180];N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [2181];N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [2182];N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [2183];N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [2184];3-(2-(5-(5-((benzylamino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [2185];3-(2-(5-(5-(((cyclopentylmethyl)amino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [2186];3-(2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [2187];3-fluoro-5-(2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [2188];3-fluoro-5-(2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [2189];3-fluoro-5-(2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [2190];3-fluoro-5-(2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [2191];3-(2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [2192];3-fluoro-5-(2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [2193];3-(2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [2194];3-(2-(5-(6-(3-aminoazetidin-1-yl)pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [2195];3-(2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [2196];3-fluoro-5-(2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [2197];N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [2198];3-fluoro-5-(2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [2199]; and3-(2-(5-(5-(2-(dimethylamino)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [2200]; or a pharmaceutically acceptable salt thereof.

28. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of: 3-fluoro-5-(2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [2201];5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol [2202];3-(2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenol [2203];2-cyclohexyl-N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2204];3-fluoro-5-(2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [2205];3-fluoro-5-(2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenol [2206];N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [2207];N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide [2208];5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [2209];4-(3-fluoro-5-methoxyphenyl)-2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2210];4-(3-fluoro-5-methoxyphenyl)-2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2211];N-((5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)ethanamine [2212];5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N,N-dimethylpyridin-3-amine [2213];N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [2214];N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [2215];N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide [2216];N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)benzamide [2217];5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N-isopropylpyridin-3-amine [2218];1-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [2219];4-(3-fluoro-5-methoxyphenyl)-2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2220];4-(3-fluoro-5-methoxyphenyl)-2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2221];N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [2222];N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [2223];N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pentanamide [2224];N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [2225];N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [2226];N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [2227];N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclohexanecarboxamide [2228];N-benzyl-1-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [2229];1-cyclopentyl-N-((5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo [4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)methanamine [2230];2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-indazol-3-yl)-4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridine [2231];4-(3-fluoro-5-methoxyphenyl)-2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2232];4-(3-fluoro-5-methoxyphenyl)-2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2233];4-(3-fluoro-5-methoxyphenyl)-2-(5-(piperidin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2234];4-(3-fluoro-5-methoxyphenyl)-2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2235];2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridine [2236];4-(3-fluoro-5-methoxyphenyl)-2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2237];2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-3-yl)-4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridine [2238];1-(6-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyrazin-2-yl)azetidin-3-amine [2239];2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridine [2240];4-(3-fluoro-5-methoxyphenyl)-2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2241];N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [2242];4-(3-fluoro-5-methoxyphenyl)-2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2243];2-((5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [2244];4-(3-fluoro-5-methoxyphenyl)-2-(5-(5-methoxypyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2245];5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol [2246];2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridine [2247];2-cyclohexyl-N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2248];4-(3-fluoro-5-methoxyphenyl)-2-(5-(pyridin-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2249];4-(3-fluoro-5-methoxyphenyl)-2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2250];2-(dimethylamino)-N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2251];2-(dimethylamino)-N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2252];2-(dimethylamino)-N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2253];2-(dimethylamino)-N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2254];2-(dimethylamino)-N-(5-(3-(4-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2255];2-(dimethylamino)-N-(5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2256];2-(dimethylamino)-N-(5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2257];2-(dimethylamino)-N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2258];2-(dimethylamino)-N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2259];2-(dimethylamino)-N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2260];2-(dimethylamino)-N-(5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2261];2-(dimethylamino)-N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2262];2-(dimethylamino)-N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2263];2-(dimethylamino)-N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2264];N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-(dimethylamino)acetamide [2265];2-(dimethylamino)-N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2266];2-(dimethylamino)-N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2267];2-(dimethylamino)-N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2268];2-(dimethylamino)-N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2269];2-(dimethylamino)-N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2270];2-(dimethylamino)-N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)acetamide [2271];4-(2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)morpholine [2272];4-(4,4-difluoropiperidin-1-yl)-2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2273];4-(1-methylpiperidin-4-yl)-2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2274];4-(2-(5-(5-fluoropyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl) morpholine [2275];2-(5-(5-fluoropyridin-3-yl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridine [2276];4-(4,4-difluoropiperidin-1-yl)-2-(5-(5-fluoropyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2277];2-(5-(5-fluoropyridin-3-yl)-1H-indazol-3-yl)-4-(1-methylpiperidin-4-yl)-1H-imidazo[4,5-c]pyridine [2278];2-(5-(5-fluoropyridin-3-yl)-1H-indazol-3-yl)-4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridine [2278];4-(2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl) morpholine [2280];4-(4,4-difluoropiperidin-1-yl)-2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [2281];2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(1-methylpiperidin-4-yl)-1H-imidazo[4,5-c]pyridine [2282];4-(2-(5-(1-cyclopropyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)morpholine [2283];2-(5-(1-cyclopropyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridine [2284];2-(5-(1-cyclopropyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(4,4-difluoropiperidin-1-yl)-1H-imidazo[4,5-c]pyridine [2285];2-(5-(1-cyclopropyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(1-methylpiperidin-4-yl)-1H-imidazo[4,5-c]pyridine [2286];2-(5-(1-cyclopropyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridine [2287];4-(2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)morpholine [2288];2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(4,4-difluoropiperidin-1-yl)-1H-imidazo[4,5-c]pyridine [2289]; and2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(1-methylpiperidin-4-yl)-1H-imidazo[4,5-c]pyridine [2290]; or a pharmaceutically acceptable salt thereof.

29. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of: N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)propionamide [1];N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide [2];5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N,N-dimethylpyridin-3-amine [7];1-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [13];N-(5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [19];N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide [28];N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [34];N-(5-(3-(4-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclobutanecarboxamide [46];5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [55];N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [61];N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [68];N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butyramide [69];N-(5-(3-(4-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [73];4-(pyridin-3-yl)-2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [82];N-(5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide [87];N-isopropyl-5-(3-(4-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [90];N-((5-(3-(4-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)ethanamine [136];N,N-dimethyl-5-(3-(4-(piperidin-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [163];3-methyl-N-(5-(3-(4-(4-methyl-1H-imidazo-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)butanamide [184];N-(5-(3-(4-(4-methyl-1H-imidazo-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl) pyridin-3-yl)pivalamide [190];N-(5-(3-(4-(4-methyl-1H-imidazo-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl) pyridin-3-yl)cyclobutanecarboxamide [202];4-(4-methylpiperazin-1-yl)-2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [234];2-(5-(4-methylpyridin-3-yl)-1H-indazol-3-yl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine [239];N-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl) butyramide [251];N-benzyl-1-(5-(3-(4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methanamine [257];N-((5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)ethanamine [266];5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)-N-isopropylpyridin-3-amine [272];1-cyclopentyl-N-((5-(3-(4-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)methyl)methanamine [284];N-(5-(3-(4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopropanecarboxamide [305];N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)pivalamide [320];5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-amine [341];4-(5-methylthiophen-2-yl)-2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [353];N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)cyclopentanecarboxamide [359];1-(5-(2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)thiophen-2-yl)ethan-1-one [368];N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide [374];N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide [400];N-(3-(2-(5-(5-((benzylamino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorobenzyl)methanesulfonamide [413];N-(3-fluoro-5-(2-(5-(pyrimidin-5-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)benzyl)methanesulfonamide [416];N1-(3-fluoro-5-(2-(5-(5-(isopropylamino)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)phenyl)-N2,N2-dimethylethane-1,2-diamine [428];N1-(3-(2-(5-(5-(((cyclopentylmethyl)amino)methyl)pyridin-3-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine [440];2-(5-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridine [1771];2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-indazol-3-yl)-4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridine [1775];5-(3-(4-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-ol [1781];4-(3-fluorophenyl)-2-(5-(pyridin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1785];4-(3-fluorophenyl)-2-(5-(pyrazin-2-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridine [1786];2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridine [1916];4-(2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-1H-imidazo[4,5-c]pyridin-4-yl)morpholine [2280]; and2-(5-(1-cyclopropyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-1H-imidazo[4,5-c]pyridine [2284]; or a pharmaceutically acceptable salt thereof.

30. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of:

31. The method of claim 1, wherein the bone or cartilage disease is osteoarthritis.

32. The method of claim 1, wherein the bone or cartilage disease is articular cartilage (chondral) defects.

33. The method of claim 1, wherein the bone or cartilage disease is degenerative disc disease.

34. The method of claim 1, wherein the bone or cartilage disease is relapsing polychondritis.

35. The method of claim 1, wherein the bone or cartilage disease is osteochondritis dissecans.

36. The method of claim 1, wherein the subject is a human.